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SUMMARY
The nucleotide sequences of the fusion (F) protein encoding gene of five 
isolates of subgroup A respiratory syncytial (RS) virus, representing the five lineages 
associated with current epidemics of RS virus-associated disease, were determined and 
compared with F gene sequences from laboratory strains. Overall natural variation in 
the fusion protein gene among subgroup A isolates is low. Amino acid identities of 
between 97% to 99.5% were deduced. The relationship of the five lineage isolates, 
based on the sequence of their fusion protein genes, agrees broadly with evolutionary 
relationships inferred from comparison of their G, SH and N protein genes.
There is a region of high amino acid variation at the C-terminal end of the F2- 
subunit, specifically between residues #101 and #105. None of the apparent amino acid 
coding changes are located in known epitopes. Using predictive structural models it is 
suggested that the few amino acid changes observed may alter the fusion protein 
structure especially in the C-terminal domain of the F2-subunit. The secondary 
structure of the Fi-subunit is predicted to remain unaltered. It is hypothesised that 
amino acid variation in the F2-subunit may result in antigenic variation, by altering a 
potential conformational epitope formed by interaction between the N-terminal region 
of Fi and the C-terminal region of F2.
Induced variation in the fusion protein gene of two candidate vaccine strains 
was investigated. Temperature-sensitive mutant MAI, derived by intensive mutagenesis 
from the A2 strain, has two distinctive phenotypes; temperature-sensitivity and a 
retarded fusion protein mobility in non-reducing gels. Previous analysis of the 
phenotypic characteristics of MAI indicated that the F gene might be the site of the ts 
mutation. The sequence data derived in this study suggest that the site of ts lesion is 
located at residue #66 (Glu —> Lys) and that the mobility phenotype is located at 
residue #102 (Pro —► Ser). Mutant MAI exhibits a complex pattern of reversion with 
two classes of revertant viruses observed; a fully revertant virus which has wild-type 
growth characteristics but still retains retarded fusion protein mobility; and a partially 
revertant virus that possesses near wild-type growth characteristics and wild-type 
mobility. In fully revertant viruses the correction of the ts phenotype has been 
identified as the reversion of amino acid #66 to the wild-type residue (Lys —> Glu) 
whilst the coding change at amino acid #102 is retained, resulting in a mobility 
phenotype similar to that found in mutant MAI. In partially revertant viruses the coding 
changes at amino acid #66 and amino acid #102 are retained. In partially revertant 
viruses the coding change correcting for the mobility phenotype, and partially 
correcting for the ts phenotype, has been tentatively identified as additional coding 
changes at residues #103 (Thr —► Ala) and/or #105 (Asn —> Ser). In vitro expression of 
the fusion gene products of mutant, revertant and wild-type viruses in mammalian cells 
has confirmed that the mobility phenotype is solely a consequence of changes in the 
fusion protein gene.
Temperature-sensitive mutant MIC is a triple ts mutant derived from the RSS-2 
strain. The mutations detected in the fusion gene of mutant MIC are conservative in 
nature and are not located in known epitopes. Therefore it is unlikely that the coding 
changes observed in the fusion protein gene account for the ts-phenotype or viral 
attenuation. It is also thought that the induced mutations have not altered the antigenic 
properties of the virus.
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CHAPTER ONE
Introduction
1.1 The family Paramvxoviridae The family Paramyxoviridae comprises pleomorphic 
enveloped viruses possessing non-segmented genomes of negative-sense, single-stranded 
RNA. These viruses infect cells by fusion of the viral envelope with the cell surface 
membrane at neutral pH. The genome is then transcribed from a single promoter into 6 to 10 
mRNAs, the majority of which are monocistronic. Independently assembled nucleocapsids 
are enveloped on the cell surface at sites containing viral envelope proteins, virions being 
released by budding. Transmission of the virus is airborne, mainly horizontal with no 
identifiable vectors involved. The effect on infected cells is cytolytic, but temperate and 
persistent infections are common. Physical features of infection are inclusion bodies, 
syncytium formation and haemadsorption.
The family Paramyxoviridae is subdivided into four genera, Paramyxovirus, 
Rubulavirus, Morbillivirus and Pneumovirus (Table 1), on the basis of measurement of 
nucleocapsid diameter and envelope surface projections by electron microscopy, antigenic or 
biochemical aspects of the large attachment glycoprotein present in the virion envelope, 
genomic order (Figure 1) and strategies used to express different P gene products (Section 
1.4.4), Biochemically the paramyxoviruses and rubulaviruses are distinguishable from the 
other two by the ability of their attachment glycoprotein to exhibit both haemagglutinin and 
neuraminidase activity (H/N) (Kingsbury et al., 1978; Matthews, 1982; Francki et al., 1991). 
The attachment protein of the morbilliviruses possess haemagglutinin activity (H) only. 
Within the Pneumovirus genus there is some variation, with PVM able to haemagglutinate 
mouse cells (Berthiaume et al., 1974; Ling and Pringle, 1989b). Analysis of the 
Paramyxoviridae at the molecular level has emphasised the relatedness that exists between 
the morbilliviruses, paramyxoviruses and rubulaviruses. The paramyxoviruses are closely 
related to the morbilliviruses in regard to genetic map, arrangement and sizes of ORFs and 
sequences of intergenic regions. In addition, the
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Table 1 The family Paramvxoviridae
Subfamily Paramyxovirinae
Genus Paramyxovirus
Human parainfluenza virus type 1 (type species)
Human parainfluenza virus type 3 
Bovine parainfluenza virus type 3 
Mouse parainfluenza virus type 1 (Sendai virus)
Simian parainfluenza virus type 10 
Genus Morbillivirus
Measles virus (type species)
Dolphin morbillivirus 
Canine distemper virus 
Peste-des-petits-ruminants virus 
Phocine distemper virus 
Rinderpest virus 
Genus Rubulavirus
Mumps virus (type species)
Avian paramyxovirus 1 (Newcastle disease virus)
Avian paramyxovirus 2 (Yucaipa virus)
Avian paramyxovirus 3 
Avian paramyxovirus 4 
Avian paramyxovirus 5 (Kunitachi virus)
Avian paramyxovirus 7
Avian paramyxovirus 8
Avian paramyxovirus 9
Human parainfluenza virus type 2
Human parainfluenza virus type 4a
Human parainfluenza virus type 4b
Porcine rubulavirus (La-Piedad-Michoacan-Mexico vims)
Simian parainfluenza virus 5
Simian parainfluenza vims 41
Subfamily Pneumovirinae
Genus Pneumovirus
Human respiratory syncytial virus (type species)
Bovine respiratory syncytial virus
Pneumonia vims of mice (murine pneumonia virus)
Turkey rhinotracheitis vims
Unassigncd viruses in the family
Fer-de-Lancc virus 
Nariva vims
Penguin paramyxoviruses
Table I Summary of the classification of individual paramyxoviruses into the four genera, 
Paramyxovirus, Rubulavirus; Morbillivirus and Pneumovirus, that comprise the 
Paramyxoviridae family. Adapted from the 6th report of the International Committee on the 
Taxonomy of Viruses (Fauquet et al., 1994).
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Figure 1. Genomic organisation of the PARAMYXOVIRIDAE
Genus Morbillivirus Measles virus
3'
NP P/C/V M F H L
5 '
Genus Paramyxovirus
NP P/C/V
3*
M
Parainfluenza virus III 
HN L
5'
Genus Rhubuiavirus Mumps virus
5'
Genus Pneumovirus Respiratory syncytial virus
1C 1B N P M SH G F 22K L
5'
Genus Pneumovirus
1C 1B N P
3' ■ ■  1
M SH
Pneumonia virus of mice 
F 22K L
5’
Genus Pneumovirus Turkey rhinotracheitis virus
1C 1B N P M  F 22K SH G L
5'
Diagramatical representation of the genomes of members of the family Paramyxoviridae , 
showing the extra genes present in the pneumoviruses. Also showing the change in 
genomic order between TRTV and the other pneumoviruses. The internal site of initiation 
(AUG) of the L gene in RS viruses within the 22K gene is also shown.
Adapted from J.Barr,( 1994).
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morbillivirus NP, P, and L proteins possess sequence relatedness to their paramyxovirus 
counterparts but less homology to the rubula- and pneumoviruses (Morgan, 1991; data for 
the L gene sequences is shown in Table 2). Nucleotide sequencing of Paramyxoviridae L, 
P and V protein genes also supports this relationship model (Stec et al., 1991).
The genomic composition of pneumoviruses is distinct, possessing four extra 
genes, one non-glycosylated envelope protein gene (22K), two non-structural protein 
genes (NS 1 and NS2), and a small hydrophobic (SH) protein gene possibly analogous to 
the SH protein of the rubulaviruses. In addition to their unique genomic structure, the 
polypeptides encoded by the pneumovirus genome are generally smaller than their 
homologues in the other genera, and display little amino acid similarity to those of other 
viruses outside the genus (Spriggs and Collins, 1986a; Barr et al., 1991; Yu et al., 1992a 
and b; Chambers et al., 1992). The exceptions to this are the L protein (Stec et al., 1991) 
and the F protein (Spriggs et al., 1986c) which both show a low but significant level of 
similarity with the corresponding proteins of other members of the family 
Paramyxoviridae.
1.1.1 The genus Pneumovirus Molecular studies comparing the known pneumoviruses 
indicate that they correspond closely by gene-map and by the numbers and types of gene 
products (Cash et al., 1977; Cavanagh and Barrett, 1988; Ling and Pringle, 1988,1989a 
and b; Lerch et al., 1989). The genomes of human and bovine RS viruses and PVM are 
identical in gene-order. There are differences; 1) the start of the L gene of human and 
bovine RS viruses lies within the 22K gene but there is no overlap in PVM (A. Easton, 
personal communication); 2) there are at least two gene products from the PVM P gene 
whereas in human RS virus there is only one (J.Barr, 1994). The pneumovirus TRTV has 
a distinctive gene-order (Ling et al., 1992; Yu et al., 1992b). The SH and G gene pair, 
and the F-22K gene pair are transposed, giving F-SH-G the same linear relationship as in 
the paramyxo-, morbilli- and rubulaviruses. However, whilst there is no firm evidence to 
suggest that TRTV possesses analogues of the RS viral NS1 and NS2 genes, the
5
Table 2 Conserved amino acids of Paramvxoviridae L proteins
Paramyxovirus Paramyxovirus Morbillivirus Rubulavirus
PIV3 SV MeV NDV
PIV3 72 50 34
SV 61 50 33
MeV 36 37 32
NDV 23 21 20
Table 2 The total number of conserved amino acids, including identical and conservative 
replacements, in each alignment pair (figures above the diagonal), and the total number of 
identical amino acids (figures below the diagonal) are expressed as a percentage of the 
aligned sequences. The sources of the published sequences are: PIV3 (Galinski el al., 
1988); SV (Shioda et al., 1986); MeV (Blumberg et al., 1988); and NDV (Yusoff et al., 
1987). Reproduced from E. M. Morgan, Chapter 5, The Paramyxoviruses, Plenum Press, 
New York, 1991.
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possession of genes 22K and SH confirms the inclusion of TRTV in the genus Pneumovirus. 
There appears to be two subgroups of the ruminant RS viruses, ovine and bovine, that differ 
antigenically (Alansari and Potgieter, 1993). Significant antigenic relatedness exists between 
human RS and bovine RS viruses (Stott et al., 1984; Lerch et al., 1989), and between human 
RS virus and PVM. There is evidence for neutralising activity to PVM or a related virus in 
27% to 75% of human adult sera (Horsfall and Hahn, 1940; Horsfall and Cumen, 1946; 
Pringle and Eglin, 1986). Antigenic cross-reactivity has also been found between human RS 
virus and PVM N (Gimenez et al., 1984; Ling and Pringle, 1989a) and P proteins (Ling and 
Pringle, 1989a).
1.1.2 Respiratory svncvtial (RS virus! virus Human respiratory syncytial (RS) virus was 
first isolated in 1957 and shown to be related to Chimpanzee coryza agent isolated in 1956. 
The virus replicates efficiently in enucleated cells (Follett et al., 1975) and does not shut off 
host cell metabolism (Levine et al., 1977). More than 90% of RS viral infectivity remains 
cell-associated (Peeples and Levine, 1980). Human RS virus has been classified into two 
subgroups on the basis of the reactivity of the G, F, M and N polypeptides with a panel of 
monoclonal antibodies (Gimenez et al., 1984; Ward et al., 1984; Mufson et al., 1985; 
Anderson et al., 1985). The A and B subgroups of human RS viruses exhibit differences in 
the molecular weights of the Fi and F2 polypeptides (Norrby et al., 1986) and the P protein 
(Cash et al., 1977; Norrby et al., 1986). Within subgroups the G protein amino acid identity 
varies from 80 to 99% (Johnson et al., 1987b; Sullender et al., 1990; Cane et al., 1992) 
whereas between subgroups the amino acid identity is only 53% (Johnson et al., 1987b). The 
other human RS viral proteins show varying degrees of difference between subgroups (Table 
3). Intra-group amino acid conservation is higher than inter-group for all proteins which 
suggests that the two subgroups have been evolving separately for some time (Collins, 1991). 
Sequence analysis of the SH and G protein genes and restriction analysis of the G and N 
protein genes of a large number of subgroup A isolates, suggest that there are at least five 
distinct isolate types that show extensive genetic divergence (Figure 2)(Cane and Pringle, 
1991, 1992; Cane etal..
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Table 3 Inter- and intra-subgroup homology of RS virus polypeptides
Polypeptide % intra-subgroup homology % inter-subgroup homology
NS1 98 87
NS2 98 87
N 99 96
P 98 90
M 99 ND
SH 84 76
G 80 to 98 53
F 97 to 99.5 91
22K 98 92
L 97 ND
Table 3 Inter-subgroup figures are taken from Collins (1991). Intra-subgroup homology 
figures quoted are from data supplied by; NS2 and NS1 (J.Evans, personal 
communication); N, P, 22K, SH and L (C.Pringle, K.Tolley, A.Simpson, personal 
communication), G (Cane et ai, 1992), and F (this Thesis). ND. Data not available.
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Figure 2. Relatedness of subgroup A isolates based on their SH and N 
genes.
Long
A2
RSB89-642 SHL5
RSB89-1734 SHL5
RSB89-5857 SHL1
RSB89-6256 SHL3
RSB89-6614 SHL4
RSB89-6190 SHL2
Simple dendrogram illustrating the relative relationships between subgroup 
A isolates based on their N and SH protein genes. Reproduced from Cane 
and Pringle, 1991.
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1992). These lineages appear to be distributed world-wide (Cane et al., 1992) but any 
difference in virus virulence and immunity at the individual and community level is unknown. 
Within subgroup B there are at least three distinct isolate types (Akerlind et al., 1988; 
Anderson et al., 1991; Mufson et al., 1991; Sullender et al., 1991; Nagai et al., 1993). 
Repeated infections of humans with RS virus has been recognised for many years (Beem, 
1966; Henderson et al., 1979). Studies have demonstrated that subgroup A and B isolate- 
types can co-circulate in the same community and that the relative frequency of their isolation 
can change from year to year (Mufson et al., 1988; Hendry et al., 1989; Breese-Hall et al., 
1990 and Anderson et al., 1991). With the recognition that these individual isolates give rise 
to varying immune responses (Robinson and Everson, 1992), it has been proposed that 
isolate variation within a subgroup (and hence subsequent antigenic variation) may contribute 
towards adult reinfection.
1.2 The RS viral genome Sequence analysis of human RS virus strain A2 vRNA (subgroup 
A) shows that the genome is a non-polyadenylated strand, 15,222 nucleotides in length and of 
negative sense (Huang and Wertz, 1982; Collins, 1991; Mink et al., 1991). cDNAs were 
obtained for 10 viral genes, accounting for 97% of the genome (Collins et al., 1984a; Collins 
et al., 1986). These genes generate 10 mRNAs, each encoding a single polypeptide whose 
Mr is consistent with the length of the major translational ORF (Cash et al., 1977; Dubovi, 
1982; Venkatesan et al., 1983; Huang and Wertz, 1982; Collins et al., 1984a; Satake et al., 
1984; Elango etal., 1985b).
1.2.1 RS virus eene start and end sequences Sequences at the gene-start and -end are 
shown in Table 4. in comparison to another pneumovirus, PVM. Each gene has a conserved 
gene-start sequence, 3' GGGGCAAAU 5', that encodes the 5' end of the corresponding 
mRNA. The conserved gene-start signal resembles the SV gene-start signal in length and 
sequence, being preceded by an A residue that remains un-transcribed. The gene-end is a 
semi-conserved 12 to 13 nucleotide sequence (3‘ UC[A.A./cu] U(„-4-7) 5’) which is
similar to other paramyxoviruses, and thought to function as a signal during
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Table 4 Gene start and end sequences of human RS virus and PVM
Gene Gene start sequence Gene en< sequence
human RS virus* PVM human RS virus* PVM
NS1 GGGGCAAAU AGGACAAGU UAGUUAAAU UAGUUAAUU
NS2 GGGGCAAAU AGGAUAAAU UAGUAAUUU UAGUUAUAG
N GGGGCAAAU AGGAUAAAU GAGUUAAU UAUUUAAUU
P GGGGCAAAU AGGACAAAU UAGUUAC UAUUUAAUU
M GGGGCAAAU AGGAUAAAU AAGUUAAU UAGUUAAAU
SH GGGGCAAAU AGGAUAAGU UAGUUAAUU UAGUUAAC
G GGGGCAAAU AGGACAAAU UAGUUACUU UAGUUAAUG
F GGGGCAAAU AGGAUGAGU UAGUUAUAU UAGUUAAUU
22K GGGGCAAAU** AGGACAAAU UAGUUAUU UAGUUAUAU
L GGGACAAAA ND AUCUUAUAAU ND
consensus GGGgCAAAu AGGAuaAaU uAgUuAauu UAgUUAauu
Table 4 Upper case letters denote total conservation of a residue, lower case letters 
identify the most common residue at positions where conservation was not total. * The 
gene start and end sequences are for human RS virus strain A2. ** the L gene start is 
located within the 22K gene. Adapted from (Chambers et al., 1990a). ND denotes that the 
sequence data is unavailable.
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sequential transcription (Spriggs and Collins, 1986b). In mRNA, the complement o f this 
sequence constitutes the 3' end immediately preceding the poly(A) tail. In RS virus the 
gene starts are well conserved but the gene ends show considerable variation, this is in 
contrast to PVM where the gene start and stop sequences are fairly well conserved. 
Human RS vims is unique, having the gene-start of the L gene 68 nucleotides upstream of 
the end of the 22K gene, thus the 22K and the L genes overlap. The L and 22K genes 
encode separate mRNAs with a common 68 nucleotide sequence, coding in the L gene but 
non-coding in 22K. The L gene-start sequence is also slightly different from those of the 
other genes, containing two nucleotide differences (3* CCCHGUUULJ). This overlap is not 
unique to the Paramyxoviridae, an analogous situation exists for the Filovirus Ebola vims 
(Sanchez et al., 1987).
During transcription the polymerase initiates gene transcription at the gene 
start signal (Collins et al., 1986). The gene end signals are believed to cause the viral 
polymerase to stall and, by reiterative copying of short poly(U) tracts, synthesise a poly(A) 
tail. It is believed that no other gene sequences other than those identified as gene start 
and gene end sequences are able to act as structural signals since these are the only regions 
that display conservation between RS vims subgroups (Collins, 1991).
1.2.2 RS virus intereenic regions There are nine short intergenic regions in the RS vims 
genome which vary in length from one nucleotide (the N-P junction) to 52 nucleotides 
(for the G-F junction) and these are considered to be non-specific spacers. RS virus and 
PVM are notable for the lack of length and sequence conservation in the intergenic 
regions, a phenomenon which appears to exist in only one other paramyxovirus, SV5 
(Paterson et al., 1984; Collins and Wertz, 1985c; Hiebert et al., 1985a; Collins et al., 
1985a, 1986). The high level of conservation in the other genera implies that these 
sequences may possess important transcriptional roles. Lack of homology in the
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pneumovirus intergenic regions may indicate a difference in transcriptional function 
compared with the corresponding regions o f many paramyxoviruses.
1.2.3 RS virus leader and trailer regions Sequences at the 3’ and 5’ ends of the 
pneumovirus genome (the leader and trailer) are believed to contain signals involved in 
RNA synthesis. In the RS virus genome, the first gene (NS1) is preceded by a 44- 
nucleotide leader region encoding a short leader RNA that initiates exactly at the 3' vRNA 
end. Human RS virus leader is shorter than other paramyxovirus leader sequences and 
unrelated in sequence, however a feature common to all is their richness in U nucleotides. 
The leader region is thought to encode at least two distinct nucleotide signals (Mink et al., 
1991); 1) the region responsible for binding the polymerase complex prior to RNA 
synthesis and 2) a site responsible for initiating encapsidation of nascent, negative sense 
genome copies (vRNAs). The importance o f the leader region in RNA replication has been 
exemplified by experiments which demonstrated that a single nucleotide substitution in the 
3' leader region can alter the efficiency of transcription (Collins et al., 1991; 1993). 
Mutational analysis of the RS leader has identified at least two regions involved in RNA 
replication (nucleotides #1-10 and #21-26; P.Collins, personal communication).
There is a 155-nucleotide trailer region at the 5' end of the RS virus genome, 
much longer than any other equivalent sequence (54, 40 and 44 in SV, MeV and PIV3), 
however there is some commonality, with the 3'-terminal nucleotide being a U residue. It 
is thought that the last 40 nucleotides are also involved in RNA replication (P.Collins, 
personal communication). In common with other viruses from related groups, the RS virus 
leader and trailer regions show complementarity extending for 21 (of the first 26) 
nucleotides. This complementarity is essential for the RNA synthesis since the 5' trailer of 
the (-) vRNA encodes the 3' leader of the positive sense genome copy (vcRNA) which is 
thought to be functionally analogous to the 3' leader of the vRNA.
1.3 Replication and transcription of negative strand non-segmented gynpme RNA 
viruses
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1.3.1 The replication-competent structure Vesicular stomatitis vims has become the 
model non-segmented negative strand RNA vims due to the knowledge that has been 
amassed concerning its replicative and transcriptive processes. The viral stmcture involved in 
RNA synthesis is the nucleocapsid, containing the polymerase (L), phosphoprotein (NS or P) 
and the nucleocapsid (N or NP) proteins plus the viral RNA. VSV L protein is considered to 
encode all RNA transcriptional activities, namely, ribonucleotide polymerase (De and 
Banerjee, 1985), cap methylase (Hendry et al., 1988b; Hercyk et al., 1988), poly(A) 
polymerase (Hunt et al., 1984) and possibly protein kinase activity that phosphorylates the 
NS protein (equivalent of human RS vims P protein) (Barik and Baneijee, 1991; Bank, 1992; 
Hammond et al., 1992; Beckes and Perrault, 1991). NS protein is required for the synthesis 
of authentic RNA products, suggesting that it functions as a polymerase accessory factor or 
transcriptional activator (De and Banerjee, 1985) and also maintains the N protein in a 
replication competent state. It is thought that this is accomplished by binding to and 
preventing N protein monomers from forming insoluble aggregates which are unable to 
support genome encapsidation (Howard and Wertz, 1989) in the form N-NS (Peluso and 
Moyer, 1988). VSV NS protein is highly phosphorylated with only the fully phosphorylated 
form (NS2) being transcriptionally active (Takacs et al., 1992). Also, VSV L is only able to 
bind to the N-RNA template in the presence of NS protein (Mellon and Emerson, 1978). The 
phosphorylation status of the NS protein was shown to regulate its ability to bind to the N- 
RNA template in the presence of L protein which is a cmcial pre-requisite for RNA synthesis 
(Chattopadhyay and Baneijee, 1987a, and b).
1.3.2 RNA synthesis Kinetic studies have shown that the five VSV mRNA species are 
synthesised in genomic order with quantities decreasing with distance from the transcription 
start site. The model for VSV RNA synthesis (Baneijee, 1987b) is the stop-start model. This 
suggests that the polymerase binds to the genome at the 3' polymerase entry site and initially 
synthesises the leader sequence. The polymerase then re-initiates RNA synthesis at the 
beginning of the N gene and continues until it meets the termination
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signal there adding the poly(A) tail. The polymerase then either dissociates from the 
template or again re-initiates, this time at the beginning of the NS gene and so the process 
goes on. The important feature of this model is that once a polymerase molecule becomes 
removed from the genome, it may only re-attach to the genome at the 3' entry site. In this 
way, 3* proximal genes are abundantly represented by mRNA while 5' proximal genes are 
considerably less so. Initiation of both mRNA transcription and genome replication begins 
when the nucleocapsid complex binds to the 3' end of the genome and begins to synthesise 
the 47 base long leader sequence. Transcription and replication have fundamental 
differences in that genome replication requires concomitant protein synthesis whereas 
transcription does not (Wertz and Levine, 1973). The requirement for ongoing protein 
synthesis is met entirely by synthesis of the nucleocapsid protein (Patton et al., 1984) and 
this led to the postulation of a mechanism for the switch between transcription and 
replication that depended upon the concentration of the N protein (Blumberg et al., 1981). 
This relies upon the ability of the N protein to encapsidate the nascent RNA molecule as it 
is synthesised. The polymerase complex begins to synthesise the positive polarity nascent 
leader RNA to which N protein molecules bind by recognition of an encapsidation signal 
(Blumberg et al., 1983) believed to reside within the first 10 nucleotides of the leader 
sequence, although for optimal encapsidation the first 19 nucleotides are needed (Moyer et 
al., 1990). As the polymerase complex passes down the genome, the growing RNA 
molecule is encapsidated by associating N protein molecules which somehow suppresses a 
transcriptional termination signal thought to be located at the leader-N junction. The 
polymerase complex is thus able to continue RNA synthesis and eventually give rise to a 
full-length anti-genome molecule fully encapsidated in N protein molecules. If N protein 
was not present at an appropriate concentration, the leader RNA species would be 
synthesised but would not be fully encapsidated and consequently the transcription 
termination signal not suppressed, leading to the generation of the 47 base long leader 
sequence. The polymerase would then either exit the genome or re
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initiate transcription at the beginning of the N gene. This model suggests a self-regulating 
system where insufficient N protein stimulates increased mRNA synthesis to produce more 
viral proteins, and excess N protein triggers genome replication which will deplete the 
pool of viral proteins. The existence of negative sense leader sequences supports this 
model since it suggests that the polymerase complex initiating on anti-genomes (which are 
not templates for mRNA synthesis) is able to switch between a mode which makes full- 
length genomes to a mode in which genome synthesis is prematurely terminated at the 
postulated termination site, with the subsequent synthesis of a (-) leader sequence. No 
provision has been made in this model for the role of the VSV matrix protein, which has 
been shown to inhibit transcription of the VSV genome both in vitro and in vivo (Kaptur 
etal., 1991).
The mechanism for paramyxovirus RNA replication is thought to be roughly 
similar to that found in VSV but the process is harder to define. The ability of the 
alternative SV P gene products (Section 1.4.4) to interact with SV nucleocapsid 
components (Yamada et al., 1990; Curran et al., 1992) and influence RNA synthetic 
operations, suggests subtle differences in the mode of RNA synthesis from the VSV 
model. Whilst having no apparent affect on replication, the C proteins are capable of 
causing inhibition of transcription (Curran et al., 1992). Thus there is speculation that the 
C proteins, like N protein, are able to act as transcriptional inhibitors, aiding the switch 
from transcription to replication. Two other products of the SV P gene, namely the V and 
W proteins have been found to act as inhibitors of genome replication (Curran et a!., 
1991a and b) and so perhaps only the P protein is essential for SV RNA synthesis, the 
negative effectors being accessory factors which are dispensable. The suggestion that the 
role played by these proteins is non-essential in the rubulaviruses and paramyxoviruses is 
supported by the finding that members of these genera do not contain a C or V ORF (Lyn 
et al., 1991; Matsuoka et al., 1991). Perhaps the most important difference between the 
RNA synthesis mechanisms of VSV and paramyxoviruses concerns the low abundance of
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leader sequence in the latter (Kolakofsky et al., 1991). In addition, two groups have 
identified large amounts of leader-N readthrough RNAs in MuV-infected cells at an 
abundance 20-fold greater than that found for leader RNA’s (Castadenda and Wong, 
1989; Chan et al., 1989). These results have been interpreted to suggest that the leader 
termination signal is either weak or absent in paramyxoviruses, and that the leader RNAs 
are not an essential operational element for paramyxovirus RNA synthesis (Blumberg et 
al., 1991). Also, cellular factors appear to influence viral mechanisms (Moyer et al., 1986, 
1990; De et al., 1991; Horikami and Moyer, 1991; Leopardi et al., 1993) and because of 
this, the paramyxovirus model does not suppose that all the processes of RNA synthesis 
are mediated exclusively by viral components.
1.3.3 RS virus mRNA transcription The 5' end of each mRNA is the complement of the 
gene-start sequence; the 3' end is the complement of the gene-end signal followed by the 
poly(A) tail. The 5' ends, by analogy to other nonsegmented negative-strand viruses, are 
capped and methylated by viral enzymatic activities associated with the nucleocapsid 
(Emerson, 1985; Kingsbury, 1985; Bank, 1992). The RS viral cap present on mRNA is 
of type cap 0 (only one methylation event) and has the structure "^GiS’jpppiS’jGp..., 
similar to the only other cap identified in a paramyxovirus, NDV (Colonno and Stone, 
1975, 1976). Capping, including methylation, appears to be coupled to transcription. 
Purified RS virus nucleocapsids were shown to be transcriptionally active after the 
addition of mock-infected cell extract (Barik, 1992) which suggested that a cellular factor 
was an obligate requirement of transcription, possibly actin (Huang et al., 1993). 
Polycistronic transcripts have been identified for every gene junction except for the one 
between the SH and G genes. They are present at 5 to 10% the level of individual 
mRNAs, although the polytranscript spanning the G-F gene junction is present at very low 
levels. The reason for this variance is unknown. They are generated by precise 
transcriptional readthrough across intergenic regions, thought to be created by polymerase 
error or by a mechanism similar to readthrough that occurs during vRNA replication. This 
has already been presupposed in RS virus by L gene transcription which initiates within
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the 22K gene, so the polymerase must transcribe across the 22K gene-end signal in order 
to synthesise full-length L mRNA. The most abundant product of L gene transcription is a 
68-nucleotide sequence, called L leader RNA, that initiates at the L gene-start and 
terminates at the 22K gene-end and contains a poly(A) tail. It possesses the first 20 
codons of the L ORF and could encode a short protein (Collins, 1991). Full length L 
mRNA is less abundant and is generated from readthrough of the 22K gene-end signal, 
thus the presence of the gene-end signal within the L gene attenuates synthesis of full- 
length L mRNA.
1.3.4 RS virus mRNA translation For most mRNAs, the translational initiation codon is 
the first methionine codon, a context favoured for efficient translational initiation (Kozak, 
1986). However the SH mRNA has an initiation codon in a unfavourable position (Collins 
and Wertz, 1985b, Johnson and Collins, 1988a) which may allow translation at the second 
AUG in the ORF, resulting in a truncated form of SH. The second exception is the G 
mRNA in which both the first and second AUG initiate translation (Section 1.7.1) (Wertz 
et al., 1985; Satake et al., 1985; Johnson and Collins, 1988a, Roberts et al., 1993; 
Mallipeddi and Samal, 1993). The first AUG initiates a short ORF of 15 to 36 codons, 
depending on the strain of virus, which overlaps the translational start of the major ORF. 
Numerous other short ORFs exist in the RS virus mRNAs but are predominantly strain 
specific and not thought to encode functional polypeptides. However there is a second 
ORF in the 22K gene that is conserved between RS virus strains. This might encode a 
small protein significant for RS virus replication. The second ORF of the 22K protein gene 
overlaps the major ORF and encodes a polypeptide of 90 amino acids with 62% sequence 
identity between strains. The RS virus P mRNA does not contain an internal ORF for a 
cysteine-rich sequence that might be analogous to that of the V proteins of the other 
paramyxoviruses (Cattaneo et al., 1989).
1.4 RS virion structure and functions The virion of RS virus consists of a 
ribonucleoprotein nucleocapsid contained within a lipoprotein envelope (Figure 3).
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Figure 3. Diagrammatic representation of the RS virion.
Virion RNP core
Reproduced by kind permission Dr. J. Randhawa(1993).
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Virions assemble at the plasma membrane of the infected cell and mature by budding, during 
which the intracellular nucleocapsid is packaged within a viral envelope. The envelope 
consists of a cellular membrane, derived by budding out of the host cell, into which are 
inserted the fusion (F) and attachment (G) glycoproteins and there is evidence to indicate that 
the SH protein is also inserted into the membrane (Huang et al., 1985). Positioned under the 
membrane and associated with it, the surface glycoproteins, and the nucleocapsid, lies the 
matrix (M) protein which is thought to play a role in virion assembly and budding out of the 
cell (Bowen and Lyles, 1982). 22K protein appears to be located on the inner face of the 
envelope (Peeples and Levine, 1979; Huang et al., 1985). The nucleocapsid consists of an 
RNA-nuclear protein (RNA-N) template and the RNA polymerase, consisting of L and P 
proteins (Colonno and Stone, 1976; Buetti and Choppin, 1977)(Section 1.3.1),
1.4.1 RS virus nucleocapsid proteins
1.4.2 The large (LI protein The L protein is presumed to be the major polymerase subunit 
responsible for viral transcription and replication (Baneijee, 1987a)(Section 1.3.1), Located 
furthest from the 3' polymerase binding site, mRNA species representing this gene are found 
in least amounts. The protein is basic and relatively hydrophobic, containing 29% 
hydrophobic residues, similar characteristics to the L proteins of the other paramyxoviruses. 
The gene is 6578 bases in size and encodes a protein 2165 residues long, with an estimated 
Mr of 250 kD (Stec et al., 1991). Human RS and bovine RS viruses have the start of the L 
gene located within the 22K gene (Collins, 1991; Stec et al., 1991; Zamora and Samal, 
1992a)(Section 1.2.1), no comparable overlapping L gene ORF is found within the 22K gene 
of other pneumoviruses (Yu et al., 1992a; Ling et al., 1992; A.Easton, personal 
communication). The protein has low overall sequence homology to the other 
paramyxoviruses, with N-terminal and C-terminal regions being poorly related, but there are 
two conserved regions. The first region (residue #775 to #786) has 58% identity with rabies 
virus and 92% identity with the comparable regions of
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the L proteins of SV, PIV3, MeV and NDV (Collins, 1991). The second region (residues 
#810 to #815) has 67% identity with rabies virus and 83% identity with SV, PIV3, MeV, 
NDV and VSV. By analogy with VSV, the pneumovirus L protein would be expected to 
possess equivalent enzymatic activities of mRNA capping, methylation and polyadenylation 
and the ability to act as a protein kinase (Hamaguchi et al., 1983; Hunt et al., 1984; Sanchez 
etal., 1985).
1.4.3 The nucleoprotein INI The function o f the N protein is presumed to be that of a 
template upon which viral RNA polymerase can act (Section 1.3.1), This template is formed 
when the N protein binds to viral RNA. In VSV it would appear that the specificity of the N 
protein for viral RNA occurs if the viral NS (the equivalent of paramyxovirus genus P 
protein) and L proteins are present (Pattnaik and Wertz, 1990). Calain and Roux (1993) 
found that in SV the nucleocapsid needs to contact exactly six nucleotides to form a proper 
template for efficient replication. RS viral N protein is encoded from a gene 1203 bases in 
size, giving a protein 391 residues long with an estimated Mr of 43 kD. It differs from the 
paramyxovirus NP protein and resembles the VSV N protein, being rich in basic amino acids 
and not found in phosphorylated forms (Cash et al., 1979; Collins et al., 1985a; Lambert et 
al., 1988). N protein is the most highly conserved RS virus protein between subgroups (96% 
identity; Johnson and Collins, 1989) however there is antigenic variation in a hydrophilic 
region, which is exposed on the surface of intact nucleocapsids (Ward et al., 1984). Between 
two strains (A2 and RSS-2) of the same subgroup there is very high conservation of amino- 
acids, approximately 99% (C.Pringle, personal communication; Collins, 1991). Comparison 
between human RS virus N protein and PVM N protein shows 60% amino acid identity. 
Homology varies within the protein sequence with 38% identity in the amino-terminal third 
rising to 74% for the remaining amino acids, and in one specific domain (residues #245 to 
315) this homology increases to 97% (Barr et al., 1991). The degree of homology possibly 
accounts for the cross-reactivity observed between human RS virus and PVM N proteins 
(Gimenez et al., 1984; Ling and Pringle, 1989a). Several structural features common to all
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paramyxoviruses have been identified (Barr et al., 1991) and may be relevant for the 
function of the protein. N protein can be cleaved by trypsin treatment into two fragments, 
14 kD and 27 kD. The 27 kD fragment appears to be released or exposed because it can be 
degraded upon further trypsinisation (Ward et al., 1984). This is similar to the NP protein 
of SV which has an N-terminal hydrophobic domain that is trypsin-resistant and a C- 
terminus that is sensitive and hydrophilic.
RS virus N protein accumulates in a cytoplasmic pool followed by association with 
intermediate filaments of the cytoskeleton (Garcia-Barreno et al., 1988). This might 
indicate an association of nucleocapsids with the cytoskeleton which is utilised in the 
replicative cycle as a structural support or transport mechanism (Hamaguchi et al., 1985; 
Bohn et al., 1986). Lambert and Pons (1983) and Huang et al. (1984) observed an 
association between the P and viral nucleocapsids of human RS viruses, Garcia et al. (1993) 
have also demonstrated the presence of N-P complexes in human RS virus infected cells, 
and demonstrated that there was interaction between the N, and the P and 22K proteins. 
Interactions between the nucleoprotein and other viral proteins have been reported for PVM 
(J.Barr, 1994), SV (Lambert and Pons, 1983; Ryan and Kingsbury, 1988; Homann et al.,
1991), and in VSV (Masters and Baneijee, 1988a). N protein is also capable of interacting 
with itself to form aggregates in measles virus (Spehner et al., 1991; Huber et al., 1991; 
Fooks et al., 1993) and SV (Buchholz et al., 1993). In SV there appears to be a 
requirement for NP-P complexes (Horikami et al., 1992) during replication. Investigating 
defective interfering (DI) viruses, they noted that a reduction or increase in expressed NP or 
P proteins inhibited replication of the DI's. Their results suggest that an imbalance in the 
N:P ratio switches polymerase function from replication to transcription.
1.4.4 The phosphoprotein (PI The P protein is acidic, hydrophilic and heavily 
phosphorylated (Cash et al., 1979; Satake et al., 1984; Lambden, 1985; Lambert, 1988). 
Navarro et al. (1991) mapped the sites of the phosphorylated residues in the RS virus P
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protein to the central region of the molecule. The P gene is 914 nucleotides long, giving a 
polypeptide 241 amino acids long with an estimated Mr of 27 kD. RS virus P protein seems 
to share little homology with other P proteins but may have low sequence relatedness with a 
central domain of the P proteins of PIV3 and MeV (Spriggs and Collins, 1986a). 
Comparison of the P protein between the two subgroups of human RS virus shows that 
there are two conserved domains (residues #1 to #58 and #86 to #241) with a total of 96% 
identity, similar to the P proteins of SV and PIV3 which have conserved N- and C-terminal 
domains. Despite an overall 90% identity between strains of the two subgroups the P 
protein shows characteristic (apparent) mobility and antigenic differences between 
subgroups (Mufson et al., 1985; Norrby et al., 1986; Gimenez et al., 1986; Morgan et al., 
1987; Akerlind et al. ,1988; Johnson and Collins, 1990). Pneumovirus P proteins share 
some sequence homology, comparing human RS to bovine RS viruses (35.6%) and human 
RS virus to PVM (28%) with more conserved domains (approximately 64% homology) in 
some regions of the protein. In PVM there is a second, smaller ORF that has the capacity to 
encode a polypeptide 137 amino acids in length. The P protein genes of RS virus and 
TRTV do not possess a second open reading frame (Satake et al., 1984; Lambden, 1985;
A.Easton, personal communication) but the presence of a second ORF in PVM P means 
that P genes with multiple ORFs is not an exclusive property of the paramyxo-.rubula- and 
morbilliviruses.
The P protein has been shown to interact with the nuclear (N or NP) protein in 
several paramyxoviruses including human RS virus (Lambert and Pons, 1983; Huang et al., 
1984; Ryan and Kingsbury, 1988; Baker and Moyer, 1988; Huber et al., 1991; Homman et 
al., 1991; Garcia et al., 1993). At least one region of the P protein of measles virus and the 
NS protein of VSV has been identified as being involved in nucleoprotein interaction, this 
region consists of approximately 40% of the C-terminal region (Gill et al., 1986; Huber et 
al., 1991; Spehner et al., 1991). The N-terminal region of P is thought to be involved in 
RNA binding as demonstrated in SV (Curran et al., 1991a), MeV (Huber et al., 1991) and 
VSV (Gill et al., 1986). The role of the P protein in transcription of human
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RS viral genes has been demonstrated using a ts mutant, and implies a role for the P protein 
in providing specificity for the N-P complex to bind virus specific RNA (Caravokyri et al.,
1992), supported by evidence from VSV (Masters and Baneijee, 1988a and b). The 
pneumoviruses (PVM excepted) encode only one polypeptide from the ORF. The other 
paramyxoviruses are capable of directing the expression of several polypeptide products, 
either utilising other reading frames or switching between ORFs by RNA editing. The 
mechanism of RNA editing has been demonstrated in a number of viruses including SV5 
(Thomas et al., 1988), MeV (Catteneo et al., 1989), SV (Vidal et al., 1990), MuV (Paterson 
and Lamb, 1990; Takeuchi et al., 1990), HPIV-2 (Ohgimoto et al., 1990; Southern et al.,
1990), HPIV-4A and 4B (Kondo etal., 1990), BPIV-3 (Pelet et al., 1991), HPIV-3 (Galinski 
et al., 1992), phocid distemper virus (Blixenkrone-Moller et al., 1992), and NDV (Steward 
et al., 1993). RNA editing activity results in the insertion of non-templated G nucleotides at 
specific sites during transcription of the P gene which causes a frame-shift, thus allowing 
access to alternative reading frames. In addition to the mechanism of RNA editing, many of 
these viruses contain alternative cistrons which are accessed by independent ribosomal 
initiation. The P gene of SV has been particularly well studied and has been found to give rise 
to 8 polypeptides (P, V, C, C’, W, X, Y1 and Y2) by using both expression strategies (Giorgi 
et al., 1983; Shioda et al., 1983; Curran et al., 1991a and b). Hendricks et al. (1993) 
investigating the C protein of SV concluded that differential phosphorylation and the 
potential for modulation of phosphorylation suggested a regulatory role for the C protein. 
Three functional domains have been defined. The N-terminal domain I is highly acidic, with 
domains II and III being basic and thought to be involved in binding to the L protein and the 
NP-RNA template. The model favoured for P protein activation is the phosphorylation 
cascade pathway proposed by Barik and Baneijee, (1991). Unphosphorylated P protein (P0) 
is converted to a phosphorylated (Pi) species by a casein kinase II -like cellular enzyme at 
domains I (Barik and Baneijee, 1992) and domain III (Villanueva etal., 1994).
l.S The membrane-associated proteins
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1.5.1 The matrix (Ml protein for M l) The M protein is a nonglycosylated inner 
component of the viral envelope (Peeples and Levine, 1979; Collins et al., 1984a; Satake and 
Venkatesan, 1984; Huang et al, 1985). The protein is encoded by a gene which is 958 
nucleotides long and generates a protein of 256 amino acids and an estimated Mr of 28 kD. 
The M protein appears to be highly conserved in amino-acid content within subgroup A 
isolates (C.Pringle, personal communication). The M protein is highly basic and occurs as 
multiple electrophoretically-distinct species that differ in intramolecular disulphide bonding 
(Gruber and Levine, 1983). M protein also undergoes phosphorylation involving a subset of 
intracellular proteins (Lambert et al., 1988). Since the M protein of the pneumoviruses is 
smaller than that o f the morbilli- and paramyxoviruses, the functions of human RS virus M 
may possibly be split between the M and 22K proteins. The M proteins of the Morbillivirus 
and Paramyxovirus genera contain a conserved hydrophobic segment in the C-terminal third 
that is thought to be involved in membrane interaction (Satake and Venkatesan, 1984; Bellini 
et al, 1986). RS virus contains a similar region (residue # 192 to #217) that is thought to 
have a similar role (Collins, 1991), however there is little sequence relatedness with the M 
protein of NDV except for a short region of apparent relatedness (residues # 150 to #220 in 
RS virus and residues #120 to #190 in NDV) (Chambers et al, 1986). The M proteins of 
many members o f the family Paramyxoviridae are believed to be involved in functions 
relating to maturation and assembly of the virion. This theory is supported by studies 
indicating that the M protein of members of the family Paramyxoviridae is able to interact 
with the nucleocapsid structure and also itself (Peeples, 1991; Homann et al., 1991; Barge et 
al., 1993). In addition, M protein is able to interact with a variety of cellular components 
such as membrane lipids and cytoskeletal elements (Caldwell arvi Lijlfo;1986; Faaberg and 
Peeples, 1988; Tashiro et al., 1993; Sanderson et al., 1993). Interaction between M and F 
proteins of NDV, and M with F or HN of SV, has also been shown (Peeples and Bratt, 1984; 
Sanderson et al., 1994). Analysis of ts mutants in the M protein of human RS virus have 
shown that viral assembly is inhibited at the non-permissive temperature by increasing 
degradation of the M protein (Caravokyri and Pringle, 1991). Thus it is thought
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that the M protein possibly interacts with F protein which protects the matrix protein from 
degradation by cellular proteases. Additionally, by analogy with VSV and SV, the matrix 
protein o f human RS virus may inhibit host cell and viral transcription by structural hindrance 
of the polymerase as it attempts to pass along the template (Marx et al., 1974; De et al., 
1982; Ogden et al., 1986; Black and Lyles, 1992; Black et al., 1993; Li et al., 1993). The 
ability of VSV M protein to independently bind to membranes (Li et al., 1993) differs from 
the situation in SV where the M protein was found to be unable to associate with membranes 
when expressed on its own (Pattnaik and Wertz, 1991; Sanderson et al., 1993). In either 
paramyxovirus, rubulavirus or morbillivirus systems, demonstration that a definitive physical 
relationship exists between M and H/N (or H) proteins has not yet been reported, although 
the observation that the cellular location of membrane bound M protein appears to be 
determined by the location of the SV glycoproteins suggests that these protein species do 
associate (Sanderson et al., 1993).
1.5.2 The 22K protein for M2) The pneumoviruses are unique in possessing a second non- 
glycosylated membrane-associated protein, 22K. The 22K protein is 194 residues long with 
an estimated Mr of 22 kD, encoded by a gene 961 nucleotides long (slightly larger than that 
found in PVM and TRTV). The amino acid sequence does not contain any region of 
sufficient hydrophobicity to suggest membrane insertion (Collins and Wertz, 1985c; Elango 
et al., 1985b) but 22K is the most basic RS viral protein (Dubovi, 1982; Huang et al., 1985; 
Collins and Wertz, 1985c) and contains three moderately hydrophobic regions which could 
be involved in membrane interactions (Collins and Wertz, 1985c). In infected cells this 
protein is resistant to trypsinisation suggesting an internal location ( Routledge et al., 1987a). 
Studies have shown 22K to be associated with internal structures of human RS virus such as 
the N and P proteins (Routledge et al., 1987a; Garcia et al., 1993; Samal et al., 1993). 22K 
protein appears to co-localise with the N and P proteins in nucleocapsids whereas M protein 
appears to co-localise with F and G at the cell membrane. This would suggest a possible role 
for the 22K protein of indirectly linking
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the N and M proteins. The kinetics o f 22K protein phosphorylation appear to be similar to 
that of the P protein and distinct from the M protein, and seem to co-ordinate with virion 
assembly and release (Lambert et al., 1988). Thus it may be that the 22K protein associates 
with nucleocapsids at an early point in virion assembly, whereas association with M might be 
at a later point that immediately precedes budding. The 22K protein exhibits strain-specific 
variations in apparent mobility and subgroup-specific antigenic differences (Norrby et al., 
1986; Morgan et al., 1987; Routledge et al., 1987b). There appear to be conformational 
variants of 22K possibly due to different disulphide-bond formation (Routledge et al., 1987a, 
b). Human RS viral 22K protein shows considerable amino acid identity to the 22K proteins 
of PVM, bovine RS virus and TRTV, and these three polypeptides have similar 
hydrophobicity profiles which indicates a degree of structural conservation over regions 
where amino acid identity is not strong (Collins and Wertz., 1985c; Ling et al., 1992; Yu et 
al., 1992a; Zamora and Samal, 1992b).
1.5.3 The small hydrophobic (SHI protein for 1A1 The SH gene is 410 nucleotides long 
and encodes a protein of 64 residues. There are four electrophoretically distinct species with 
an estimated Mr of 4.8, 7.5, 13 to 15, and 21 to 30 kD. (Olmsted and Collins, 1989). The Mr
7.5 kD species appears to be the full-length, unglycosylated, unprocessed form. The Ml 4.8 
kD is also unglycosylated and lacks the N-terminal amino acids, due to ribosomes initiating at 
a second AUG methionine codon (met-23 in the amino acid sequence)(Section 1.3.4). The 
other two major forms of the SH protein are glycosylated (Olmsted and Collins, 1989) and 
derived from the Mr 7.5 kD species. Most SH accumulates intracellularly as unglycosylated 
Mr 4.8 kD and Mr 7.5 kD species with the process being independent of other viral proteins 
(Olmsted and Collins, 1989). Glycosylation of SH is thought to be a late event, occurring in 
or beyond the trans-Golgi compartment (Collins and Mottet, 1993). All four forms of SH 
protein appear to be integral membrane proteins with greater stability in membrane 
association than that found in the M and 22K proteins ( Olmsted and Collins, 1989). SH 
protein is expressed at high
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level at the cell surface but does not appear to be secreted (Olmsted and Collins, 1989; 
Collins and Mottet, 1993). Collins and Mottet (1993) have demonstrated that SH 
assembles into homo-oligomers that co-sediment with the F protein tetramer. The C- 
terminus of the Ml 7.5 kD species is trypsin-sensitive and thus extracellular with the N- 
terminus presumably cytoplasmic (Collins and Mottet, 1993). The Mr 7.5 kD and 30 kD 
species are probable structural components of the virion (Huang et al., 1985). The SH 
protein shares 76% homology between the two subgroups, with the two potential 
glycosylation sites and the second methionine codon at position 23 being conserved. 
Within subgroups, SH shows 84% homology, the cytoplasmic and transmembrane regions 
(residues #1 to 41) are highly conserved (89%) but the extracellular domain less so (43%), 
possibly indicative of response to immunological pressure (Collins, 1991; Collins and 
Mottet, 1993). Thus the transmembrane and cytoplasmic domains may have functional 
importance, with the extracellular domain acting as an anchor to fix SH in the membrane. 
A small hydrophobic protein is also found in other paramyxoviruses such as SV5 and 
MuV (44 amino acids and 57 amino acids respectively)(Collins and Wertz, 1985b; Hiebert 
et al., 1985b). There is also a small integral membrane protein in the influenza viruses 
types A and B (the 97-amino acid M2 protein and the 100-amino acid NB 
protein)(Williams and Lamb, 1986; Zebedee and Lamb, 1988). These other viral proteins 
are also inserted in the membrane with the C-terminus orientated extracellularly. One 
hypothesis of SH function is that it forms ion channels, as does the M2 protein of 
Influenza A (Pinto et al., 1992). Experiments reported by Hemingway et al. (IXth 
International Congress of Virology, 1993) suggest that SH plays a critical role in the 
formation of syncytia in an, as of yet, undefined manner.
The nucleotide sequence of the RS virus SH protein gene has revealed the 
presence of four potential N-linked glycosylation sites, with two located at the amino- 
terminal end and two located at the carboxyl-terminal end o f the protein. The predicted 
amino acid sequence of the TRTV SH protein has revealed the presence of a potential N-
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linked glycosylation site and this site is thought to be used (Ling et al., 1992). An additional 
species with a molecular weight of 180 kD was also identified and believed to represent an 
oligomer composed o f four or five cross-linked pentameric subunits. Cane and Pringle,
(1991) analysed the SH gene sequences of twelve RS virus isolates and described 76% 
deduced amino a J J  identity between subgroups A and B, but little variation in deduced 
amino acid homology within the subgroups (93% to 99%). They then used restriction enzyme 
analysis of the SH gene sequence of forty-two isolates obtained from a single epidemic 
season (autumn/winter 1989) and identified at least six different isolate-types of RS virus 
circulating at the same time in the same geographical region. Five of these isolate-types 
(termed SH lineage, abbreviated to SHL) were shown to belong to the subgroup A class of 
RS virus.
1.6 The non-structural proteins
1.6.1 The 1C protein for NS11 The NS1 protein is 139 amino acids in length and is 
encoded by a 532 nucleotide gene located at the 3' end of the genome and is the first gene to 
be transcribed. As a consequence of the 3’ leader proximal position of the NS1 gene, NS1 is 
the most abundant protein in infected cells. However, it has not been detected in the virion. 
The protein has a net charge of -1 at neutral pH and an approximate Mr of 15.6 kD. 
However on SDS-PAGE the NS1 protein has an approximate size of Mr 13.6 kD (J.Evans, 
personal communication). There appears to be the same degree of protein sequence 
conservation both within and between subgroups as is found in the NS2 sequence. An 
association with the M protein has been observed, suggesting that NS1 may be involved in 
maturation (J.Evans, personal communication). PVM NS1 gene has a second open reading 
frame which is accessed by the third AUG codon from the 5' end of the mRNA, and is 
capable of encoding a polypeptide 69 amino acids in length. In addition, the first AUG codon 
of the PVM NS1 gene is followed by a second initiation codon only nine nucleotides 
downstream. Neither o f  these AUGs are in good context for initiation (Kozak, 1986) but it is 
possible that they are both used since two closely migrating forms of the
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NS1 polypeptide are seen in PVM-infected BS-C-1 cells (Ling and Pringle, 1989b). 
Perhaps the poor initiation context for these two in-frame AUG codons allows scanning 
ribosomes to access of the second ORF
1.6.2 The IB protein for NS21 The NS2 gene lies at the 3' end of the genome 
downstream of the first gene, NS1. The protein has a net charge of +6 at neutral pH and 
has an estimated Mr of 14.7 kD, and is 124 amino acid residues in length. It is encoded by 
a gene of 503 nucleotides. The NS2 protein is of basic nature and is present in high 
concentrations in the infected cell, and whilst there is no direct evidence showing that it is 
post-translationally modified, it does appear to have a short half-life and appears to 
undergo conformational change soon after synthesis (J.Evans, personal communication). 
The function of NS2 is not known but it appears to be absent from the virion and this, 
combined with its basic nature, suggests that it could be involved in RNA interactions 
(Collins and Wertz, 1985d). There is very high sequence conservation (approximately 
98%) of the NS2 sequence within subgroup A isolates (J.Evans, personal communication). 
Between subgroups there is slightly less conservation, with amino acid homology 
approximately 87% (Collins, 1991).
1.7 The major surface glycoproteins
1.7.1 The attachment (G1 protein The G protein is one of two main glycoproteins 
found on the surface of the virion (Walsh et al., 1984b; Levine et al., 1987). The G 
protein gene is 923 nucleotides long and encodes a protein of 298 or 292 amino acids 
depending on subgroup (Wertz et al., 1985; Satake et al., 1985; Johnson et al., 1987b; 
Sullender et al., 1990, 1991; Sullender and Wertz, 1991) with an estimated Mr of 84 kD 
to 90 kD. The G protein of PVM is slightly larger (363 amino acids), possibly as a result 
of the acquisition of the region responsible for haemagglutination. Two forms of human 
RS virus G have been observed, one is associated with the virion, the other a soluble form 
(Gs), lacking the first 65 or 74 amino acids which includes the membrane anchor region
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(Hendricks et al., 1988). The Gs protein is synthesised from an internal translation 
initiation site on the same mRNA as the membrane-inserted G protein and appears to be 
cleaved downstream of the AUG. Cleavage is suggested to remove the membrane-anchor 
region, thus preventing retention of the G protein in the cellular membrane and therefore 
allowing secretion to occur (Roberts et al., IXth International Congress o f Virology, 1993; 
Mallipeddi and Samal, 1993).
Full length attachment protein lacks detectable sequence relatedness with its 
counterparts in the other paramyxoviruses, the HN and the H proteins (Spriggs et al., 
1986c),and lacks haemagglutination and neuraminidase activities (Richman et al., 1971). 
The first initiation codon is followed soon after by a termination codon and this 
arrangement of initiation codons is likely to down-regulate expression of G protein as 
scanning ribosomal 40s subunits will probably initiate at the 5' proximal AUG. 
Interestingly, the first AUG of the TRTV G gene is not followed soon after by a 
termination codon, and thus expression of TRTV G may not be down-regulated. However 
down-regulation of TRTV G protein expression relative to other TRTV proteins may 
occur as a consequence of the position of the G gene on the TRTV genome, since in 
TRTV the G gene is further from the 3' proximal promoter region (Yu et al., 1992b) and 
therefore less frequently transcribed. The amino acid sequence of the protein contains a 
single major hydrophobic domain near the N-terminus (residues #38 to #66). This region 
has all the structural information required for membrane insertion and anchoring 
(Hendricks e ta l ,  1987, 1988; Olmsted etal., 1989; Lichtenstein et al., 1991). In common 
with the other paramyxovirus attachment proteins, RS virus G protein is orientated in the 
membrane with the N terminus on the cytoplasmic side and the C-terminus extracellular. G 
protein is heavily modified intracellularly (approximately 60%) by the addition o f both N- 
linked and O-linked carbohydrate, giving a mature form of G with a much larger Mr than 
is predicted (Collins et al., 1984a; Wertz et al., 1985; Hiebert et al., 1985a; Satake et al., 
1985), the presence of O-linked glycosylations being unique to the pneumoviruses in the 
Paramyxoviridae (Collins, 1991). The number and location of N-linked glycosylation sites
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in the G protein are not conserved within or between subgroups (Johnson et al., 1987b) and 
the situation is similar for O-linked glycosylation sites. However these do appear to fall into 
two clusters, one near to the membrane anchor region and the other near to the C-terminus, 
with O-linked sugars divided equally between the two clusters (Olmsted et al., 1989). The 
ectodomain of the G protein, unlike the membrane and intracellular domains, is rich in proline 
residues which disrupt secondary structure and are thought to contribute to P-tums (Chou 
and Fasman, 1978). There is also a high degree of serine and threonine residues in the 
ectodomain, which in other proteins have been shown to contain sites of attachment of O- 
linked sugars when present in proline-rich regions (Hill et al., 1977; Fiat et al., 1980; 
Eckhardt et al., 1987). Thus the extracellular structure of G might be similar to that of mucin 
proteins which share these features with the G protein (Collins, 1991). The high serine and 
threonine content is one of the few conserved features between the G proteins of the two 
subgroups. A second feature is the conservation of the four cysteine residues (Alansari and 
Potgieter, 1993).
Oligomerisation of the G protein can occur as both homo- and hetero- 
oligomerisation. Lambert (1988) described an Mt 175 kD protein consisting of two 
disulphide-bonded G proteins being present on SDS-PAGE under nonreducing conditions, 
and described a purified fraction of G protein which was disulphide bonded to F protein. 
Close association of the attachment and fusion glycoproteins has also been observed in MeV 
(Malvoisin and Wild, 1993). Oligomerisation, O-glycosylation and incorporation of G into 
virions can occur in the absence of N-linked sugars, and even fully unglycosylated G is 
incorporated into virions (Gruber and Levine, 1985a; Femie et al., 1985; Satake et al., 1985; 
Lambert, 1988; Wertz et al., 1989). Also the absence of either type of sugar has a modest 
effect on maturation. However absence o f all glycosylation results in a 10-fold reduction in G 
protein surface expression (Wertz et al., 1989) thus it would appear that both types of sugar 
side-chain contribute in some undefined way to G protein maturation.
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1.7.2 G protein glvcosvlation The method of post-translational processing of the G 
protein remains unclear, but it appears that a glycosylated species (Mr 45 kD) is a major 
intermediate of the mature G protein (Gruber and Levine, 1985a, b; Femie et al., 1985; 
Hendricks et al., 1987, 1988; Wertz et al, 1989). This species is predominantly N-linked 
glycosylated and appears to accumulate prior to migration to the trans-Golgi compartment 
where most of the O-linked sugars are added (Collins and Mottet, 1992). The intracellular 
maturation of G is relatively rapid , with the half-time for mature G formation being 
approximately 15 to 30 minutes (Femie et al., 1985; Gruber and Levine, 1985b). Human 
RS viral G protein may be glycosylated to a greater degree than PVM G protein, with 
carbohydrate increasing the G protein molecular weight by approximately 50 kD 
compared with 20 kD (Ling et al., 1992). The large molecular weight difference attributed 
to O-linked sugars may however be an artefact due to reduced SDS binding on account of 
the O-linked sugars (Collins and Mottet, 1992). Investigations by several groups have 
determined that the N-linked sugars are added co-translationally whereas the O-linked 
sugars are added post-translationally (Femie et al., 1985; Wertz et al., 1989).
1.7.3 G protein variation Akerlind et a/.(1988) attributed variation in SDS-PAGE 
mobility of human RS virus G proteins to strain differences in glycosylation. Sullender et 
al. (1991) and Cane et al. (1991) observed extensive sequence variation among naturally 
occurring isolates. Analysis of the carboxy-terminal third o f the G protein gene of 
subgroup A isolates revealed a region prone to polymerase errors resulting in the insertion 
or deletion of adenosine residues (Cane et al., 1993). Sequence divergence in the G 
proteins of the two subgroups is localised to two large segments (residues #70 to #163 
and residues #177 to 298) that comprise most of the extracellular domain, however the 
overall hydropathic profile remains similar. In contrast the membrane anchor and 
cytoplasmic domains are conserved between subgroups (84% homology) but no 
sequences critical for G protein synthesis and processing have been identified. The 
ectodomain contains a short segment of exact sequence identity between subgroups
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(residues #164 to #176), however this region only shows 50% conservation between bovine 
and ovine G proteins (Alansari and Potgieter, 1993). This region is proposed as a candidate 
for attachment to cellular receptors (Johnson et al., 1987a). The fact that it is not conserved 
between bovine, ovine and human RS virus suggests that it could relate to host specificity 
(Lerch et al., 1991). The cysteine residues are clustered in an amino acid grouping, 14 
residues long, that overlaps the conserved sequence. This is the most hydrophobic region of 
the ectodomain and has fewer potential glycosylation acceptor sites. The region is also 
flanked by hydrophilic regions high in potential carbohydrate acceptor sites. Secondary 
structure predictions define this region as a tight turn between two p-sheets and this sort of 
structure could be stabilised by intramolecular disulphide bonds which would require the 
conservation of the cysteine residues (Collins, 1991). The cysteine-rich region of the 
ectodomain is relatively conserved between subgroups so is thought not to be a factor in the 
inefficiency of cross-subgroup protection; i.e. that it is weakly antigenic. Escape mutants 
raised against Mab c793 which recognises a conserved epitope shared by all human isolates 
(Mufson et al., 1985), were found to have lost one of the four conserved cysteine residues 
(cysteine #182 or #186). Thus losing most of the conserved and subgroup-specific epitopes, 
whilst retaining strain-variable epitopes (Rueda et al., 1994). The adjacent hydrophilic 
domains probably would be antigenic but structural heterogeneity could reduce the efficiency 
o f cross-strain neutralisation. This could be brought about by partial utilisation of O- 
glycosylation sites which could result in an antigenically diverse population of molecules even 
within a genetically homogeneous virus population (Collins, 1991). Epitope mapping using 
synthetic peptides has shown that these flanking hydrophilic domains (amino acids #134 to 
#158 and #174 to #208) are indeed the most reactive peptides in binding to convalescent and 
monoclonal antibodies (Norrby et al., 1987). Experiments by Palomo et al. (1991) ; Garcia- 
Barreno et al. (1989) have demonstrated the crucial role of carbohydrates for evasion of host 
immune responses. Major changes in the carbohydrate content could occur by frame shift 
mutations in the G gene. Characterisation of human RS viral escape mutants against a 
neutralising anti-G monoclonal antibody has produced evidence that most escape mutants do 
indeed arise
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because of frame shift mutations affecting the terminal third of the molecule (Garcia- 
Barreno et al., 1990; Rueda et al., 1991). Frame-shift mutations have also been observed in 
isolates of subgroup B (Sullender et al., 1991). Thus frame shift mutations in the G gene 
could potentially alter the carbohydrate content and lead to changes in antigenicity.
1.7.4 The fusion (F) protein The fusion protein is the second major surface glycoprotein, 
forming a membrane-associated spike which is involved in fusion of the virion to the host 
cell, and is also involved in syncytium formation by fusing neighbouring cells together in 
cell-cell spread of the virus. However the fusion protein when expressed separately does not 
initiate cellular fusion and syncytium formation efficiently and it appears that other viral 
proteins are involved. In vitro expression experiments suggest that the attachment (G) and 
SH proteins are required (Heminway et al., 1994) whereas in MuV, MeV and bovine 
parainfluenza virus 3, the neuraminidase enzyme of the HN glycoprotein is involved in 
modulating cell fusion cytopathology (Waxham and Wolinsky, 1986; Morrison et al., 1991; 
Horvath and Lamb, 1992; Tanabayashi et al., 1992). The F gene is 1901 nucleotides long 
and encodes a protein of 574 amino acids with an estimated Ml 68 kD to 70 kD, from a 
single major ORF which is 1722 nucleotides long. The F protein of human RS virus is 40% 
homologous to the fusion proteins of the other pneumoviruses (Chambers et al., 1992). 
Human RS virus F protein has general structural similarities with the fusion proteins of 
other paramyxoviruses, which form a more closely-related group (Collins et al., 1984b; 
Elango et al., 1985a; Spriggs et al., 1986c; Barrett et al., 1987) but only has low sequence 
homology (<20% ). These similarities include overall length, the location of hydrophobic 
domains and cleavage site and the approximate locations o f carbohydrate side chains and 
cysteine residues.
1.7.5 F protein structure Nucleotide sequence analyses has revealed the presence in the 
inferred protein product of various secondary structural elements that were well conserved 
between the F proteins of all morbilliviruses, rubulaviruses and paramyxoviruses (Chambers 
et al., 1992). Features common to the fusion proteins of all paramyxoviruses
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are illustrated in the generalised RS virus F protein (Figure 4). The F protein contains an 
N-terminal hydrophobic signal peptide that directs cotranslational translocation into the 
rough endoplasmic reticulum, and which is cleaved in the vicinity of amino acids #21 to 
#25. The most hydrophobic domain is located near the C-terminus (amino acids #525 to 
#550) and serves as a stop-transfer signal and membrane anchor, leaving a 24-amino acid 
cytoplasmic domain. The F protein is synthesised as a precursor, Fq, transported to the 
Golgi apparatus via the endoplasmic reticulum during which the signal region is removed, 
and then cleaved by a cellular protease to generate two disulphide-linked subunits, NH2- 
F2 -ss-Fj-COOH (Femie and Germ, 1982; Gruber and Levine, 1983; Huang et al., 1985; 
Gruber and Levine, 1985b; Femie et al., 1985). This feature is characteristic of all 
paramyxoviruses (Choppin and Scheid, 1980). In Sendai virus the disulphide linkage is 
between the single cysteine residue in the F2 subunit (residue #70) and residue #199, the 
most upstream of the cysteine amino acids (Iwata et al., 1994). By analogy with the 
Sendai virus model, disulphide linking of the two subunits of the RS virus fusion protein is 
thought to involve either/or both cysteine residues in the C-terminal domain of the F2 
subunit and the most upstream cysteine (residue #212) of the Fi subunit. Proteolytic 
cleavage occurs following amino acid #136 in human RS virus (Elango et al., 1985a). 
Intracellular cleavage occurs before transport to the trans-Golgi region (Gruber and 
Levine, 1985b; Collins and Mottet, 1991). Like the other paramyxoviruses, cleavage is 
obligatory for fusion activity and is potentially a factor in tissue tropism. Investigations 
into the mechanism responsible for cleavage determined that amino acid changes in the Fi 
subunit (located in the cysteine-rich region or thereabouts) caused loss of F0 cleavage, 
thus alteration of one region of the F protein can influence changes in another that is 
spatially separate, possibly by affecting protein folding (Anderson et al., 1992). 
Investigations by Buckland et al. (1992) determined that amino acid changes in the C- 
terminal region of the F( subunit (in a putative “leucine-zipper” region located adjacent to 
the membrane-anchor) could interfere with the fusion function. The cleavage site of RS 
virus F is highly conserved, with six arginine and lysine residues present, compared to five, 
four, three and one for SV5, MeV, MuV, PIV3 and SV (Galinski and Wechsler, 1991). In
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are illustrated in the generalised RS virus F protein (Figure 4). The F protein contains an 
N-terminal hydrophobic signal peptide that directs cotranslational translocation into the 
rough endoplasmic reticulum, and which is cleaved in the vicinity of amino acids #21 to 
#25. The most hydrophobic domain is located near the C-terminus (amino acids #525 to 
#550) and serves as a stop-transfer signal and membrane anchor, leaving a 24-amino acid 
cytoplasmic domain. The F protein is synthesised as a precursor, Fq, transported to the 
Golgi apparatus via the endoplasmic reticulum during which the signal region is removed, 
and then cleaved by a cellular protease to generate two disulphide-linked subunits, NH2- 
F2 -SS-Fj-COOH (Femie and Gerin, 1982; Gruber and Levine, 1983; Huang et al., 1985; 
Gruber and Levine, 1985b; Femie et al., 1985). This feature is characteristic of all 
paramyxoviruses (Choppin and Scheid, 1980). In Sendai virus the disulphide linkage is 
between the single cysteine residue in the F2 subunit (residue #70) and residue #199, the 
most upstream of the cysteine amino acids (Iwata et al., 1994). By analogy with the 
Sendai virus model, disulphide linking of the two subunits of the RS virus fusion protein is 
thought to involve either/or both cysteine residues in the C-terminal domain of the F2 
subunit and the most upstream cysteine (residue #212) of the Fi subunit. Proteolytic 
cleavage occurs following amino acid #136 in human RS virus (Elango et al., 1985a). 
Intracellular cleavage occurs before transport to the trans-Golgi region (Gruber and 
Levine, 1985b; Collins and Mottet, 1991). Like the other paramyxoviruses, cleavage is 
obligatory for fusion activity and is potentially a factor in tissue tropism. Investigations 
into the mechanism responsible for cleavage determined that amino acid changes in the Fi 
subunit (located in the cysteine-rich region or thereabouts) caused loss of F0 cleavage, 
thus alteration of one region of the F protein can influence changes in another that is 
spatially separate, possibly by affecting protein folding (Anderson et al., 1992). 
Investigations by Buckland et al. (1992) determined that amino acid changes in the C- 
terminal region of the Fi subunit (in a putative “leucine-zipper” region located adjacent to 
the membrane-anchor) could interfere with the fusion function. The cleavage site of RS 
virus F is highly conserved, with six arginine and lysine residues present, compared to five, 
four, three and one for SV5, MeV, MuV, PIV3 and SV (Galinski and Wechsler, 1991). In
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Figure 4. General features of the RS virus fusion protein.
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Diagramatical representation of the generalised RS virus fusion protein. Potential 
N-glycosylation sites are denoted b y l and the variable N-glycosylation site 
denoted by A . Cysteine residues are represented byi . The precise cysteine 
residues involved in disulphide-bonding between subunits are unknown and so are 
not shown. The three hydrophobic domains are highlighted in shaded boxes, whilst 
important structural domains are highlighted in unshaded boxes.
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SV F protein, cleavage of the F0 precursor results in a major conformational change (Hsu 
et al., 1981), as it does also in NDV, where alteration in the cleavage site has an effect on 
pathogenicity (Toyoda et al., 1987; Glickman et al., 1988). In RS virus F protein, 
however, uncleaved F0 is antigenically similar to the cleaved form F2 -Fj . Thus perhaps 
the conformational change is localised to the F2  _F1  junction and does not alter the major 
antigenic sites (Collins, 1991). The N-terminus of Fj, created by cleavage, is hydrophobic 
and thought to initiate fusion by directly interacting with the host cell membrane. The 
sequence of the F ] N-terminus is highly conserved among viruses of the Morbillivirus and 
Paramyxovirus genera but the corresponding sequence in RS virus is distinct. The first 
three residues o f the Fj subunit of all paramyxoviruses are conserved: Phe-X-Gly (Collins 
et al., 1984b; Elango et al., 1985a). However, in some NDV strains the terminal amino 
acid is Leu not Phe, indicating that even this triplet is not obligatory. Also present in the 
N-terminus of F j is a semi-conserved sequence, Gly-Val-Ala, located just downstream of 
the N-terminus in RS virus and present slightly upstream in the other paramyxoviruses. 
However this motif is not exactly conserved within RS virus strains, being Gly-Ile-Ala 
(strains RSS-2 and 18537; subgroups A and B respectively) and Gly-Thr-Ala [( strain 
Long; subgroup A)(Baybutt and Pringle, 1987; Johnson and Collins, 1988b; Lopez et al., 
1988)]. The lack of sequence identity between RS viruses and the other paramyxoviruses 
in this region o f F j may indicate that there is a general requirement only for 
hydrophobicity and that there is an extended unordered or helical structure at the N- 
terminus of Fj. There are five or six potential acceptor sites for N-linked carbohydrate 
within the F protein of RS virus, with estimates of carbohydrate content suggesting that at 
least five are utilised (Collins et al., 1984b). All but one of these sites occur within the F2  
subunit. This suggests that the F2  subunit is weakly antigenic due to either shielding or 
alteration of antigenic sites (Skehel et al., 1984; Elder et al., 1986; Sjoblom et al., 1987) 
and could explain the observation of differences in immunogenicity of F2  compared to Fi 
(Walsh et al., 1985). The carbohydrate side chains are not required for cleavage of F0 or 
the incorporation of F protein into virions (Huang et al., 1983; Lambert, 1988). The 
fusion proteins o f the pneumoviruses are unusual in that their F2  subunits have two or
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three cysteine residues depending on strain, whereas those of morbilli- and 
paramyxoviruses only have one. It is possible that both of these cysteines could be 
involved in disulphide bond formation with the Fj subunit. Another common feature of 
paramyxovirus F proteins is a cysteine-rich region in the Fj subunit (Spriggs et al., 1986c; 
Barrett et al., 1987). In the viruses of the Morbillivirus and Paramyxovirus genera, a 100- 
amino acid domain, which begins approximately 220 residues from the N-terminus of Fj 
and ends approximately 75 residues before the membrane anchor, contains eight cysteine 
residues that are exactly conserved in number and spacing (Galinski and Wechsler, 1991; 
Yu et al., 1991). In RS vims there is an analogous domain that is somewhat distinct: it is 
longer (127 amino acids), begins 176 residues from the N-terminus and ends 85 residues 
before the membrane anchor. It contains 11 cysteine residues and these differ in sequence 
position from the other paramyxoviruses thus giving a different pattern of disulphide 
bonding. However the number and position of cysteine residues is conserved between and 
within subgroups. In Sendai vims the cysteine-rich domain is thought to form internal 
disulphide pairings, giving rise to a bunched secondary structure containing at least two 
tandem cysteine loops (Iwata et al., 1994). The region between the proposed loops in the 
Sendai vims fusion protein is hydrophilic, suggesting that the bunched structure is exposed 
to the molecular surface. This is compatible with the supposition that the cysteine-rich 
domain is recognised by monoclonal antibodies. The situation is thought to be similar for 
the RS vims fusion protein, and epitope mapping has identified a major fusion-inhibiting, 
neutralising epitope to this region of the fusion protein (Section 1.7.8),
The secondary stmcture of a generalised fusion protein for all paramyxoviruses has 
been proposed by Chambers et al. (1992) and this is shown diagramatically in Figure 5. 
The N-terminus of the F2  subunit is separated from the C-terminal helical region (F2 h) by 
a region predicted to form a loop stmcture. The N-terminus of the F j subunit (the fusion- 
related domain) is thought to be involved in the fusogenic activity of the protein. There is 
a sequence of heptad repeats (H) (Chambers et al., 1990b) next to the fusion-related
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Figure 5. Secondary structure of a generalised paramyxovirus fusion protein
outside
inside
COOH
Suggested arrangement of potential a-helices in paramyxovirus F proteins. Proposed 
a-helical regions are shown as rectangles with B-sheet and turn-rich regions as circles. 
The F2-subunit contains one a-helical region (F2h) and one B-sheet region (F2b). The 
F1-subunit contains several a-helical regions: the ftjsion related domain (Fusion): the 
transmembrane domain (TM); an amphipathic alpha-helix region (H); a leucine zipper-like 
domain (Z); and a final a-helical domain (F1h). There are two B-sheet/turn-rich regions: 
the cysteine-rich domain; and a intracellular anchor region (Anc). The inferred disulphide 
bond is denoted by the dotted line between two cysteine residues (c). Reproduced from 
Chambers eta!., (1992).
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domain. Heptad repeats are sequences of amino acids arranged with a seven residue 
periodicity in which positions 1 and 4 are predominantly occupied by small hydrophobic or 
neutral residues. These heptad repeat regions suggest the presence of extended a-helical 
conformations, and there is evidence to suggest that at least in the case of NDV, the H 
region interacts with the F2-subunit (Wang et al., 1992). Downstream of the H region is 
another loop-forming sequence which is followed by a second hydrophobic region with a 
relatively low prediction for a-helix (Fjh). The cysteine-rich domain is predicted to 
possess p-sheet structures, but no overall structure could be determined for this region 
because this region is proline-rich. Located C-terminal of the cysteine-rich domain is 
another hydrophobic heptad repeat sequence region (Z). This is analogous to the leucine 
zipper region of paramyxovirus proteins identified by Buckland and Wild (1989). The 
extreme C-terminus of the F j subunit contains a final hydrophobic domain thought to be 
the membrane anchor region. By specific alteration of residues in the hydrophobic terminal 
domain of paramyxovirus F proteins it has been shown that amino acid changes that 
increase the helical content of this transmembrane region, increase the cell-fusion activity 
of mutant F proteins (Horvath and Lamb, 1992).
Human RS virus F protein can be recovered as a non-covalently linked homodimer 
(2 X F2 -Fi)(Walsh et al., 1985). SV F protein can be isolated as a tetramer of two dimers, 
and this tetramer is thought to be the membrane spike (Sechoy et al., 1987). Given the 
general structural similarities between RS virus and SV F proteins, the higher-order 
structure of RS virus F protein might be similar (Markwell and Fox, 1980; Sechoy et al., 
1987; Ng et al., 1989; Collins and Mottet, 1991). On the other hand RS virus F has been 
isolated as a dimer associated with the G protein monomer (Arumugham et al., 1989). 
This would suggest the possibility that the RS virus F and G proteins are not segregated 
into different spikes (Collins, 1991). Fusogenic activity of the SV5 fusion protein has been 
demonstrated to be dependent on transport of the protein to the cell surface (Horvath and 
Lamb, 1992). The heptad repeat sequence (the H box region) of the Fj subunit has been 
shown to be crucial in fusion protein transport in SV5 (Horvath and Lamb, 1992) and
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NDV (Wang et al., 1992). Anderson et al. (1992) have suggested that cleavage of human 
RS virus F protein can be disrupted by amino acid changes distal to the cleavage site, 
suggesting a conformational change such that the cleavage site is rendered inaccessible to 
host cell proteases. Intracellular processing of human RS virus fusion protein has been 
investigated by comparing the maturation and stability of wild-type F, uncleaved mutant F 
and chimeric F proteins expressed by recombinant vaccinia viruses (Anderson et al., 
1992). They found that mutations at residues #301 (Val to Ala) and #447 (Val to Met) 
resulted in the expression of uncleaved F protein. They also noted that the uncleaved F 
protein was associated with GRP78-BiP in the ER for a longer time than the wild-type F 
protein and that protein transport was inefficient. In addition the uncleaved F protein was 
not recognised by a panel of monoclonal antibodies in ELISA or indirect 
immunofluorescence assays, suggesting that the protein was miss-folded, and as a result 
not transported properly or cleaved.
1.7.6 F protein variation The F proteins of human RS virus subgroup A and B strains 
are highly conserved, exhibiting a high degree of sequence conservation (91%; Collins,
1991). Despite the high degree of sequence conservation there are strain-specific mobility 
differences and some epitopic variation (Mufson et al., 1985; Norrby et al., 1986; Baybutt 
and Pringle, 1987; Johnson and Collins, 1988b). Within the human fusion proteins there 
are two regions of divergence, both occurring in the F2-subunit. The first is the signal 
peptide with only 34% homology, indicating that its function is dependent on 
hydrophobicity rather than amino acid sequence. The second region, amino acids #111 to 
#129, has only 50% identity. Analysis of the fusion proteins of RS virus subgroup A 
strains reveals that there is a higher degree of homology, with strains A2 and RSS-2 
thought to be 98% identical (Baybutt and Pringle, 1987). Their fusion proteins also reveal 
the two regions of divergence identified above, the signal peptide is 79% homologous, but 
the second region, amino acids #111 to #129, has much higher identity of 90% as well as 
containing an extra N-linked glycosylation site found in strain RSS-2 but not in strain A2. 
This region is relatively hydrophilic suggesting that it might be exposed in the folded
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molecule, contributing to a subgroup specific B- or T-cell epitope (Anderson el al., 1985; 
Mufson et al., 1985; Pemberton etal., 1987).
1.7.7 F protein Antigenicity The F protein of RS virus has been shown to be a major 
antigen that efficiently induced serum neutralising antibodies, specific cytotoxic and helper T 
lymphocytes, and a high level of resistance to challenge with homologous virus in rodents and 
monkeys (Olmsted et al., 1986; Bangham and Askonas, 1986; Walsh et al., 1987b; Wertz et 
al., 1987; Pemberton et al., 1987; Wathen et al., 1989). Studies in cotton rats have suggested 
that the F protein is the most important RS virus protective antigen, and the protective 
immunity induced is equally effective against both viral subgroups (Olmsted et al., 1986; 
Johnson et al., 1987a). Immunising mice or cotton rats with recombinant vaccinia viruses 
expressing the fusion protein demonstrated protection against challenge and the induction of 
neutralising antibodies (Olmsted et al., 1986; Walsh et al., 1987b; Wertz et al., 1987). By 
analogy to PIV-3, the degree of F protein glycosylation is not thought to be relevant in order 
to elicit a protective response (Ewasyshyn et al., 1993).
1.7.8 F protein B-cell epitopes Three functional types of monoclonal antibody that bind to 
the F protein have been described using in vitro assays (Walsh et al., 1987a). These consist of 
1) non-neutralising, non-fusion-inhibiting antibody; 2) neutralising, non-fusion-inhibiting 
antibody; and 3) neutralising, fusion-inhibiting antibody. However the situation is far from 
clear cut, with all monoclonal antibodies that are fusion inhibiting able to neutralise virus but 
not vice-versa, and not all neutralising monoclonal antibodies able to protect mice by passive 
immunisation (Taylor et al., 1984; Walsh et al., 1989). It is thought that fusion inhibition 
correlates with protection but protection has been described with monoclonal antibodies that 
are neither neutralising nor fusion-inhibiting; and monoclonal antibodies that are neutralising 
but not fusion-inhibiting (Taylor et al., 1992). The F protein has been mapped using sets of 
functionally defined murine monoclonal antibodies in competitive binding assays to define 
topological relationships between
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antigenic areas. At least three antigenic areas have been defined by this method (A, B and 
C) all of which have been found to bind neutralising monoclonal antibodies, and one of 
which includes fusion-inhibiting monoclonal antibodies (antigenic area #IV) (Walsh et al., 
1987a; Anderson et al., 1986; Trudel et al., 1987a and b; Beeler and Van Wyke- 
Coelingh, 1989; Garcia-Barreno et al, 1989). Initially it was supposed that three of the 
four antigenic areas were partially inter-related, leaving one independent fusion-inhibiting 
antigenic area (Walsh et al., 1987a; Trudel et a l., 1987a and b; Garcia-Barreno et al., 
1989; Beeler and Van Wyke-Coelingh, 1989; Trudel et al., 1991). It is now thought that 
the antigenic areas of the neutralising, non-fusion-inhibiting monoclonal antibodies overlap 
with the fusion-inhibiting site (Walsh et al., 1987b; Beeler and Van Wyke-Coelingh, 
1989; Taylor et al., 1992). In terms of epitopes on the fusion protein, the neutralising and 
fusion-inhibiting antibodies map to two specific regions, the cysteine-rich region and a 
second region downstream of the fusion-related domain (Martin-Gallardo et al., 1991; 
Arbiza etal., 1992; Lounsbach et al., 1993).
Positional mapping of the B cell epitopes using peptide analysis has revealed a 
major binding site of an RS virus neutralising non-fusion-inhibiting monoclonal antibody 
(antigenic area #1) at positions #205 to #236 (Trudel et al., 1987a and b; Trudel et al., 
1991; Bourgeois et al., 1991). Peptides that corresponded to amino acids #205 to #225 
were able to induce a neutralising antibody response in rabbits. Polyclonal anti-RS virus 
rabbit antiserum loses neutralising capacity when reacted with this peptide. However it 
also lost neutralising capacity when reacted with a peptide corresponding to amino acids 
#259 to #278 (Bourgeois et al., 1991; Trudel et a l., 1991); this region has been defined as 
antigenic area #11 (#255 to #288)(Trudel et al., 1991; Arbiza et al., 1992; Lounsbach et 
al., 1993). A third antigenic area has been mapped between amino acids #283 to #298 
(Martin-Gallardo et al., 1991; Paradiso et al., 1991). The fourth antigenic region has been 
mapped to amino acids #417 to #450 (Scopes et al., 1990; Arbiza et al., 1992). Epitope 
maps are summarised in Table 5. There is some uncertainty using peptide mapping
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Figure 6. Location of epitopes in the RS virus fusion protein.
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Map of the B- and T-cell epitopes and antigenic sites. B-cell epitopes are 
shown as B #l -IV, representing antigenic areas #l to #IV. The T-cell epitope 
is shown as T1. The potential regions of structural interaction in the folded 
protein are shown linked by a dotted line.
Table 5 Summary of Fusion protein epitopes
Antigenic areas Residue # Antibody Group Reference
B-Cell Epitopes
I 205 236 Group A Brideau e t aL, 1991
n 255 -> 288 Group A Lopez et aL, 1990
hi 283 -» 298 Group A Martin-Gallardo et aL, 1991
IV 417 -► 450 Group C Scopes e t aL, 1990
T-Cell Epitopes
#1 338—>355 n.a. Levely e t aL, 1991
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techniques in defining an antigenic region since the peptide could be just a small linear part of 
a complex antigenic site. For instance one monoclonal antibody (MAb L4) shows a 100-fold 
greater binding efficiency to F in dimer form than to reduced F j . This suggests that its native 
antigenic site is conformational (Paradiso et al., 1991).
An alternative method to epitope mapping is to raise monoclonal antibody-resistant 
escape mutant viruses and map the base changes that have occurred. Escape mutants raised 
against monoclonal antibodies that are in the same competitive binding assay group have 
shown sequence alterations at amino acids #262, #268 or #272 (Trudel et al., 1987a and b; 
Garcia-Barreno et al., 1989; Arbiza et al., 1992). However mutant viruses with alterations at 
#268 and #272 are also resistant to the binding of a non-neutralising monoclonal antibody. 
Thus the area between amino acids #262 and #272 must be involved in more than one 
functional epitope. Changes at amino acids #268 and #272 prevent the binding of a 
monoclonal antibody that has been mapped to amino acids #222 to #232 (antigenic area #1). 
However escape mutant viruses raised to this monoclonal antibody had two amino acid 
changes at #190 and #258. This suggests that the two linear regions around antigenic area #1 
(#222 to #232) and antigenic area #11 (#259 to #278) could be involved in a conformational 
epitope (Arbiza et al., 1992; Lopez et al., 1993). Evidence supporting the existance of a large 
antigenic site consisting of two or more antigenic areas was reported by Trudel et al., (1991) 
who found that Mab 7C2 reacted with peptides containing regions #221 to #232 (antigenic 
area #1) and also containing regions #275 to #288 which overlap antigenic areas #11 and #111. 
Other escape mutant viruses exhibited changes at amino acid #429 (Arbiza et al. 1992), 
confirming the mapping of antigenic area #IV at this region as defined by Scopes et al., 
(1990). This region could be the independent fusion-inhibiting antigenic site described by 
Beeler and Van Wyke-Coelingh (1989); Garcia-Barreno etal. (1989); Trudel et al. (1991).
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1.7.9 F protein T-cell epitopes RS virus infection in humans and in experimental animals 
induces a vigorous cell-mediated response. Target proteins for RS virus-specific cytotoxic T 
lymphocytes include the fusion protein (Pemberton et al., 1987; Nicholas et al., 1990; 
Leverly et al., 1991; Cherrie et al., 1992; Connors et al., 1992). Peptide scanning of the 
fusion protein has identified an immunodominant T-cell epitope spanning residues #338 to 
#355 on the Fi subunit (see Figure 6). The response appears to be MHC class 2 restricted 
and mediated by the CD4+ subset of T cells (Leverly et al., 1991). Similar studies carried out 
in BALB/c mice identified the immunodominant T-cell epitope as spanning residues #51 to 
#65 on the F2-subunit. It is therefore possible that recognition of different regions of the 
fusion protein by T cells from humans and mice results from differences in the nature of 
exposure to antigen.
1.8 RS virus immunobiology Neutralising antibody is only partially effective in providing 
protection since repeated infections occur and not until the third infection is there an 
appreciable reduction in the severity of RS virus disease in children (Hall, 1980). Re-infection 
may thus be necessary to elicit substantial immunity since there is a pattern of gradually 
increasing levels of serum antibody with successive infections (Stott and Taylor, 1985). The 
epidemic pattern may be similar to the antigenic drift observed in the haemagglutinin (HA) 
and neuraminidase (NA) of Influenza A virus isolates (White and Fenner, 1986), suggesting 
some immunological pressure (Nagai et al., 1993). Both serum and secretory antibodies are 
produced upon RS virus infection with higher levels of protection in mice conferred by anti-F 
rather than anti-G antibodies (Stott et al., 1986; Olmsted et al., 1986; Johnson et al., 1987a; 
Walsh et al., 1987b).
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Both subgroup A and B strains are known to co-circulate within the same community 
(Mufson et al., 1988; Hendry et al., 1989), thus the immune response may vary depending on 
the strain or subgroup exposure. Anti-G antibodies have been demonstrated to be 13-fold less 
effective against heterologous subgroup challenge than against homologous challenge 
(Johnson et al., 1987a; Stott et al., 1987), with a possible explanation lying in the sequence 
variation of the G gene (Cane and Pringle, 1992). The role of T-cell immunity is less clear, 
but cross-reactive RS virus-specific murine cytotoxic T cells have been identified which 
probably recognise a conserved internal viral antigen which is thought to be the 22K protein 
(Openshaw et al., 1988; Connors et al. 1992).
1.8.1 The humoral response to RS viral infection Studies in mice have demonstrated that 
antibodies to the F and G proteins neutralise RS virus infectivity, and have also shown that 
passively transferred monoclonal antibodies to G or F protect animals from lower respiratory 
tract infection (Taylor et al., 1984; Walsh et al., 1984a). However, in human infants 
maternally derived antibodies can decrease antibody response to RS viral glycoproteins G and 
F (Murphy et al., 1986). Murphy et al. (1988) have showed that cotton rat RS virus 
hyperimmune antiserum suppresses the antibody response to RS viral F and G and renders 
the rats more susceptible to RS viral infection. Also immunosuppressed animals developed F 
and G antibodies with low neutralising activities. Thus pre-existing serum RS virus antibodies 
have a quantitative and qualitative effect on the immune response to RS viral infection. This 
evidence is also supported by work by Popow-Kraupp et al. (1989) and Ward et al. (1983). 
The F and G proteins have been demonstrated to give a strong, lasting protective humoral 
response when maternal antibodies are absent (Olmsted et al., 1986; Stott et al., 1986; Wertz 
et al., 1987). On the other hand the P, M, SH, NS1 and NS2 proteins are shown to give 
weak antibody responses (Taylor et al., 1984; Connors et al., 1992), whilst any protection 
derived from the N and 22K proteins appears to be short-lived (Connors et al., 1992). The 
degree to which the F and G proteins contribute to protection against RS virus infection 
indicates that both contribute significantly towards immunity (Brideau et al., 1989). However
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this result highlights the difficulties in designing a vaccine to RS virus, because whilst the F 
protein is well conserved between subgroups (Collins et al., 1984b; Elango et al., 1985a; 
Baybutt and Pringle, 1987; Johnson and Collins, 1988b) the G protein shows significant 
differences both within and between subgroups (Anderson et al., 1985; Akerlind et al., 
1988; Garcia-Barreno et al., 1989; Sullender et al., 1991; Cane et al., 1991).
1.8.2 Cell-mediated response to RS viral infection Cannon et al. (1989) suggest that the 
level of the Tc response is critical, although the T„ response clears viral infection, an 
excessive response could play a role in the pathogenesis of infantile bronchiolitis and/or 
pneumonia. Work by Ananaba and Anderson (1991) supports this view. The Th response to 
specific viral proteins in BALB/c mice has been investigated, using vaccinia expressing 
recombinants, and it has been observed that there is a good response to F and N but a weak 
response to G (Openshaw et al., 1988). There was no apparent recognition of expressed SH 
and NS2 proteins. Nicholas et al. (1990) further investigated and found that 22K was the 
major target protein for the CD8+ cytotoxic T lymphocytes. Immunodeficient children are 
at high risk of complicated, prolonged and fatal RS virus infections probably because of 
defective cellular immunity (McIntosh and Fishaut, 1980). Welliver et al. (1985) noted that 
children recovering from RS bronchiolitis had reduced CD8+ levels in their peripheral 
blood. Other indicators of the importance of cellular responses are that the transfer of 
primed T cells to persistently infected immunodeficient mice will lead to rapid viral 
clearance in the absence o f antibodies (Cannon et al., 1987). However as with the case for 
the humoral response, the situation is far from clear-cut, murine Tc cells have been shown 
to recognise different antigenic subtypes of RS virus (Bangham and Askonas, 1986; 
Openshaw et al., 1988). Cherrie et al. (1992) found that whilst the T-cell response in 
humans to RS viral proteins proceeded in the order N > S H > F > M > 2 2 K ,  the level of 
recognition of F and 22K was proportional to increased levels of serum IgG, indicative of 
recent RS virus infection. Connors et al. (1992) concluded that resistance to RS virus
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infection in mice is mediated by CD8+ T cells recognising the 22K protein, but was also 
mediated by antibodies recognising F and G.
1.9 Vaccine development RS virus is the major cause of severe lower respiratory tract 
infections in children during the first year of life (Kim e t al., 1973a; Stott e t a l., 1980). The 
presence of serum neutralising antibody however, does not prevent reinfection which can 
occur throughout life at roughly 36-month intervals (Hall et al., 1980). The identification of 
discrete isolate types within RS virus subgroups (Section 1.1.2) has suggested that antigenic 
variation is sufficient to be a determining factor in reinfection (Hendry e t al., 1988a, 1989; 
Mufson e t al., 1988; Breese-Hall et a l., 1990, Cane e t al., 1991; Anderson e t a l., 1991).
Difficulties have been encountered in the development of vaccines for children. 
Inactivated vaccine was considered undesirable due to results where a formalin-inactivated 
RS virus vaccine administered to children not only failed to protect, but exacerbated the 
disease response on exposure to virus (Chin et al., 1969; Kim et al., 1969; Kapikian e t al., 
1969). It is thought that the formalin-inactivation modified some of the epitopes on RS virus 
F and/or G glycoproteins so that immunisation resulted in an unbalanced immune response, 
producing non-neutralising antibodies which may have contributed to an Arthus-type 
reaction. After these results, interest in vaccine development moved to the use of attenuated 
virus vaccines. Local immunity is thought to play an major role in resistance to illness, 
consequently a live attenuated virus restricted to replicating in the upper respiratory tract 
without producing disease was thought to be desirable because lower respiratory tract 
diseases are the main cause of mortality and severe disease, usually manifesting as 
bronchiolitis or pneumonia. Temperature-sensitive mutants that are attenuated and have 
growth restricted to the upper respiratory tract have been derived for many members of the 
Param yxoviridae  (Wright e t al., 1973; Portner e t al., 1974; Tsipis and Bratt, 1976). 
Temperature-sensitive mutants have been derived from subgroup A RS viruses, the A2 wild- 
type strain, after treatment with 5-fluorouridine and S-fiuorouracil
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(Gharpure e t al., 1969) and from the RSS-2 wild-type strain after treatment with 5- 
fluorouracil and ICR compounds (McKay e t al., 1988), and from the RSN-2 strain of 
subgroup B (Faulkner et al., 1976). Temperature-sensitive mutants derived from the A2 
strain have been classified into 3 complementation groups , A (toAl), B(toA2) and C 
(toA7) (Gharpure e t al., 1969; Richardson et al., 1977; Belshe et al., 1977, 1978; Gimenez 
and Pringle, 1978; Pringle et al., 1981), all seemingly having a maturation defect defined 
by reduced surface antigen as detected by immunoflourescence and SDS-PAGE. Two of 
these ts mutants, toAl and toA2, have been tested as potential live vaccines. The toAl 
mutant did not produce any symptoms when administered intranasally to adult volunteers 
and was found to be genetically stable, inducing resistance to challenge with the wild-type 
virus (Wright et al., 1971). However problems occurred when toAl was inoculated into 
sero-negative infants because genetically altered revertant viruses were recovered. Also 
some sero-negative children developed mild symptoms of disease (Kim e t al., 1973b). 
These revertants emerged late in infection and presented a complex pattern of mainly 
partial (90%) and some full (10%) revertants (Hodes et al., 1974). Attempts to produce 
more stable mutants were undertaken by isolating second-stage mutant clones of toAl 
after exposure to nitrosoguanidine (Richardson e ta l ., 1977), however these were found to 
be over attenuated (Belshe et a l., 1978). Trials with toA2 showed that this mutant was 
unsuitable as a candidate vaccine due to low infectivity when administered intranasally; 
however it did appear to be genetically stable (Wright et al., 1982).
Another candidate vaccine has been developed as a third-stage ts mutant (tolC) of 
the RSS-2 strain, which has been derived entirely in human diploid cells (MRC-5). A high 
level of protection against wild-type challenge with low disease-inducing capacity was 
observed in preliminary trials in adult volunteers (McKay e t al., 1988; Watt e t a l., 199Q 
Pringle e t al., 1993). Mutant tolC was sequentially derived from the wild-type RSS-2 
strain via the intermediate viruses tol A and to IB, using different mutagenising agents. The 
three mutants tol A, tolB and tolC have restrictive temperatures of 39°C, 38°C and 37°C 
respectively (McKay et al., 1988; Pringle e t al., 1993). The use of different mutagens to
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obtain a triple ts mutant was designed to lessen the likely-hood of loss of temperature- 
sensitivity by reversion. All three mutant viruses have RNA positive phenotypes and 
synthesise viral polypeptides intracellularly at their non-permissive temperatures. The single 
mutant Ml A, when administered intranasally in low dose to adult volunteers, reduced 
disease-inducing potential in comparison to the wild-type virus RSS-2 but produced a poor 
immune response. The double (mIB) and triple (MIC) mutants, however, gave the greatest 
reduction in disease-inducing potential with approximately equal levels of immunogenicity 
(Pringle et al., 1993).
Another approach to vaccine development adopted in recent years is that of 
administering purified fusion (F) or attachment (G) glycoproteins. The role of RS virus 
proteins in the immune response has been described previously (Section 1.8). Merz et al. 
(1980) suggested that a successful subunit vaccine should induce antibody to inhibit fusion 
activity but also induce a balanced immune response. Consequently, immunisation with a 
fragment of the F protein able to induce both neutralising and fusion-inhibiting antibody 
responses might constitute a safe and effective vaccine. RS virus F and G glycoproteins 
have been expressed in a variety of systems such as vaccinia virus recombinants (Olmsted et 
al., 1986; Stott et al., 1986), baculovirus vectors (Wathen et al., 1989), bacterial systems 
such as expression in E.coli (Lounsbach et al., 1993) and mammalian cells (Belshe et al.,
1993). Protection against RS virus infection has been achieved by immunisation of Cotton 
rats with F or G proteins (Stott et al., 1986; Walsh et al., 1987b) or with chimaeric 
proteins consisting of both F and G sequences (Brideau et al., 1989) but the nature of the 
protective immune response remains to be clearly defined.
1.10 Objectives of this study The primary question to be examined by this study is 
whether variation in the fusion gene products of human RS virus subgroup A isolates is 
greater than that previously reported for subgroup A strains A2, RSS-2, Long and 
Edinburgh (Chapter 3). It is thought that sequence variation in the fusion gene product 
could provide a basis for antigenic variation within a specific subgroup of human RS
viruses. Therefore providing a possible explanation for reinfection with RS virus in human 
adults.
Secondary goals are to establish the location and nature of the ts lesions in the 
candidate vaccine strains /sAl (Chapter 4) and candidate vaccine strain £slC (Chapter 
5). It is also hoped to provide an explanation for the complex nature of reversion of 
mutant ¿sAl to non-ts phenotype.
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CHAPTER TWO
Materials and methods
2.1 CELLS AND VIRUSES
2.1.1 Mammalian cells MRC-5 and BS-C-1 G23 cells were provided by Professor C .R. 
Pringle (University o f Warwick) and grown in GMEM 5% FCS. The 293 cell line 
(Graham and Van der Eb, 1973) was provided by Dr. C. Caravokyri (University of 
Warwick) and grown in DMEM 10% Calf serum. All cells were grown in a humidified 
incubator at 37°C under 5 % CO2
2.1.2 Viruses RS virus strains A2 and RSS-2 (and their ts mutants) were obtained from 
Professor C. R. Pringle. The A2 wild-type and its mutant teAl were originally isolated by 
Dr. R. Chanock (NIH, Maryland, USA). Strain RSS-2 was originally isolated by Professor 
P. Gardner (University of Newcastle). Mutants tel A, telB and telC were originally 
isolated by McKay et al., (1988). Virus strains RSB89-6190; RSB89-5857; RSB89-6256; 
RSB89-6614 and RSB89-1734 (subgroup A isolates) were provided by Dr. P. Cane 
(University of Warwick) and were isolated from nasopharyngeal aspirates (Cane and 
Pringle., 1991).
Culture media, trypsin, versene, agar, neutral red, amino acids and antibiotic solutions, 
PBS and double distilled water were provided by the Virus Group media preparation 
laboratory.
2.1.3 Materials All solutions described in this chapter show compounds along-side their 
final concentrations.
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Crystal violet stain Stock solution of 1.5% (w/v) crystal violet dissolved in ethanol was 
made, then diluted 1 in 40 with water before use. This was stored at ambient temperature.
Glasgow modification of Eagle’s medium (GMEMi Eagle’s minimum enabled medium 
was supplemented with non-essential amino acids as described previously in McKay et al., 
(1988), plus the following at the final concentrations given; 0.2 mM glutamine, 100 
units/ml penicillin, 100 (ig/ml streptomycin and 5% or 10% (v/v) bovine FCS. This was 
sterilised by filtration and stored at 4°C.
Dulbeco's modification of Eagles medium fDMEMl Eagle’s minimum enabled medium 
was supplemented with non-essential amino acids as described previously Graham and 
Van der Eb (1973), plus the following at the final concentrations given; 0.2 mM 
glutamine, 100 units/ml penicillin, 100 pg/ml streptomycin and 10 % (v/v) bovine calf 
serum. This was sterilised by filtration and stored at 4°C.
Overlay agar An equal volume of double strength supplemented GMEM was added to 
melted Noble agar (1.8%) which had been cooled to 46°C. The overlay was maintained at 
46°C until used.
Glutaraldehvde A working solution of 1% (v/v) glutaraldehyde in PBS was prepared and 
stored at ambient temperature until use.
Neutral red overlay 5 ml of a neutral red stock solution (0.1% w/v) was added to 200 ml 
overlay agar and maintained at 46°C until needed.
Versene Solutions consisting of 0.02% (w/v) EDTA (disodium salt) and 0.002% (w/v) 
phenol red in PBS pH 7.4 were prepared and stored at ambient temperature.
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TD Solutions consisting of 0.14 M sodium chloride, 5 mM potassium chloride, 0.5 mM 
di-sodium orthophosphate and 25 mM Tris were prepared and adjusted to pH 7.5 with 
concentrated hydrochloric acid. Solutions were then autoclaved and stored at ambient 
temperature.
TDE Solutions were prepared from TD solution by the addition of 0.2 ml 0.25 M 
EDTA/100 ml pH 8.0, sterilised by autoclaving and kept at ambient temperature until use.
Foetal calf serum from Gibco BRL (Gaithesburg, U S A) and tissue culture plastic-ware 
were from Northumbria Biologicals (Northumberland, U.K.). Crystal violet was from 
Sigma (St.Louis, U.S.A.) and glutaraldehyde from BDH (Poole, U K ).
2.1.4 Cell culture BS-C-1 G23 and MRC-5 cells were grown in 175 cm^ tissue-culture 
flasks in supplemented GMEM 5% FCS at 37°C and passaged at 3 to 4 day-intervals. 
Cells were washed with 20 ml versene twice and once with 20 ml trypsin/versene (1 in 5, 
v/v). A small amount of the latter was left in the flask for further incubation at 37°C, until 
all the cells became detached from the flask surface. The cell suspension was then diluted 
with supplemented GMEM containing 5% FCS and one-tenth aliquots were pipetted into 
new flasks and fresh 50 ml GMEM 5% FCS added.
293 cells were grown in 90 mm2 tissue culture Petri-dishes in supplemented DMEM 
containing 10% Calf serum at 37°C and passaged at 3 day-intervals. Cells were washed 
once with TD and then removed from the monolayer with 2 ml TDE and 0.2 ml trypsin. 
The cell suspension was added to 0.5 ml Calf serum, pelleted at 10,000 x g for 5 minutes 
and the pellet resuspended in 10 ml supplemented DMEM. One-fifth aliquots were then 
pipetted into new dishes.
2.1.5 Preparation of virus stocks Confluent monolayers of either MRC-5 or BS-C-1 
G23 cells in 25 cm^ tissue-culture flasks were inoculated with 200 pi virus (m.o.i. of
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approximately 1 pfu/cell), placed at 33°C for one hour, and 5 ml supplemented GMEM 
containing 5% FCS added. Cells were then incubated at 33°C until 80% CPE was 
observed. Virus was harvested by immediate freezing of infected cells at -70°C.
2.1.6 Viral titre Confluent MRC-5 or BS-C-1 G23 cells were infected with 200 pi viral 
stock (m.o.i. of approximately 1 pfu/cell) through a dilution series down to 10‘®. The cells 
were then incubated at 33°C for 1 hr and the supernatant removed. 2.5 ml of overlay agar 
was then added and the cells incubated at 33°C until syncytia observed. The cells were 
fixed by adding 1% glutaraldehyde solution onto the agar overnight. The agar was then 
removed. The cells were then stained with crystal violet for 5 minutes at room temperature 
and excess stain removed by washing with water. Plaques were then counted under a light 
microscope.
2.1.7 Selection of ts revertants BS-C-1 G23 cells were infected with 200 pi viral stock 
(m.o.i. of approximately 1 pfu/cell) through a dilution series down to 10"3 as described for 
viral titres. Cells were then incubated for 7 days at the non-permissive temperature of 
39°C. Cells were stained overnight with 2 ml neutral red overlay placed on top of the agar 
overlay. Viral plaques were identified , removed using a sterile Pasteur pipette and viral 
stocks grown at 39°C. The revertant viruses were plaque purified a further two times 
using the above procedure.
2.2 ANALYSIS OF VIRAL PROTEINS
All chemicals mentioned in this and subsequent sections were obtained from BDH 
(unless otherwise stated) and were of AnalaR grade. Radioisotopes for protein labelling, 
the fluorographic agent Amplify™, biotinylated anti-human and anti-bovine IgG, 
biotinylated peroxidase-streptavidin complex, biotinylated fluorescein-streptavidin 
complex and nitro-cellulose (Hybond-C) were purchased from Amersham International 
pic. Protein markers were obtained from Sigma. X-ray films were from Fuji Photo Film
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approximately 1 pfu/cell), placed at 33°C for one hour, and 5 ml supplemented GMEM 
containing 5% FCS added. Cells were then incubated at 33°C until 80% CPE was 
observed. Virus was harvested by immediate freezing of infected cells at -70°C.
2.1.6 Viral titre Confluent MRC-5 or BS-C-1 G23 cells were infected with 200 pi viral 
stock (m.o.i. of approximately 1 pfu/cell) through a dilution series down to 10"6. The cells 
were then incubated at 33°C for 1 hr and the supernatant removed. 2.5 ml of overlay agar 
was then added and the cells incubated at 33°C until syncytia observed. The cells were 
fixed by adding 1% glutaraldehyde solution onto the agar overnight. The agar was then 
removed. The cells were then stained with crystal violet for 5 minutes at room temperature 
and excess stain removed by washing with water. Plaques were then counted under a light 
microscope.
2.1.7 Selection of ts revertants BS-C-1 G23 cells were infected with 200 pi viral stock 
(m.o.i. of approximately 1 pfu/cell) through a dilution series down to 1 0 '-* as described for 
viral titres. Cells were then incubated for 7 days at the non-permissive temperature of 
39°C. Cells were stained overnight with 2 ml neutral red overlay placed on top of the agar 
overlay. Viral plaques were identified , removed using a sterile Pasteur pipette and viral 
stocks grown at 39°C. The revertant viruses were plaque purified a further two times 
using the above procedure.
2.2 ANALYSIS OF VIRAL PROTEINS
All chemicals mentioned in this and subsequent sections were obtained from BDH 
(unless otherwise stated) and were of AnalaR grade. Radioisotopes for protein labelling, 
the fluorographic agent Amplify™, biotinylated anti-human and anti-bovine IgG, 
biotinylated peroxidase-streptavidin complex, biotinylated fluorescein-streptavidin 
complex and nitro-cellulose (Hybond-C) were purchased from Amersham International 
pic. Protein markers were obtained from Sigma. X-ray films were from Fuji Photo Film
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Co.(Japan). The monoclonal antibodies used in the subsequent experiments were a kind gift 
from Drs.E.Ndrrby and C.Orvell (Karolinska Institute, Stockholm, Sweden). Polyclonal 
bovine anti-human anti-RS serum was provided by Drs. Stott and Taylor (IAH, Compton 
Laboratory).
2.2.1 Materials
SDS-PAGE gel fixing solution Fixing solution was prepared by the addition of 50% (v/v) 
methanol and 7% (v/v) acetic acid in distilled water and was stored at ambient temperature 
before use.
Methionine-free GMEM A 1 litre stock solution containing GMEM plus dialysed foetal calf 
serum (5% final volume) plus 2 mM leucine, 2 mM valine and 4 mM glutamine. 0.01% (v/v) 
sodium hydrogen carbonate, 100 units/ml of Penicillin and 100 |ig/ml of Streptomycin was 
prepared and sterilised by filtration. This working solution was stored at 4°C.
Phenvlmethvlsulphonvl fluoride fPMSFl Working stock solutions of 100 mM PMSF 
(supplied by Sigma) in ethanol were prepared and stored at 4°C. When mentioned in 
conjunction with buffers, PMSF was added immediately before use to a final concentration of 
1 mM.
Phosphate buffered saline fPBS pH 7.41 Stock solutions were prepared, consisting of 2.5 
mM potassium chloride, 0.15 M sodium chloride, 1.5 mM potassium dihydrogen 
orthophosphate and 6.5 mM di-sodium hydrogen orthophosphate, and were sterilised by 
autoclaving and stored at ambient temperature.
Tris buffered saline (TBS pH 7.61 Stock solutions were prepared, consisting of 150 mM 
sodium chloride, 5 mM potassium chloride and 25 mM Tris-base adjusted to pH 7.6 and 
sterilised by autoclave.
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PBS-T Stock solutions were prepared prior to use, and consisted of PBS as above, with 
the addition of 0.1% (v/v) of Tween 20.
Preparation of immunoprecipitin CIMPl Immunoprecipitin (formalin-fixed S. aureus A 
cells, BRL) was pelleted at 10,000 x g for 2 minutes. The supernatant was discarded and 
the pellet resuspended in the buffer used for immunoprécipitation of viral polypeptides 
(RIP buffer). IMP solutions were stored at 4°C.
RIP buffer RIP buffer consisting of 0.01 M Tris-HCl (pH 7.4), 0.15 M sodium chloride, 
1% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100 and 0.1% (w/v) SDS, was made 
and sterilised by autoclaving and stored at ambient temperature.
RIP washing buffer Stock solutions were prepared, consisting of 0.5 M lithium chloride 
and 0.15 M Tris-HCl (pH 8.5). The solution was sterilised by autoclave and stored at 
ambient temperature.
SDS-PAGE reducing sample buffer (3 X concentrate! This buffer consisted of 0.15 M 
Tris-HCl (pH 6.7) with 30% (v/v) glycerol, 15% (v/v) P-mercaptoethanol, 6% (w/v) SDS 
and 0.15 mg/ml bromophenol blue.
SDS-PAGE non-reducing sample buffer (2X concentrate) Stock solutions were prepared, 
consisting of 0.1 M Tris-HCl (pH 6.7), 20% (v/v) glycerol, 4% (w/v) SDS and 0.1 mg/ml 
bromophenol blue.
SDS-PAGE running buffer Running buffer consisted of 0.6% (w/v) Tris-base, 0.4% (w/v) 
glycine and 0.1% (w/v) SDS, and was made up immediately prior to use.
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SDS-polvacrvlamide single-concentration gels Gel solutions were prepared using a 30% 
stock solution of acrylamide/bisacrylamide at a w/w ratio of 28.5 to 1.5. All resolving gels 
were used at a concentration of 10% acrylamide-bis, 0.4 M Tris-HCl (pH 8.9) and 0.1% 
(w/v) SDS. The gels were polymerised by adding 200 pi 10% ammonium persulphate and 20 
pi TEMED.
The stacking gel used in the SDS-PAGE experiments consisted of 3.7% acrylamide-bis, 
0.25M Tris-HCl (pH 6.7) and 0.1% (w/v) SDS. The gel was polymerised by adding 150 pi 
10% ammonium persulphate and 6 pi TEMED. Acrylamide (electrophoresis grade) was 
obtained from Fisons (Loughborough, U.K.) and the bisacrylamide from Kodak Chemicals 
Ltd. (Liverpool, U.K.). Ultrapure ammonium persulphate was from Pharmacia (Uppsala, 
Sweden) and TEMED from Sigma.
Western transfer buffer Western buffer consisted of 20% (v/v) methanol, 0.3% (w/v) Tris- 
base and 1.5% (w/v) glycine.
Western blot-blocking solution This solution was prepared immediately prior to use and 
consisted of 10% (w/v) powdered skimmed milk (Marvel, Cadburys) in 100 ml of PBS.
Western blot-colour development 0.06% (w/v) 4-chloro-l-napthol (supplied by Bio-rad) was 
dissolved in 20 ml methanol, and added immediately to 0.06% (v/v) hydrogen peroxide in 
100 ml of PBS. The solution was mixed immediately before use and developed in the absence 
of light. The colour reaction was stopped by air drying the filter.
2.2.2 In vivo labelling of transfected proteins with l3£sl-methionine 293 cells were 
grown in a 90 mm2 tissue-culture Petri-dishes and when confluent, were induced to take up 
foreign DNA. After 40 hours the supernatant was removed and the cells incubated for four 
hours in 1 ml of prewarmed methionine - free medium containing 100 pCi/ml of [-^Si- 
methionine (specific
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activity:>800 Ci/mmol). Cells were then harvested by removal with a sterile policeman and 
prepared by immunoprécipitation.
2.2.3 Immunoprecipitation of viral proteins Cells were collected as a pellet after a 30 
second centrifugation at 10,000 x g. Pellets were resuspended in 1 ml o f ice-cold 
TBS/PMSF. Cells were pelleted once more at 10,000 x g. The final cell pellet was 
resuspended in 1 ml of TBS/PMSF and the cells lysed by the addition of NP-40 detergent 
(final concentration of 2% {v/v}), for half an hour on ice. Cellular debris was removed by 
centrifugation at 10,000 x g for 1 minute. The supernatants were precleared by incubation 
with 50 pi of IMP for half an hour on ice (to reduce non-specific background). After the 
removal of the precipitate by centrifugation, supernatants were reacted with 10 pi 
polyclonal anti-RS virus serum or specific MAb, for more than 4 hours on ice. Samples 
were then incubated with IMP (at an IMP: Ab volume ratio of 10:1) on ice for 60 minutes. 
Immune complexes were pelleted at 10,000 x g and washed twice with cold RIP washing 
buffer and the pellets resuspended in SDS-PAGE sample buffer (reducing or non- 
reducing) and stored at -20°C. Before electrophoresis, samples were boiled for 3 minutes 
and clarified from the IMP by a 1 minute centrifugation at 10,000 x g.
2.2.4 Preparation of SDS-PAGE samples Cell monolayers were scraped into 
suspension with sterile policeman. Cells were collected as a pellet after a 30 second 
centrifugation at 10,000 x g. Pellets were resuspended in 1 ml of ice-cold PBS/PMSF. 
Cells were pelleted once more at 10,000 x g. The final cell pellet was resuspended in 100 
pi of PBS/PMSF and the cells lysed by the addition of NP-40 detergent (final 
concentration of 2% {v/v}), for half an hour on ice. Cellular debris was removed by 
centrifugation for 2 minutes. An equal volume of 2 X SDS-PAGE sample buffer (reducing 
or non-reducing) was then added to the protein-containing supernatant. Before 
electrophoresis, samples were boiled for 3 minutes.
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2.2.5 Polyacrylamide gel electrophoresis fSDS-PAGEl The discontinuous system of 
Laemmli. (1970) was used. Resolving gel containing 10% polyacrylamide, were cast 
directly inside the assembled gel plates (250 x 220 mm with 1.5 mm spacers). Stacking gel 
was applied on top of the resolving gel once this had set. Gels were run overnight at a 
constant current of 14 mA until the dye front had reached the bottom of the gel.
2.2.6 Fluorographv For radiolabelled-protein samples, gels were fixed with two changes 
of fixer for 1 hour. Fluorography was carried out by gentle shaking of fixed gels in 
Amplify™ for 30 minutes. Gels were then dried onto a 3MM Whatman paper under 
vacuum for 2 hours (BIO-RAD gel drier) and exposed to pre-flashed X-ray film at -70°C.
2.2.7 Western blotting For most experiments viral proteins were transferred directly to 
nitro-cellulose, the electrophoretic transfer of which was performed according to Towbin 
et al. (1979). Both immunoprecipitated and total cell lysates were used. The 
electrophoresis gels were equilibrated, after running, in Western transfer buffer for 30 
minutes and then laid on pre-wetted 3 MM Whatman paper, resting on a fibre pad which 
was placed on the bottom half of a gel holder of the Trans-blot™ apparatus (BIO-RAD). 
A piece of nitro-cellulose (21 x 16 cm), pre-soaked in transfer buffer, was applied tightly 
onto the gel. Assembly was completed by placing another pre-wetted filter paper on top of 
the nitro-cellulose and a second fibre pad on top of the paper. The gel holder was inserted 
into the Trans-blot™ tank, which had been filled with transfer buffer, with the nitro­
cellulose towards the anode. Transfer took place at a constant voltage of 70 V for 4 
hours. The gel holder was then taken out of the tank, opened and the nitro-cellulose sheets 
then incubated in 10% blocking solution for 30 minutes at room temperature to allow 
blocking of non-specific binding sites. Blots were then washed four times in PBS-T and 
incubated with antibody diluted 1:200 in 1% (w/v) BSA; PBS-T for 3 hours at room 
temperature. Unbound antibody was removed by washing four times with PBS-T and 
blots incubated with biotinylated second antibody (anti-mouse, -human or -bovine) diluted 
1:400 in 1% (w/v) BSA; PBS-T for one hour at room temperature. After another four
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washes in PBS-T, blots were incubated with biotinylated peroxidase - streptavidin 
complex, diluted 1:3000 in 1% (w/v) BSA ; PBS-T for one hour. Blots were finally 
washed 3 times in PBS-T and twice in PBS alone (to remove residual detergent) prior to 
colour development.
2.3 RECOMBINANT DNA TECHNIQUES
2.3.1 Bacterial Cells used in cloning experiments E. coli strain TG2 was used in all 
experiments. The genotype is shown below:
supE hsdA5 thi A(lac-proAB) A(srl-recA)306: :Tn 10(Tetr)
2.3.2 Bacterial plasmids and phage used in cloning experiments All DNA subcloning 
was carried out in the Bluescribe™ (pBSM13) plasmid obtained from Stratagene Cloning 
Systems, (San Diego, California, U S A.). DNA sequencing was performed using the 
bacteriophage M13 mpl8/19 vectors described by Messing and Vieira. (1982).
2.3.3 Materials
Luria-Bertani fLBl medium This medium contained 1% (w/v) tryptone, 0.5% (w/v) 
sodium chloride and 1% (w/v) yeast extract. Medium was made sterile by autoclaving at 
121°C for 20 minutes. LB agar plates were made with the same ingredients but containing 
1.5% Bacto-agar and sterilised as above. Indicator plates for selection of recombinant 
clones also contained 0.5 mM X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactoside), 1 
mM IPTG (isopropyl-thiogalactoside) and ampicillin (100 pg/ml).
H-Top medium H-top medium was used in transformation of Ml 3 phage and contained 
0.8% (w/v) Tryptone, 0.5% sodium chloride, 0.5% (w/v) yeast extract and 0.6% (w/v) 
Bactoagar. Media was sterilised by autoclaving for 20 minutes at 121°C.
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TE Stock solutions were prepared, consisting of 10 mM Tris-HCl (pH 8.0) and 0.1 mM 
EDTA
TNE Stock solutions were prepared, consisting of 10 mM Tris-HCl (pH 8.0), 100 mM 
sodium chloride and 1 mM EDTA
10 X TBE Stock solutions were prepared, consisting of 0.89 M Tris-HCl (pH 8.0 ), 0.89 
M boric Acid and 20 mM EDTA (pH 8).
6 X Tracking buffer Stock solutions were prepared, consisting of 0.25% bromophenol 
blue and 30% glycerol.
3 X Boiling mix Stock solutions were prepared, consisting of 15% 2-mercaptoethanol, 6% 
SDS, 100 mM Tris (pH 6.7) and 30% glycerol. Bromophenol blue was added till a dark 
blue colour was obtained.
Phenol Distilled phenol was melted at 65°C and equilibrated against several changes of 
equal volumes of TNE.
Phenol/Chloroform Consisted of a mixture of equal volumes phenol and chloroform.
2 X HEPES Consisted of 0.3 M sodium chloride, 0.01 M potassium chloride, 0.01 M 
glucose and 0.05 M HEPES in distilled water. The solution was sterilised by filtration and 
stored at 4°C as a stock solution.
100X Phosphate salts A stock solution was prepared, consisting of 0.08 M di-sodium 
hydrogen orthophosphate (anhydrous). The solution was sterilised by filtration and stored 
at 4°C.
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TS Stock solutions were prepared from TD stock solution by the addition of 0.5 ml 20 
mg/ml Ca2+/Mg2+ salts and then sterilisation by filtration. Stocks were kept at 4° C.
Isotonic lvsis buffer This solution was made up with 0.15 M sodium chloride; 1.5 mM 
magnesium chloride; 0.65% NP40 (v/v) and 1 mM Tris. The solution was made up to pH 
7.8 and sterilised by autoclaving. The solution was stored at room temperature until use.
Phenol extraction buffer The solution comprised 7 M Urea; 0.4 M sodium chloride; 1 
mM EDTA; 1% SDS and 1 mM Tris. The solution was made up to pH 7.8 and sterilised 
by autoclaving. The solution was stored at room temperature until use.
2.3.4 Small scale plasmid preparation fmini preps) The method used was a slightly 
modified version o f Serghini et al. (1989). 1,5 ml o f culture grown overnight at 37°C with 
minimal shaking was centrifuged for 5 minutes at 15,000 x g and the cell pellet 
resuspended in 100 pi of TNE buffer and 100 pi of phenol/chloroform, and centrifuged for 
a further 5 minutes at 15,000 x g. The top aqueous layer was transferred to fresh 
eppendorf tubes to which 35 pi of a 10 M solution of ammonium acetate and 270 pi of 
cold 100% ethanol had previously been added. The mixture was incubated at 4°C for 20 
minutes after which the nucleic acids were pelleted for 10 minutes at 15,000 x g. The 
alcohol supernatant layer was removed and traces of ethanol removed by desiccation 
under vacuum. The pellet of nucleic acids was resuspended in either 30 or 40 pi of 
distilled water since the yields of plasmid DNA obtained were dependent upon plasmid 
copy number. Aliquots of 10 pi were used in restriction enzyme analysis in the presence of 
5 pg of RNAse A.
2.3.5 Large scale plasmid preparation (Maxi preps) Plasmid DNA was prepared 
using the alkali lysis method of Bimboim and Doly. (1979). Briefly, cells from a 500 ml 
overnight culture were pelleted at 2,000 x g for 20 minutes and resuspended in 8 ml of
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solution I (50 mM glucose, 10 mM EDTA (pH 8.0) and 25 mM Tris-HCl solution containing 
lysozyme at a final concentration of 5 mg per ml). After a 10 minute interval, 10 ml of 
solution II (1% SDS and 0.2 M sodium hydroxide) was added, mixed by inversion and kept 
on ice for 10 minutes. 12 ml of cold 5M potassium acetate was added , mixed by inversion 
and iced for another 10 minutes followed by centrifugation for 30 minutes at 30,000 x g, 4°C. 
The cleared supernatant was subsequently treated with an equal volume of a 
phenol/chloroform solution and the two immiscible phases separated by centrifugation for 30 
minutes at 2,000 x g, 4°C. The aqueous layer was transferred to fresh tubes and 0.6 times the 
volume of isopropanol was added and the mixture left at room temperature for 15 minutes. 
DNA was recovered by centrifugation for 30 minutes at 2,000 x g, 4°C. The alcohol layer 
was removed and the nucleic acid pellet desiccated under vacuum. The pellet was 
resuspended in 1.5 ml distilled water RNAse treated (10 |ig/ml) at 37°C for 30 minutes.
2.3.6 Caesium chloride gradient DNA banding The method used was as described in 
Maniatis et al. (1982). DNA prepared using the large scale plasmid prep described above was 
diluted to a final volume of 3.8 ml with distilled water to which 4.2 g of caesium chloride and 
50 jxl of a 10 mg/ml solution of ethidium bromide were added. The mixture was then 
transferred to Beckman heat seal tubes (5 ml) and filled up with a solution of 3.8 ml water, 
4.2 g caesium chloride and 50 |il of 10 mg/ml solution of ethidium bromide. The tubes were 
sealed and centrifuged for at least 18 hours at 400,000 x g, 20°C. Banded DNA was excised 
from the caesium gradient and the ethidium bromide removed by extraction with 6 rounds of 
equal volumes of amyl alcohol. Plasmid DNA was then dialysed overnight against 5 litre of a 
0.1% solution of SSC in order to remove the caesium chloride. The DNA was precipitated by 
addition of 1/10 volume of a 3 M sodium acetate solution and 2.5 times the volume of 100% 
ethanol, stored at either -70°C for 4 hr or -20°C overnight and then pelleted at 10,000 x g at 
4°C for 30 minutes. Traces of alcohol were removed by desiccation under vacuum and the 
total concentration of plasmid DNA estimated by optical density reading at 260 nm of 
resuspended DNA.
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2.3.7 Preparation of competent E.coli. Method used was the same as that described in 
Maniatis et al. (1982). 70 ml of LB medium was inoculated with 1 ml of E. coli cells were 
grown at 37°C with minimal shaking to an optical density (O.D.) reading at 650 nm of ~0.4 
and kept on ice for at least 30 minutes. 50 ml of cells were pelleted at 2,000 x g, 4°C for 5 
minutes, resuspended in 25 ml of a cold freshly made solution of magnesium sulphate and 
pelleted once again at 2,000 x g, 4°C for 5 minutes. The pelleted cells were then resuspended 
in 2.5 ml of a cold freshly made solution of calcium chloride and kept on ice for 1 hour before 
beginning the transformation procedure.
2.3.8 Transformation of competent E. coli with plasmid DNA The method of bacterial 
transformation was derived from that of Cohen et al. (1972) . Plasmid DNA was added to 
100 pi aliquot of competent cells and kept on ice for 30 minutes, shocked at 42°C for 2 
minutes, replaced on ice for a further 5 minutes and then left at room temperature for 5 
minutes. 1 ml of sterile LB medium was added and the cells incubated at 37°C with minimal 
shaking for 40 minutes. 0.25 ml aliquots were then plated onto LB agar plates containing the 
appropriate selection antibiotic.
2.3.9 Transformation of competent £. coll with phage M13 DNA M l3 vectors derived 
by Messing and Vieira. (1982) were transformed into competent TG2 bacteria using a 
protocol similar to that described above except that after the 42°C shock, cells were kept on 
ice for 5 minutes and then added to a mixture of 3 ml of molten H-Top agar containing 75 
mM of X-Gal, 150 mM of IPTG and 80 pi of an E.coli culture that had been grown 
overnight, diluted 1/100 with LB medium and incubated at 37°C with minimal shaking for 1 
hour. This whole mixture was then poured onto LB plates, the H-top allowed to set before 
incubating overnight at 37°C.
2.3.10 Preparation of phage M13 single stranded DNA Using the method described in 
Maniatis et al. (1982), 5 ml of LB medium was inoculated with Ml 3 and grown for 6
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hours at 37°C with minimal shaking. 1.5 ml of Ml 3 infected E. coli cells were pelleted at 
10,000 x g for 5 minutes. 1.2 ml of the supernatant was transferred to fresh tubes to which 
250 pi of a 20% (v/v) polyethylene glycol 6000/3 M sodium chloride solution had been 
added. The two were mixed by inversion and kept at room temperature for 30 minutes. 
The PEG precipitated M13 was pelleted (10,000 x g, 4 minutes) and the supernatant 
removed. Any remaining supernatant was removed after re-spinning the tubes for 20 
seconds at 10,000 x g. The cell pellet was then resuspended in 120 pi of Tris-HCl (pH 
8.0) and 50 pi of buffered phenol was the added. The two immiscible phases were the 
separated by centrifuging at 10,000 x g for 5 minutes. 100 pi of the top aqueous layer was 
transferred to fresh tubes and 50 pi of chloroform was added and again the two phases 
separated as before. 80 pi of the aqueous layer was transferred to fresh tubes and 10 pi of 
a 3 M sodium acetate solution and 250 pi of cold 100% ethanol were added.
2.3.11 Transfection of mammalian cells Plasmid DNA was introduced into 
mammalian cells using a modified protocol of Chen and Okayama.(1987). Before the start 
of the experiment, the medium was replaced with supplemented DMEM plus 10 % Foetal 
calf serum for at least 3 hours. The DNA-calcium phosphate precipitate was then prepared 
by adding 10-20 pg DNA and 3 pg salmon sperm DNA to 100 pi 1.25 M calcium chloride 
and making up the volume to 500 pi with sterile distilled water. This solution was then 
added slowly to a solution of 10 pi 100 X phosphate salts solution and 490 pi 2 X 
HEPES. The mixture was allowed to precipitate for 0.5 hours at room temperature. The 
media was then removed from the cells and 1 ml of supplemented DMEM plus 10% FCS 
added, plus 500 pi of the DNA-phosphate precipitate. The precipitate was allowed to 
settle on the cells for 5 hours whilst the cells were maintained in a 37°C incubator under 
5% CC>2 . After 5 hours the cell media was removed and the cell monolayer induced to 
take up the bound DNA by the addition of 2 ml 80% glycerol in TS. The glycerol shock 
was stopped after 50 seconds by removal of the glycerol and washing once with 5 ml TS 
solution. This was immediately removed and 10 ml supplemented DMEM plus 10% calf
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serum was added to the cells. The cells were then incubated for 2 days at 37°C under 5% 
CC> 2  before harvesting.
2.3.12 Restriction endonucleases DNA to be analysed by restriction digests was 
prepared either by the mini-,maxi- or large scale preparation methods described above. All 
digests were carried out in the manufacturer's recommended buffers in the presence of 1-2 
units of enzyme and 50p.g/ml bovine serum albumin. All digests were carried out at the 
recommended temperature for between 2-6 hours. Restriction enzymes were supplied by 
either Amersham, Gibco-BRL or Pharmacia.
2.3.13 De-phosphorvlation of linearised vector DNA 2-5 units of calf intestinal 
phosphatase (CIAP) were added during the last hour of restriction endonuclease digestion 
of vector DNA so as to minimise vector re-ligation by removal of the 3' terminal 
phosphate of linearised DNA.
2.3.14 Blunting 3’ overhanging DNA T4 DNA polymerase when compared with DNA 
polymerase I (Klenow Fragment) possesses an equivalent 5->3' polymerase but more 
active 3—>5' exonuclease activity. In the presence of excess deoxynucleotides, the amount 
of 3—>5' exonuclease activity is reduced considerably when compared to 5—>3 polymerase 
activity. Additionally it's 3—>5' exonuclease activity is only functional on ssDNA or on 
dsDNA with 3' overhangs but not on 5' overhangs (3' recess). Thus, T4 DNA polymerase 
was chosen in place of DNA polymerase I (Klenow fragment) for blunting of 5' and 3' 
overhangs of dsDNA following digestion with restriction enzymes. Restriction 
endonuclease treated DNA was first phenol/chloroform extracted and the ethanol 
precipitated by the method used in the mini-prep protocol. DNA was then blunted in the 
presence of 0.25 mM dATP, dTTP, dGTP, dCTP, 33 mM Tris-HCl (pH 7.5), 66 mM 
potassium acetate, 10 mM magnesium acetate, 0.5 mM DTT, 0.1 pg BSA and 1-2 units of 
T4 DNA polymerase and the reaction incubated at 37°C for 45 minutes. Blunted DNA
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was then either purified from LMP agarose gels or phenol/chloroform extracted and ethanol 
precipitated as described above.
2.3.15 DNA Ligation Ligation of DNA fragments was carried out overnight at 16°C in the 
presence of 66 mM Tris-HCl (pH 7.6), 5 mM magnesium chloride, 5 mM DTT, 0.1 pg BSA,
1 mM hexamminecobalt chloride, 1 mM ATP, 0.5 mM spermidine-HCl and 1-2 units T4 
DNA ligase. Typically the final reaction volume was between 20-25 pi. DNA fragments 
purified from LMP agarose gels were heated to 65°C for 10 minutes and the ligation carried 
out in a final volume of between 60-100 pi, where the final volume was in at least 8 fold 
excess of the volume of DNA fragment added.
2.3.16 Isolation of RNA from RS virus-infected cells This method is based on that of 
Kumar and Lindberg.(1972). When infected cells reached 40% syncytium formation the cells 
were scrapped off the monolayer using a sterile policeman. The cells were pelleted at 10,000 
x g for 5 minutes in a MSE™ chillspin. Pellets were then washed once in 10 ml PBS and lysed 
on ice in 5 ml isotonic lysis buffer for 30 minutes. 5 ml of phenol extraction buffer was then 
added along with 10 ml phenol/chloroform. The solutions were mixed by inversion and the 
mixture centrifuged for 10 minutes at 10,000 x g, the clear top-layer being extracted. To this 
was added a further 10 ml phenol/chloroform and the preceding step repeated a further time. 
The top-layer was cleared of residual phenol by the addition of 8 ml chloroform, further 
mixing and spinning for another 10 minutes at 10,000 x g. Total RNA was ethanol- 
precipitated, centrifugation at 10,000 x g for 20 minutes, and the resulting pellet dried under 
vacuum. The pellet of total RNA was then resuspended in 50 pis sterile distilled water and 
stored at -20°C.
2.3.17 cDNA synthesis from purified RNA The 1st strand of cDNA was synthesised from 
the total RNA from RS virus-infected cells using avian myeloblastosis virus (AMV) reverse 
transcriptase (Life Sciences, Inc.). Reverse transcription was carried out in the presence of 
0.5 mM each of dATP, dCTP, dGTP, dTTP, 50 mM Tris-HCl (pH 8.3), 6
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mM magnesium chloride, 40 mM potassium chloride, 3 pg of pd(T) (12-18; Pharmacia) 
and 10 units AMV reverse transcriptase.. The reaction was incubated at 42°C for 45 
minutes, phenol/chloroform extracted and ethanol precipitated. cDNA was resuspended in 
30 pi of distilled water. 3 pi aliquots were used to amplify DNA fragments using the 
polymerase chain reaction.
2.3.18 Amplification of DNA by polymerase chain reaction fPCRl Amplification was 
based on the method of Saiki et al. (1988) and was achieved by 30 cycles of ; DNA 
dénaturation at 93°C for 0.75 minutes, oligonucleotide annealing at 56°C for 0.75 minutes 
and extension at 74°C for 2 minutes in the presence of 10 mM potassium chloride, 10 mM 
ammonium sulphate, 20 mM Tris-HCl (pH 8.8), 2 mM magnesium sulphate, 0.1% (v/v) 
Triton X-100, 100 pg/ml BSA, 0.5 mM each of dATP, dTTP, dCTP, dGTP and 1 unit of 
Vent™ DNA polymerase (New England Biolabs, MA, USA).
2.3.19 Oligomer primers used in PCR and sequencing experiments Two primers were 
used for cDNA synthesis and PCR amplification experiments; PCRF1 which is complimentary 
to the 3’ end of the fusion gene; and PCRF2, complimentary to the 5’ end. Six internal 
primers (SEQF1 —> SEQF6) and the M13 primer (-40)(Table 6) were used to determine the 
gene sequence.
2.3.20 Agarose gels Restriction endonuclease digested DNA was visualised under UV 
illumination after running on either a 1% or 2% agarose gel depending upon the size of 
DNA fragments Agarose was dissolved in 1 X TBE solution containing 0.05 pg/ml of 
ethidium bromide and then cast in either a 6 x 8, 8 x 10.5, 11.5 x 14 or 20 x 25 cm 
horizontal tray. 6 X tracking dye buffer was added to samples to be analysed and the gel 
run in the presence of 1 X TBE buffer at between 100 and 180 volts.
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Table 6 Oligomers used during sequencing. cDNA synthesis and PCR amplification
PRIMER NUCLEOTIDES SEQUENCE 5' —> 3' (mRNA sense)
PCRF1 30mer GGATCCCGGGGC AAAT AAC AATGGAGTTGC
PCRF2 33mer GGATCCCGGGTT ACT AAATGC AAT ATT ATTT AT
-40 17mer CAGCACTGACCCTTTTG
SEOF1 18mer CACATTACCTTGTCTACG
SEOF2 16mer CGAC AT AGATTCC AGG
SEOF3 16mer GGTCCCTT AAATCACA
SEOF4 17mer GT GT GT AGGGG AG AT AC
SEOF5 15mer GAGACGTTGT AACTG
SEOF6 17mer C AGAGAT AC ATTTTCC A
Primers PCRF1 and PCRF2 were complimentary to the 5’ (mRNA sense) ends of 
the fusion protein gene and were used to amplify the target gene prior to cloning and 
sequencing. At the immediate S’ ends of these oligomers were included a BamHl 
(GGATCC) and Smal (CCCGGG) restriction endonuclease DNA sequence. These were 
used to clone the PCR product into the vector DNA. All other primers were used for 
sequencing experiments and were designed to anneal to different unique DNA sequences 
within the fusion gene.
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2.3.21 Sequencing reactions All sequencing reactions were carried out using a method 
derived from that of Sanger et al. (1977) and as described in the sequenase™ kit 
instructions. Radioactive labelling of the target DNA was achieved using a-labelled 
35SdATP.
2.3.22 Sequencing Gels Sequencing reactions were run on a 5.7% acrylamide, 0.3% 
bis-acrylamide, 7 M urea dissolved in IX TBE gel. To polymerise the gel, 265 pi 10% 
(w/v) ammonium persulphate and 112 pi TEMED were added. A 31 x 38.5 cm gel was 
cast horizontally between two glass plates separated by a 0.4—>1.2 mm wedge spacer. The 
gel was run in the presence of 1 X TBE running buffer at a constant 80 watts.
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CHAPTER THREE
Comparison of fusion protein genes and their products from RS virus 
subgroup A isolates
3.1 Introduction Investigations of the role of RS virus proteins in the immune response 
have established the importance of the fusion protein as the major antigenic unit responsible 
for protection (Section 1.8.1). Characterisation by limited nucleotide sequencing and 
restriction mapping of five discrete subgroup A isolate-types circulating during a winter 1989 
epidemic in the Birmingham, U.K. area (Cane and Pringle, 1991; SH lineages SHL1 to 
SHL5) has led to the hypothesis that strain-variation may lead to changes in antigenicity, 
accounting for reinfection. Evidence supporting this hypothesis comes from work by 
Sullender et al. (1991) and Cane et al. (1991) who observed extensive sequence variation in 
the G protein gene among naturally occurring RS virus isolates. Changes observed in the 
attachment (G) protein gene included frame shift mutations leading to major alterations in the 
carbohydrate content (Garcia-Barreno et al., 1990; Rueda et al., 1991). Therefore the major 
aim of this project was to determine whether there was similar variation in the fusion protein 
gene of RS virus subgroup A isolates, and determine the potential effects of this variation on 
fusion protein structure in an attempt to explain whether amino acid variation could lead to 
antigenic variation.
3.2 Results All RS viruses analysed belonged to subgroup A and included the prototype 
strain A2 and five natural isolates, RSB89-5857, RSB89-6190, RSB89-6256, RSB89-6614 
and RSB89-1734, representing isolate-types SHL 1 to 5 respectively (described by Cane and 
Pringle, 1991). All RS viruses were grown in the BS-C-1 G23 cell line.
3.2.1 SDS-PAGE variation Analysis of the fusion proteins of both subgroup A (strains A2 
and RSS-2 and isolates RSB89-1734 and RSB89-1202) and subgroup B (isolates RSB89- 
5987 and RSB89-5832) viruses by SDS-PAGE under non-reducing conditions (Figure 7) 
revealed characteristic differences in electrophoretic mobility of
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Figure 7. SDS-PAGE analysis of subgroup A and subgroup B RS viral proteins .
Lane
1 2 3 4 5 6 7
Total protein was harvested from virus-infcclcd BS-C-1 cells and analysed by 10% SDS-PAGE under 
non-reducing conditions and the proteins transfered via Western-blotting onto a nitrocellulose filter which 
was developed with bovine polyclonal anti-RS virus antibody as described in Chapter 2. Four RS viral 
proteins arc shown.thc attachment protein (G), the fusion protein (F), the nuclcoprotcin (N) and the 
phosphoprotcin (P). Fusion protein breakdown products (X). identified by anli-F monoclonal antibodies 
(data not shown), arc also seen. In lane 4 the 4K kD product might possibly represent a precursor protein of 
the mature F. Lancs I and 2 arc subgroup B virus proteins (RSB89 -5987 and RSB89-5832 respectively), 
lanes 3, 4, 5 and 6 arc subgroup A viral proteins (RSB89-1202, RSB89 -1734, RSS-2 and A2 
respectively). Lane 7 is a negative control of BSC-1 cellular protein.
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viral proteins between the two RS viral subgroups. The phosphoprotein (P) has 
accelerated mobility in the subgroup B viruses whereas the nucleoprotein (N) appears 
conserved between subgroups. The attachment glycoproteins of each virus sample show 
differences in mobility as well as differences in their reactivity with the bovine polyclonal 
anti-RS antibody, indicating that there is heterogeneity both within and between RS virus 
subgroups. Figure 7 shows also that there are differences in mobility of the fusion proteins 
both between and within subgroups. This suggested that variation in the fusion proteins of 
subgroup A RS viruses might be greater than previously reported.
The fusion protein mobility differences could be explained as a consequence of 
variation in the number and position of cysteine residues leading to alterations in the 
structure of the protein, however the cysteine residues are absolutely conserved in number 
and position throughout subgroup A viruses (Collins, 1991). Fusion protein mobility 
differences could also be a consequence of variation in the number and position of 
potential N-linked glycosylation sites, and there has been a difference in the number of 
glycosylation sites reported between strain A2 and other subgroup A viruses (Collins, 
1991), with strain A2 possessing five sites and strain RSS-2, Long and Edinburgh 
possessing six sites. An alternative explanation is that amino acid substitutions could alter 
the secondary structure of the fusion protein. It is this final suggestion that this study 
sought to address.
3.2.2 Variation in the fusion gene and its predicted product Determination of the 
nucleotide sequence of the fusion genes of five recent RS virus subgroup A isolates, 
representing five lineages defined by Cane and Pringle (1991), was carried out by PCR 
amplification of the major ORF via a cDNA intermediate generated from total RNA from 
RS virus-infected cells. At least two plaque-purified colonies of phage Ml 3 containing the 
fusion genes of each isolate were sequenced by di-deoxy chain termination. Ambiguity in 
the sequence data was deemed to have possibly arisen from errors in either the cDNA or 
PCR process. Therefore extra fusion protein genes were sequenced from the product of a
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different cDNA/PCR reaction. The full nucleotide and predicted amino acid sequences for 
the five isolates and laboratory strain A2 are shown in Figures 8 and 9.
3.2.3 Fusion protein identity in subgroup A viruses The relative relatedness of both 
nucleotide and predicted amino acid sequences of each subgroup A virus are summarised in 
Tables 7 and 8 respectively. Table 7 summarises the nucleotide data presented in this 
thesis, and Table 8 includes an additional three F protein gene sequences described in the 
literature. Comparison of the fusion gene product from subgroup A isolates shows that 
amino acid identity between subgroup A viruses is very high, ranging from 97% to 99.5%, 
whilst at the nucleotide level the pattern is very similar with homologies from 94.7% to 
99.4%. The relationship of each isolate type is shown diagramatically in Figure 10.
Within the fusion protein gene, amino acid changes are not uniformly distributed. 
The F! subunit is highly conserved (96.2%) among subgroup A isolates, whereas the F2 
subunit is less conserved (86.1 %). Within the fusion protein gene the spread of nucleotide 
substitution is roughly uniform, however there are proportionally more amino acid changes 
in the F2 subunit. Thus in the F2-encoding region of the gene nearly 50% of nucleotide 
changes cause amino acid changes. Within the F !-encoding region of the gene, only 16.5% 
of nucleotide changes lead to coding changes. Overall, most of the nucleotide changes 
(70%) occur in the third position of codon triplets, 15% occur in the first position and 9.5% 
in the second position. There are also double nucleotide changes (5.5%), usually involving 
the first and third positions. These results reflect a pattern of random nucleotide 
substitutions in the fusion gene. Most of the amino acid coding changes are conservative, 
maintaining size, charge and hydrophobicity profiles. The location and number of N-linked 
glycosylation sites and cysteine residues of all subgroup A isolates and strains, are highly 
conserved, with the exception of the loss of one glycosylation site in the F2-subunit of strain 
A2 and isolate RSB89-1734.
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Fifim c 8. The fusion gene sequence from subgroup A isnlntps compared
to wild-tvne strain A2.
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1701
A 2  AUA AAU AAU AUU GCA UUU AGU AAC UAAAUAAAAAUAGCACCUAA 1744
Gl 90
5 8 5 7
1 7 3 4
625G
6614
Nucleotide sequence data (shown in codon triplets) for the fusion genes o f  five isolate-types o f  RS 
virus subgroup A. All isolates are described in Section 2.1.2, The fusion gene sequence for subgroup 
A isolates representative o f  cacli lineage is shown below the fusion gene sequence o f the prototype 
strain A2. Nucleotide numbers are aligned above the sequence data.
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Figure 9, Fusion protein sequences from RS virus subgroup A isolates
compared to wild-tvne strain A2
Signal domain Conserved C# 1
A2 m e l l il k a n a it t il t a v t f c f a s g c In it Ie e f y o s t c s a v s k g y l s a l r t
619 0 p T A L S
1734 p I I s
585 7 p T A A L
62 5 6 p T A L S V I
6614 p T A L S
Conserved C# 1
A2 GWYTSVITI F.LSNIKENKCfTG^DAKVKLIKOELDKYKNAVTELOLLMOST
61 9 0
1734
5857 S T
62 5 6
6614
Cleavage site
C-terminal yfc ^  FRD
A2 PPTNNRARRELPRFMfrYTjlJNNAlKKlfrrVflLSKKRKRRFLGFLLGVGSAIAS
61 9 0 AA S T N
1734 AA S T
5857 T N
6 2 5 6 AA T N
6614 SAA T N
Conserved C#2 \
A2 GVAVSKVLHLEGEVNKIKSALLSTNKAWSLSNGVSVLTSKVLDLKNYID
6190 I
1734 I T
585 7 I
625 6 I T
6614 I
A2
6190
1734
5857
6 2 5 6
6614
J Conserved C#2
KQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTY
250
A2
61 9 0
1734
5857
625 6
6614
Conserved C#2 300
MLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYV
A2
6 1 9 0
1734
585 7
6 2 5 6
6614
cysteine-rich domain 350
VQLPIYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVS
A2
6 1 9 0
1734
585 7
6 2 5 6
6614
A2
6 1 9 0
1734
5857
6 2 5 6
6614
cysteine-rich domain 400
FFPQAETCKVQSNRVFCDTMNSLTLPSEINLCNVDIFNPKYDCKIMTSKT
V
D V I
L V I
V I
V I
__________ cysteine-rich domain______________ Conserved C#3 450
DVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGMDTV
V
V
V
V
V
A2
61 9 0
1734
5857
62 5 6
6614
A2
6190
1734
5857
6 2 5 6
6614
Conserved C#3 500
SVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKlgr
Conserved C#3 Trunsineinbrune domain
550
2^LAFIRKSDELLHNVNAGKSTTNIMITTI I IV I IV I LLSLIAVGIjLLYC
L F
A2
619 0
1734
585 7
6 2 5 6
6614
Cytoplasmic tail 574
"RXr s t p v t l s k d q l s g in n ia f s n
Deduced amino acid sequence data for the fusion genes of five isolate-types of RS 
virus subgroup A. All isolates are described in Section 2.1.2. The fusion protein 
sequence for each isolate is shown below the fusion protein sequence of the prototype 
1 strain A2. N-linked glycosylation sites are denoted as hatched boxes. The variable N- 
1 linked glycosylation site is marked by an asterix above the box. Above the amino acid 
! sequence are markings indicating areas of conserved residue identity throughout 
subgroup A viruses (C#l to C#3). Three hydrophobic regions are also denoted : 1) the 
signal peptide; 2) the putative fusion related domain, FRD; 3) the transmembrane 
domain. The cleavage site is also highlighted.
Table 7..Homology of the nucleotide sequences of the fusion genes of five subgroup
A isolates and two laboratory strains, A2 and RSS-2
Isolate A2 RSB89
-6190
RSS-2 RSB89-
1734
RSB89-
5857
RSB89-
6256
RSB89-
6614
A2 96.7 97.3 97.0 97.0 96.2 96.5
RSB89-
6190
57 98.3 95.3 98.5 97.8 97.8
RSS-2 46 29 95.8 99.5 98.0 98.0
RSB89-
1734
51 81 73 95.3 94.9 94.9
RSB89-
5857
52 26 9 81 98.0 98.1
RSB89-
6256
66 38 35 88 35 98 4
RSB89-
6614
60 38 34 88 32 24 p ' w n
N.B. reading below the diagonal gives the actual number of nucleotide changes. Reading 
above the diagonal gives the percentage identity between isolates. The published sequence 
data of subgroup A strains A2 and RSS-2 are included for comparison. Sequence data for 
strain A2 was determined by Collins et al., 1984b, and strain RSS-2 by Baybutt and 
Pringle, 1987.
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Table 8..Homology of the predicted amino acid sequences in the fusion proteins of five
isolate-types and four laboratory strains
| Isolate A2 RSB89
-6190
RSS-2 Long Edinb* RSB89-
1734
RSB89-
5857
RSB89-
6256
RSB89-
6614
| A2 ! 97.2 97.6 98.1 97.7 97.6 97.6 97.2 97.6
RSB89-
6190
16 j 98.3 97.9 98.8 97.7 97.9 98.6 98.9
RSS-2 14 10
■
97.9 99.1 97.4 99.4 98.6 98.9
Long 11 12 12 98.4 97.7 97.6 97.9 98.3
Edinb* 13 7 5 9 97.9 98.9 99.1 99.5
RSB89-
1734
14 13 73 13 12 •••> 97.0 97.7 98.1
RSB89-
5857
14 12 2 14 7 17 98.3 98.6
RSB89-
6256
16 8 8 12 5 13 10 99.3
RSB89-
6614
14 6 6 10 3 11 8 4
N.B. Reading below the diagonal gives the actual number of amino acid changes, reading 
above the diagonal gives the percentage identity between isolates. The amino acid data was 
obtained from the following references, strain A2 (Collins et al., 1984b), strain RSS-2 
(Baybutt and Pringle, 1987), strain Edinburgh (Elango et al., 1985a) and strain Long (Lopez 
et al., 1988). *Edinb denotes the Edinburgh strain.
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Figure 10 Relatedness of F gene sequences within subgroup A isolates
Graphical representation of relative relatedness of the fusion gene products 
from subgroup A strains and isolates. Fusion sequence data for SHL 1 - 5 isolates 
(This Thesis). Strain A2 sequence (Collins et al.,1984b); RSS-2 (Baybutt and Pringle, 
1987); Edinburgh (Elango et al.,198Sq) and Long (Lopez et al.,1988). Data analysed 
by the Clustal computer data handling program (Higgins and Sharp, 1988).
8 9
3.2.4 Variation in the F?-subunit of the fusion protein The analysis of amino acid 
variation is based on the total number of coding changes for all five isolates. All coding 
changes are defined as amino acid differences in comparison with the published sequence 
data for a consensus of fusion gene cDNAs from strain A2 (Collins et al., 1984b). The A2 
strain is the only strain of RS virus fully sequenced, and is regarded as the prototype 
subgroup A RS virus.
The nucleotide sequence encoding the F2-subunit possesses three defined regions; 
1) a hydrophobic signal domain; 2) a conserved region (C#l) situated between the signal 
and C-terminal domains, and 3) a C-terminal region (Section 3.2.2 Figure 9). The 
aggregate of all coding changes in comparison to the prototype strain A2 and present in 
the F2-subunit are shown in Table 9.
The signal domain possesses the lowest degree of amino acid sequence identity 
throughout the fusion protein, with approximately 59.6% residue homology. Within the 
signal region domain (residues #1 to #22) there are equal numbers of coding and non­
coding nucleotide changes. There are seven coding changes in this region of the gene, of 
which three occur in the first coding position of the triplet (residues #8; #13 and #16), two 
coding changes that in the second position (residue #4 and an alternative change in residue 
#16), and two multiple nucleotide substitutions (both in the first and third positions of the 
triplet), at residue #6 and #20. All but one o f the amino acid changes observed are 
conservative with residue characteristics remaining unchanged. The exception to this is the 
coding change at residue #4 (Leu —> Pro) that is a non-conservative change. Despite the 
low degree of homology, the overall pattern o f hydrophobicity of the encoded protein as 
defined by Kyte and Doolittle (1982) remains very similar (data not shown). It therefore 
appears that amino acid changes are tolerated in this region as long as the overall 
hydrophobic nature is retained.
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Table 9 Total number of coding changes in the F> subunit-encoding region of the 
fusion gene
Residue # Amino acid nucleotide
change
Comments Domain
#4 Leu -* Pro CUA -> CQA Non-conservative Signal
#6 Leu -> lie CUC -> AUU Conservative Signal
#8 Ala —> Thr GCA -> ACA Conservative Signal
#13 Thr —> Ala ACA ^  GCA Conservative Signal
#16 Thr -> Ala ACU -> GCU Conservative Signal
Thr —> lie ACU-> AUU Conservative Signal
#20 Phe —» Leu UUIJ-+CUC Conservative Signal
#25 Gfy Ser QGU -> AGU Non-conservative Conserved C#1
#39 Ala -» Val GCA -+ GUA Conservative Conserved C#1
#50 Thr —> He ACU -> AUU Conservative Conserved C#1
#88 Asn —> Ser AAU -> AGU Conservative C-terminal
#97 Met -* Thr AUG -> ACG Conservative C-terminal
#101
#102
Pro -> Ser 
Pro «•» Ala
QCA-+UCA Non-conservative
Non-conservative
C-terminal
C-terminal
#103 Thr-> Ala ACA GCA Conservative C-terminal
Thr -> Ala ACA —> GCC Conservative C-terminal
#105 Asn —>Ser AAU -> AGU Conservative C-terminal
#122 Ala —» Thr QCC ACC Conservative C-terminal
#124 Lys -* Asn AAA-*AA1J Non-conservative C-terminal
Nucleotide bases that are underlined and in bold character denote the position and nature 
of change. Those changes considered to be of structural importance are shown in 
highlighted boxes.
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The conserved region (C #1) of subunit F2 (residues #24 to #87) has 98.5% 
homology within subgroup A viruses. There are nine non-coding nucleotide changes and 
three amino acid coding substitutions in this region of the fusion protein, with nucleotide 
changes in either the first codon position (residue #25) or the second position (residue #39 
and #50). This region of the protein appears to be less tolerant of amino acid alterations, with 
two of the identified coding changes (residues #39 and #50) being conservative substitutions. 
The coding change at residue #25 (Gly —> Ser) is a non-conservative change removing the 
potential of glycine to disrupt a-helixes. The two potential N-glycosylation sites in this 
domain (residues #25 to 28 and residues #70 to 72) are conserved in all subgroup A viruses.
The C-terminal region of subunit F2 contains a relatively variable region (residues #88 
to #136) with 83.33% homology. There are four non-coding nucleotide changes and nine 
coding changes in the F2-subunit C-terminal region of the gene (Table 9). Four of these base 
substitutions occur in the first codon position (residue #101, #102, #103 and #122) and three 
nucleotide substitutions in the second codon position (residue #88, #97 and #105). There is 
also a nucleotide substitution in the third codon position at residue #124 and a multiple 
nucleotide substitution at residue #103. The pattern of coding changes in this domain of the 
fusion protein highlights a highly variable region between residues #101 and #105 inclusive. 
There are two or three N-linked glycosylation sites in this domain depending on strain, with a 
coding change at residue #122 forming the extra N-linked glycosylation site in all subgroup A 
viruses except strain A2 and isolate RSB89-1734. Not all amino acid substitutions in this 
region are conservative in nature, with the changes at residues #101 and #102 retaining 
charge characteristics but altering the structural characteristics of these residues as defined by 
Chou and Fasman (1978). The change at residue #124 (Lys —> Asn) changes the residue 
charge from basic to neutral with possible structural effects. The consequences of these 
residue changes will be discussed later.
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The cleavage site (residues #131 to #136) of all subgroup A isolates is located at 
the C-terminal end of this domain and remains unaltered in subgroup A viruses, with only 
one non-coding nucleotide change at residue #131 (Lys AAA —> AAQ). being observed.
3.2.5 Variation in the Fi-subunit of the fusion protein The Fi subunit is highly 
conserved in amino acid sequence, with overall amino acid identity of 96.2%. The region 
of the fusion gene encoding the Fi subunit can be divided into six distinct regions; 1) a 
hydrophobic fusion related domain (FRD), believed to be the functional domain of the 
fusion protein; 2) a conserved sequence (C #2) between the FRD and a cysteine-rich 
domain; 3) a cysteine-rich domain believed to be an important structural region, and by 
analogy to the fusion protein gene of SV, possessing intra-molecular disulphide bonds that 
form at least two loop structures thought to lie at the molecular surface of the protein 
(Iwata et al., 1994); 4) a conserved region (C #3) between the cysteine-rich and 
transmembrane domain; 5) a hydrophobic transmembrane region; and 6) a cytoplasmic tail 
domain believed to interact with the matrix protein (Section 3.2.2 Figure 9). The 
aggregate of all coding changes in comparison to the prototype strain A2 and present in 
the Fi-subunit are summarised in Table 10.
The FRD (residues #137 to #166) is well conserved within subgroup A viruses 
(93.4% amino acid identity), with only two out of eight coding triplets affected by 
nucleotide substitutions giving rise to amino acid coding changes. The coding changes are 
conservative in type and involve changes in either the first position of the triplet (residue 
#152) or the second position (residue #148). The first three residues of the FRD (Phe- 
Leu-Gly) are conserved throughout all subgroup A isolates, thus preserving the conserved 
Phe-X-Gly found in all paramyxoviruses (Collins et al., 1984b; Elango et al., 1985a). The 
semi-conserved sequence, Gly-Val-Ala, located just downstream of the N-terminus in the 
fusion related domain at residues #151 to #153 does show variation from the A2 
consensus sequence, with residue #152 (Val) being substituted for lie, and this is in 
agreement with data published by Baybutt and Pringle.(1987), Johnson and Collins
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Table 10 Coding changes in the gene region encoding the Fi-subunit
Residue Amino Nucleotide Comments Domain
# acid change
#148 lie —> Thr AUC -» ACC Conservative FRD
#152 Val -> lie £U U ->  AUU Conservative FRD
#173 Ser —> Thr XJCC -> ACC Conservative Conserved #2
#197 Asn —> Thr AAC -> ACC Conservative Conserved #2
#354 Gin —> Leu CAA -> CUA Conservative Cysteine-rich
#356 Glu —» Asp GAA GA£ Non-conservative Cysteine-rich
#379 lie -> Val AUA GUA Conservative Cysteine-rich
#384 Val -> He GUU-> AUU Conservative Cysteine-rich
Val -> He GUU -»■ AUA Conservative Cysteine-rich
#447 Met -» Val AUG £UG Conservative Conserved #3
Met -> Val AUG GUA Conservative Conserved #3
#540 Ser -» Leu U £ A ^ U JJA Non-conservative Membrane anchor
#547 Leu —► Phe c u e  HUC Conservative Membrane anchor
Nucleotide bases that are underlined and in bold character denote the position and nature 
of change. Those changes considered to be of structural importance are shown in 
highlighted boxes.
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(1988b) and Lopez et al. (1988). Neither change is thought to affect this important region of 
the fusion protein.
The conserved region (C#2; residue #167 to #306), exhibits 98.56% amino acid 
identity. This is a relatively large region of the gene and contains eighteen nucleotide changes. 
However, only two of the eighteen result in coding changes (Table 10). The two coding 
changes are located at residue #173 (Ser —¥ Thr); and residue #197 (Asn —> Thr). These 
changes only occur in one isolate in each case, RSB89-1734 at residue #173 and isolate 
RSB89-6256 at residue #197, and both changes result in conservative amino acid 
substitutions that are not expected to affect the structure of this region of the fusion protein.
The cysteine-rich region (residue #307 to #431) is also highly conserved between 
subgroup A isolates (96.77%) with the number and location of cysteine residues remaining 
unaltered. There are four coding changes in this domain. These are a mixture of nucleotide 
substitutions in the first codon position (residue #379 and residue #384); second codon 
position (residue #354), third codon position (residue #356), or a combination of first and 
third positions (residue #384). All but one of the four amino acid substitutions are 
conservative in nature. The change at residue #356 (Glu —» Asp) retains the acidic charge but 
alters the structural characteristics of the amino acid from a strong P-sheet breaker to an 
indifferent residue (Chou and Fasman, 1978). It is not known whether these changes would 
disrupt the intra-molecular disulphide bonding, but if so then this would have important 
consequences to the structure (and possibly antigenicity) of the fusion protein.
The conserved region (C #3) between the cysteine-rich and transmembrane domains 
(residue #432 to #524) has 97.4% homology between subgroup A isolates, and possesses 
fourteen non-coding nucleotide substitutions and only one amino acid coding change at 
residue #447 (Met —» Val) which is considered a conservative change. This coding change is 
found in all subgroup A isolates examined, and will be discussed later in
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this chapter. There is one potential N-linked glycosylation site (residues #500 to #502) in 
the C #3 domain, and this is conserved in all subgroup A viruses examined in this study.
The transmembrane (membrane anchor) domain (residue #525 to #551) possesses 
eight non-coding nucleotide changes and in all but one isolate-type virus there is 100% 
amino acid homology. The exception is isolate RSB89-6190 which shows 90% homology 
(Table 10) with two coding nucleotide changes, one in the first position of the codon 
triplet at residue #547 (Leu —> Phe), and in the second codon position at residue #540 
(Ser —> Leu). The change at residue #547 is conservative whereas the change at residue 
#540 is non-conservative, but it still retains the hydrophobic characteristics required in this 
membrane-anchor region.
The intracellular tail region (residues #552 to #574) has six non-coding changes. 
The lack of variation in the cytoplasmic domain may relate to the function of this region, 
which may interact with the matrix protein.
3.3 Discussion
3.1.1 The pattern of amino acid changes Conservation in amino acid content between 
subgroup A viruses is very high (97 to 99.5%, depending on strain). Whilst most amino 
acid changes observed in the different fusion proteins are present in one or more isolates, 
there are some changes that appear in all isolates except the prototype strain A2 (Table 
11.). Collins et al., (1984b) observed nucleotide heterogeneity among different F gene 
cDNA clones derived from strain A2 The published sequence is therefore a consensus 
sequence. This heterogeneity may be a consequence of RNA polymerase error and/or 
errors in reverse transcription during cDNA synthesis. A second explanation is that these 
amino acid changes may reflect adaptation to different cell culture regimes, but this is 
unlikely as no changes were observed in the hypervariable region of the G protein after ten 
passages in different cultured cells (Cane et a!., 1993). The third explanation is that the A2
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Table 11 Changes found in »11 isolates except strain A2
Residue # Amino acid nucleotide change Comments Domain
#4 Leu —> Pro CUA -* CCA Non-conservative F2 Signal
#16 Thr-> Ala ACU -> GCU Conservative F2 Signal
Thr -» lie ACU —» AUU Conservative F2 Signal
#152 Val —> He £U U ->A U U Conservative F, FRD
#379 lie -> Val AUA -+ £UA Conservative Fi Cysteine-rich
#447 Met —» Val AUG -> GUG Conservative F, Conserved #2
Met -> Val AUG -> GUA Conservative Fi Conserved #2
Nucleotide bases that are underlined and in bold character denote the position and nature 
of change.
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strain itself is heterogenous. Evidence supporting this theory comes not only from the 
amino acid variation observed in the fusion protein gene of this strain, but also from the 
mobility profiles of the phosphoprotein, which runs as a triplet on SDS-PAGE analysis 
(Caravokyri, 1990; and Section 4.3 and Figure 16), and not as a single band as 
previously published (Lambden, 1985). There is also evidence that the sequence of at least 
one other gene of the A2 substrain used in this project does not correspond exactly with 
the published sequence; specifically the NS1 gene (J.Evans, personal communication) 
where there are two reported coding changes. There may be two substrains of the A2 
virus in use in different laboratories.
Anderson et al., (1992) identified the amino acid change at residue #447 in a 
cleavage mutant derived from the A2 strain, and suggested that it might play a role in that 
phenotype, possibly by disrupting the correct protein-folding required for transport 
through the ER and Golgi apparatus where cleavage occurs.
There are other amino acid changes that occur in only one isolate; isolate RSB89- 
1734 (#6 Leu -> lie; #148 lie -> Thr; and #173 Ser -> Thr); isolate RSB89-5857 (#13 
Thr —> Ala; residue #88 Asn —> Ser; #97 Met —> Ser; and #354 Gin —> Leu); isolate 
RSB89-6190 (#540 Ser -> Leu; and #547 Leu -> Phe); isolate RSB89-6256 (#39 Ala -> 
Val; #50 Thr —> He; and #197 Asn —> Thr); and isolate RSB89-6614 (#101 Pro —> Ser).. 
It is not known whether these are an accurate reflection of sequence divergence or errors 
in the fusion gene introduced during the cDNA and PCR amplification process.
The C-terminal region of the F2-subunit (residues #101 to #105) is highly variable. 
The pattern of amino acid changes here is of interest, showing several coding changes 
from the A2 consensus sequence. Residue #102 is changed in all isolates except RSB89- 
5857, as is also the case at residue #103. The change at residue #102 is in a position where 
nucleotide variability has been reported previously (Collins et al., 1984b; Anderson et al.,
1992). Residue #105 is changed only in isolates RSB89-6190 and RSB89-1734. The
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potential consequences of changes in amino acid sequence in this region are discussed in the 
next section.
3.3.2 F^-subunit variation within RS viruses The previously published sequences of the 
RS virus subgroup A strains RSS-2, Edinburgh and Long (Baybutt and Pringle, 1987; Elango 
et al., 1985a; and Lopez et al., 1988), the subgroup B strain 18537 (Johnson and Collins, 
1988b), and the bovine strains RB94, A51908 and 391-2 (Walravens et al., 1990; Himes and 
Gershwin, 1992; and Lerch et al., 1991) are considered together in this section (Figure 11). 
They are also considered in relation to the structural features common to all paramyxovirus 
fusion proteins (Chambers et al., 1992).
Variation in the signal region appears to leave the hydrophobic nature of this domain 
unaltered and it is thought that this is the principal requirement for signal function with 
sequence motif being less important (Collins, 1991). The predicted amino acid sequence for 
the F2-subunit signal region of strains Long, RSS-2 and Edinburgh show overall agreement 
with one change at residue #10 (Ala —¥ Thr) in strain Edinburgh that is not found in other 
strains and isolates. This coding change is conservative in nature. Changes at residues #16 
and #20 are also found in the subgroup B strain 18537 virus (Johnson and Collins, 1988b) 
although the significance of this similarity is unclear. Within subgroup A viruses the signal 
domain identity is 59.6%, whereas between subgroups there is 45.8% homology (based on 
the comparison of subgroup A strain A2 and subgroup B strain 18537). Analysis of bovine 
RS virus signal domain sequences (strains RB94, Walravens et al., 1990; A51908, Himes and 
Gershwin, 1992; and 391-2, Lerch et al., 1990) revealed that of 24 amino acid residues, only 
one was shared in common, the initial methionine. However the hydrophobicity profile in this 
region is similar to that of subgroup A and B viruses (data not shown).
The conserved region (C #1) of subunit F2 has 98.5% amino acid identity within 
subgroup A viruses and shows lower homology (93.6%) with subgroup B strains (Johnson 
and Collins, 1988b) and much lower homology with bovine RS virus strains (77.8%;
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Figure 11. Fusion protein sequences from subgroup  A isolates a»d strains, a s 
com pared to subgroup B and  bovine RS virus strains
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Summary of tlie amino acid sequence for the fusion proteins of human and bovine RS viruses 
including data derived from this diesis, and die published sequence data for subgroup A strains A2 
(Collins et al., 1984b); RSS-2 (Baybutt and Pringle, 1987); Edinburgh (Elango et al., 1985a); Long 
(Lopez et at., 1988). Also include are subgroup B strain 18537 (Johnson and Collins, 1988b), and 
bovine strains RB94 (Walravens et al., 1990); A51908 (Himes and Gershwin, 1992) and 391-2 
(Lerch et al., 1991). Possible sites of N-linked glycosylation are denoted by hatched boxes. Important 
structural features identified by Chambers et al., (1992) as common to paramyxovirus fusion proteins 
are shown below die amino acid sequence. Detailed explanation of these structural features can be 
found in Section 1.7.5.
Himes and Gershwin, 1992). Chambers et al., (1992) suggest that this region consists of a fi­
shed forming region (F2b; residues #23 to 61) followed by a loop structure (residues #62 to 
78) of variable length, containing both the conserved cysteine residues found in the F2- 
subunit. Most variation between human and bovine strains occurs in the predicted loop 
structure, but how this affects the structure of the F2-subunit is unclear. There is evidence 
(Section 4; this thesis) that a single coding change in the conserved C#1 region can lead to 
restricted growth at temperatures above 37°C. This supports the theory that the structure of 
this region is crucial for correct fusion protein function.
The C-terminal domain of F2 is variable within subgroup A viruses. The cleavage site 
of all human and bovine strains and isolates is strictly conserved, with the sequence motif 
(residue #131 to #136 Lys-Lys-Arg-Lys-Arg-Arg). The extra (fifth) N-linked glycosylation 
site present in the C-terminal domain is found in all bovine and human RS viruses except two 
subgroup A viruses. This might explain the observed differences in fusion protein mobility on 
SDS-PAGE described in Section 3.2.1. The degree of amino acid homology within the C- 
terminal domain of subgroup A viruses is 76% (only the signal domain is more divergent) and 
between subgroups is approximately 69.7%, and between human and bovine strains 
considerably lower at 17.3%. Variation in the C-terminal end of subunit F2, may have an 
effect on fusion protein function. This region (residues #79 to 100) has been suggested to 
comprise an a-helical structure (F2h; Chambers et al., 1992) and alterations in this region 
may affect the secondary structure of the protein and also account for the mobility 
differences. The analysis of mutant teAl and its revertant viruses described in Chapter 4 of 
this thesis support this theory, and suggest that these changes can partially correct for 
alterations in the loop structure encoded by the conserved C#1 region.
3.3.3 Fj-subunit variation within RS viruses The Fpsubunit FRD shows high amino acid 
identity (96%) amongst all RS viruses, both human and bovine. Isolate RSB89-1734 
possesses an exclusive coding change at residue #148 and actually demonstrates lower 
identity (92%) with strain A2 than that found between bovine strains and strain A2 (96%).
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It was originally considered to be a sequencing error, but further sequencing of this region of 
isolate RSB89-1734 using PCR product from separate cDNA preparations verified the 
observation. The change from the strain A2 sequence at residue #152 is found in both 
subgroup A and B viruses, although in subgroup A strain Long the change is to threonine.
The conserved region (C #2) of the Fi-subunit is well conserved within subgroup A 
(97.8%), between subgroups (92.8%), and between human and bovine strains of RS viruses 
(87.1%). It possesses three discrete structural regions, two a-helixes (H and Fih) separated 
by a loop-forming sequence (Chambers et al., 1992). The a-helical regions are well 
conserved in both bovine and human strains, but the loop-forming sequence does show 
variation. This mirrors the change found in the loop-forming sequence present in the F2- 
subunit, although the reason for this is unknown. The non-conservative substitution at residue 
#213 (Ser —> Arg) is only present in strain Long and subgroup B strain 18537. This change 
could disrupt the loop structure and alter the folding in the F!-subunit and possibly alter the 
antigenicity of the protein by disrupting epitopes in antigenic area #1 which has been mapped 
to this region of the protein (Section 1.7.8). There is an extra coding change present in 
subgroup B and bovine strains, consisting of a conservative substitution of Asp by Ser at 
residue #276. This change also occurs in a region defined as a major epitope (antigenic area 
#11; Section 1.7.8), Therefore both these changes could potentially contribute to the antigenic 
difference of subgroups A and B, as well as between subgroup A and bovine viruses.
The cysteine-rich domain of Fi does not possess any identifiable structural features, 
and yet is highly conserved between and within human subgroups (96.0%) and between 
human and bovine strains (92.7%). The coding changes reported in strain RSS-2 (residue 
#428 Asn —» Asp and residue #434 Thr —> Arg) are exceptional and appear to be errors in the 
sequence published by Baybutt and Pringle (1987) and shown in this thesis, Section 5.2.2. It 
is also thought that the substitution at residue #379 (He —» Val) which is observed in all 
human and bovine isolates of RS viruses may be an error in the sequence
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published by Collins el al., (1984b). This is supported by the nucleotide sequence of a 
temperature-sensitive mutant (teAl) derived from the wild-type strain A2, which exhibited 
the same sequence at this position as all other subgroup A isolates (Section 4.2.2.) and thus 
differed from the published sequence of strain A2. The number and position of the cysteine 
residues remain unaltered and these are thought to contribute to an extended open structure 
(possibly consisting of at least two stem loops) formed by intra-molecular disulphide bonding. 
Epitope mapping (Section 1.7.8) has identified a T-cell epitope at residues #338 to 355 and a 
major fusion-inhibiting, neutralising B-cell epitope (antigenic area #IV) that are present in this 
domain.
The conserved region (C #3) of Fi possesses one identified structural feature (the 
leucine zipper, Z) which is thought to comprise an oc-helical region immediately upstream of 
the transmembrane anchor region. This structural feature is highly conserved in both human 
and bovine RS viruses, suggesting an essential structural requirement. The C#3 domain has 
97.4% homology within subgroup A viruses, and 94.6% homology with subgroup B strain 
18537, and 88.1% homology with bovine strains. There is a conservative amino acid 
substitution at position #442 (Val -» Ala) in strain Long that is not found in other strains and 
isolates. The change in amino acid #447 occurs in both subgroups of human RS viruses and 
also in bovine RS virus strains and also reflects the variable nature of this residue identified by 
Collins el al., (1984b). This is supported by the nucleotide sequence of mutant /sAl which 
exhibited the same residue at this position as that found in all viruses reported in this study 
(Section 4.2.2.), There is one coding change only found in strain Long at residue #515 (Asn 
—» His). This could imply an error in the published sequence, however there is a change at 
this position in bovine RS viruses. It is unclear therefore, whether this coding change is truly 
present in the Long strain. If this change is real it could potentially alter the predicted protein 
structure in this region by replacement of a a-helix indifferent residue with a strong a-helix 
forming residue and alter the residue charge from neutral to basic. This could potentially 
lengthen the series of a-helixes formed by the leucine zipper (Z) region described in Section 
1.7.5. The consequences of this are unclear, however it might be
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a response to the coding change at residue #213 (Ser —» Arg) which has the potential to 
disrupt the loop feature downstream of the H box and FRD.
The transmembrane (membrane anchor) domain of Fi is nearly exactly conserved 
within subgroup A viruses (100% homology within all strains except isolate RSB89-6190 
which is 90% homologous). Between viruses of both human subgroups there is less 
homology (96.2%), and even less between human and bovine strains (69.2%). The two 
coding changes found in isolate RSB89-6190 are unique in viruses of both subgroups. The 
change at residue #547 (Leu —» Phe) is conservative, whilst the change at residue #540 (Ser 
—» Leu) is non-conservative. This therefore, may alter the structure of the membrane anchor, 
but it is unclear what likely effect this might have on function. However, because this change 
is present in a naturally occurring isolate, it is presumed unlikely that this is a deleterious 
change. The possibility that these coding changes were errors in the derived sequence data 
was considered and so this region of the fusion protein gene was re-sequenced from new 
molecular clones derived from a separate PCR product obtained from a different cDNA 
preparation. No nucleotide errors in the derived sequence data were found, thus indicating 
that the sequence at this region is correct.
The cytoplasmic tail domain is completely conserved within subgroup A viruses, and 
is also conserved (87.5%) between human RS virus subgroups, but is less homologous 
(66.7%) between human and bovine strains of RS viruses. The total conservation of amino 
acid sequence within subgroup A strains and isolates highlights the importance of this region 
of the protein which is thought to interact with some inner component of the virus, possibly 
the matrix (M) protein.
3.3.4 Fusion protein (FI and F2) relatedness within subgroup A isolates The sequence 
data generated in this study found that the deduced amino acid identities for the fusion 
proteins of subgroup A isolates varied from 97% to 99.5%. This is a higher degree of 
homology than that found in the attachment (G) proteins of the same isolates (Cane et
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al., 1991). It was also found that the relative relatedness of individual isolates based on their 
fusion proteins (Figure 10) varied slightly from that reported for their SH and N protein 
genes (Cane and Pringle, 1991)(Section 1.2 Figure 2). The isolates can be arranged into 
three main groupings based on the relatedness of their fusion proteins; the first consists of 
isolates RSB89-6256, RSB89-6614, RSB89-6190 and the Edinburgh strain. The second 
group consists of isolate RSB89-5857 and strain RSS-2, and the third consisting of isolate 
RSB89-1734 and strain Long. Strain A2 appears to be more distantly related to each of the 
other isolates and strains.
The differences in the consensus sequence of strain A2 (Collins et al., 1984b) and its 
possible causes have been discussed in Section 3.3.1. The divergence of the A2 strain is not 
related to its earlier time of isolation, because the Long strain predates it. The nucleotide and 
predicted amino acid sequences for RS virus subgroup A isolates reported in this study are 
presented in comparison to the published A2 sequence. The reason for this is historical and is 
not meant to indicate that all isolates deviate from strain A2, but rather that strain A2 is 
somewhat different from all other subgroup A strains and isolates, possibly because of the 
reasons mentioned above. Overall, however, the range of nucleotide and predicted amino acid 
homology identified in this study would remain unchanged even using the modified A2 data. 
Relatedness of subgroup A fusion genes is similar but not identical to the pattern exhibited by 
their attachment (G) protein genes. However, the fusion protein gene data are less definitive 
in discriminating strain differences due to the small numbers of amino acid changes present.
3.3.5 Predicted fusion protein secondary structure In order to determine whether 
changes in amino acid residues could alter the secondary structure of the fusion proteins, 
predictions of the fusion protein structure of isolates representing each of the five SHL 
lineages, and the prototype strain A2, were carried out using a model based on the algorithm 
derived by the Chou and Fasman (1978) method and analysed on the GCG™ computer 
programme (Devereux et al., 1984). Their predictions may be no more than 50% accurate 
but in the
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absense of definitive structural analysis by X-ray crystallography, are useful for purposes of 
inter-strain comparison. Structural changes predicted by computer analysis are only intended 
as an indication of possible disruption of conserved and identifiable structural features, and no 
conclusion as to the actual structure of the protein can be drawn. The Chou and Fasman 
predictions were confirmed with an alternative model using the algorithm derived by Gamier- 
Osguthrope-Robson (1978) and analysed using the Microgenie™ computer programme 
(Queen and Korn, 1984). These predictions are based solely on the primary amino acid 
sequence and do not predict the effects of post-translational modification, such as intra­
molecular disulphide bonding, on the folding of the fusion protein.
For the purposes of this discussion the fusion protein structure is separated into the 
component subunits, F2 and F], The Chou and Fasman predictions for six F2-subunits 
corresponding to the prototype strain A2 and isolates representative of the five lineages are 
shown in Figure 12 and the corresponding Gamier-Osguthrope-Robson prediction shown in 
Figure 13.
The predicted F2-subunit structure of the lineages falls into five distinct groups. The 
first of these contains strain A2 and isolate RSB89-5857 which are nearly identical except for 
the number of N-linked glycosylation sites at the C-terminal end of the subunit which is 
greater in isolate RSB89-S8S7. This group is also unique in possessing an orientation 
opposite to that found in the other four groups. The secondary structure predictions show 
variation in the number of coil-forming motifs located in the conserved P-sheet region (F2b) 
identified by Chambers et al., (1992). Isolate RSB89-6256 possesses fewer random coil- 
forming residues than those found in other viruses. It is thought that amino acid changes at 
residues #39 (Ala —> Val) and #50 (Thr —> lie) account for these structural modifications. 
There is also variation between the five groups in the position and size of the a-helix region 
(F2h) located in the C-terminal region and identified by Chambers et al., (1992). Variation in 
this region gives rise to three distinct structural groups with isolates
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Figure 12 Secondary structure predictions for the F2-subunits of five natural subgroup 
A isolates and wild-type strain A2: using the algorithm of Chou and Fasman. 1978.
Predicted secondary structure of the F2-subunit of the fusion proteins representative of each 
of the five lineages identified by Cane and Pringle, (1991). Secondary structure predictions 
used the method of Chou and Fasman (1978), which is based solely on the primary amino 
acid sequence and does not take into account the effects of post-translational modifications of 
the protein. However the GCG™ computer programme used for graphically displaying the 
predicted structures, indicates the position of potential sites of N-linked glycosylation (Le. the 
tripeptide sequence Asn-X-Ser/Thr). Explanations of the symbols used to depict regions of 
random coil, a-helical or (i-sheet structure are given in the box on the left, a-helical and (S- 
sheet regions are also indicated on the structure plot. Five discrete structural groups are 
predicted, with strain A2 and isolate RSB89-5857 possessing similar structure but differing in 
the number of N-linked glycosylation sites in the C-terminal region of the subunit. Detailed 
descriptions of the differences between structural groups are given in the text.
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Fieure 13 Secondary structure predictions for the F2-subunits of five natural subgroup 
A isolates and wild-type strain A2; using the algorithm of Garnicr e t aL, 1978,
Predicted secondary structure of the Fj-subunits of the fusion proteins representative of each 
of the five lineages identified by Cane and Pringle, (1991), according to the algorithm of
Gamier et al., (1978). Computation of the data and the graphic output of predicted structures
»
were obtained with the Microgenie™ computer programme. The relative probabilities of the 
four secondary structures occurring along each protein (a-helix : Alph; (i-sheet: Beta; P-tum 
: Turn; and random coil : Coil) are shown in four separate graphs, one above the other. 
Values above the horizontal axes are considered as positive. Especially high values in a graph 
(peaks’) indicate that there is a greater (predicted) probability of that structure being 
formed. In any given region, the protein is most likely to have the type of secondary structure 
which corresponds to the graph with the highest positive value at that position. Positions of 
differing structural predictions are marked as [1] and [2],
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RSB89-6256; RSB89-619 and RSB89-1734 possessing an extended a-helical region 
around residue #100, isolate RSB89-6614 has this a-helical sequence truncated and 
positioned further downstream, and isolate RSB89-5857 and strain A2 have an a-helical 
sequence disrupted by coil-forming residues. Amino acid substitutions at residues #88, 
#101, and #102 are thought to be responsible for these changes in the length and position 
of the a-helical region (F2h).
The Chou and Fasman predictions for six Fi-subunits corresponding to the 
prototype strain A2 and isolates representative of the five lineages are shown in Figure 14 
and the corresponding Gamier-Osguthrope-Robson prediction shown in Figure 15. It 
appears that the predicted structure of the Fi-subunit is highly conserved, with two distinct 
groups differing only in their orientation. Similar to that found in the predicted structure of 
the F2-subunit, strain A2 and isolate RSB89-5857 show identical structural predictions, 
whilst the remaining isolates have Fi-subunits which are predicted to be identical. The 
change in orientation of the Fi-subunit is due to changes found in the F2.subunit, and 
because this is cleaved from the Fi-subunit during post-translational modification, the 
altered orientation of the Fi-subunit predicted in this model is probably an artefact. This is 
supported by the secondary structure predictions using the Gamier et al. (1978) algorithm 
described in Figure 15. Therefore no change in the orientation of this subunit is thought to 
exist. Additionally, the computer predictions do not give an indication of true protein 
structure merely the position of certain features, so changes in orientation would be 
irrelevant.
3.3.6 Conclusion From this study it can be concluded that fusion protein gene variation 
among subgroup A isolates is low (homology 97 to 99.5%). From the predicted structural 
models it would appear that the few coding changes observed have the potential to change 
fusion protein structure especially in the C-terminal domain of the F2-subunit, whereas the 
secondary structure of the Fi subunit remains conserved. Comparing the location of 
coding changes in subgroup A strains to identified epitopes on the fusion protein
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Figure 14 Secondary structure predictions for the Fl-subunits of five natural subgroup 
A isolates and wild-type strain A2; usin^thjc algorithm of Chou and Fasman, 1978..
Predicted secondary structure of the Fr subunit of the fusion proteins representative of each 
of the five lineages identified by Cane and Pringle, (1991). Secondary structure predictions 
used the method of Chou and Fasman (1978), which is based solely on the primary amino 
acid sequence and does not take into account the effects of post-translational modifications of 
the protein. However the GCG™ computer programme used for graphically displaying the 
predicted structures, indicates the position of potential sites of N-linked glycosylation (i.e. the 
tripeptide sequence Asn-X-Ser/Thr). Explanations of the symbols used to depict regions of 
random coil, a-helical or (i-sheet structure are given in the box on the left, a-helical and fi­
sh eet regions are also indicated on the structure plot. Structural analysis predicts very similar 
structural features, the two groups differing only in orientation, which is a prediction of 
protein structure that the computer models are not sufficiently accurate to make. These two 
groups are shown along with their representative viruses.
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Figure 15 Secondary structure predictions for the Fl-subunits of five natural subgroup 
A isolates and wild-type strain A2 using the algorithm of Garnicr e t aL, 1978,
Predicted secondary structure of the Fi-subunits of the fusion proteins representative of each 
of the five lineages identified by Cane and Pringle, (1991), according to the algorithm of 
Gamier et al., (1978). Computation of the data and the graphic output of predicted structures 
were obtained with the Microgenie™ computer programme. The relative probabilities of the 
four secondary structures occurring along each protein (a-helix : Alph; [1-sheet : Beta; |J-tum 
: Turn; and random coil : Coil) are shown in four separate graphs, one above the other. 
Values above the horizontal axes are considered as positive. Especially high values in a graph 
(‘peaks’) indicate that there is a greater (predicted) probability o f that structure being 
formed. In any given region, the protein is most likely to have the type of secondary structure 
which corresponds to the graph with the highest positive value at that position. The 
predictions suggest that all the Fi-subunits possess very similar structural features. Two 
predictions of secondary structure (strain A2 and isolate RSB89-6190) are therefore 
presented as representative for all viruses analysed.
V
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(Section 1.7.8) has revealed that changes in structural features occur away from known 
epitopes which are located in the conserved Fi-subunit. However changes in amino acids 
distal to epitopes could possibly lead to alterations in the secondary structure of the 
protein which might sufficiently alter antigenic sites and lead to antigenic variation. The 
possibility of this has already been suggested by Arbiza et al., (1992) and Lopez et al., 
(1993) who identified a monoclonal antibody escape mutant at residue #190 which 
allowed escape from selection at antigenic site #1 (residues #205 to #236), an area fifteen 
residues downstream from the amino acid change. Thus the amino acid variation observed 
in the F2-subunit may result in antigenic variation, possibly by altering the conformational 
epitope suggested as being formed by antigenic areas #1 to #111 (Section 1.7.8 Figure 6) 
and involving interaction between the H box region of Fi and the F2h region of the F2- 
subunit.
The coding change found in subgroup B strain 18537 and bovine RS viruses at 
amino acid #276 (asparagine to a serine) occurs in a region defined as a major epitope 
(Section 1.7.8) in subgroup A viruses. This change could potentially contribute to the 
antigenic variation between subgroups A and B, by disrupting an antigenic site in 
subgroup A strains or creating a different antigenic site in subgroup B strains.
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CHAPTER FOUR
Temperature—sensitive mutant teAl-a putative fusion (F) protein gene 
mutant
4.1 Introduction Several temperature-sensitive (ts) mutant viruses have been derived 
from wild-type strains of RS virus in efforts to produce candidate vaccines. The first 
candidate vaccine was derived from strain A2 by Chanock and colleagues (Gharpure et 
al., 1969; Wright et al, 1982). This mutant was found to induce a good immune response, 
with growth restricted to the upper respiratory tract. A secondary phenotype has been 
described for this mutant. The mobility of the F protein in SDS-PAGE analysis was 
retarded under non-reducing conditions (Belshe et al., 1978). When this candidate vaccine 
was used in children, non-ts revertant viruses were isolated from the lower respiratory 
tract. These revertants emerged late in infection and in most cases represented incomplete 
reversion to the wild-type phenotype (Hodes et al., 1974) with viral titres lower than that 
of the wild-type virus at the non-permissive temperature.
Analysis of the phenotype of mutant toAl suggested that the lesion was present in 
the fusion gene, possibly in the F2-subunit encoding region of the gene (Belshe et al., 
1978; Caravokyri, 1990). The nature of the reversion phenomenon appeared to be 
complex with two types found. The terminology of Caravokyri, (1990) is used here. 
(1) 90% of clones were fully revertant viruses which had wild-type growth characteristics 
at the non-permissive temperature. However these revertants still retained the mutant 
mobility phenotype. (2) 10% of clones were partial revertant viruses which had 
intermediate growth characteristics at the non-permissive temperature but had reverted to 
the wild-type fusion protein mobility.
It was therefore the purpose of this study to identify the nature of the ts lesion and 
to examine any nucleotide changes in the fusion protein gene of the two classes of 
revertant viruses in an effort to explain the nature of reversion.
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4.2 Results All viruses were grown in BS-C-1 G23 African green monkey kidney cell 
culture at the appropriate temperatures. Fusion genes were amplified using PCR from total 
RNA from RS virus-infected cells via a cDNA product. The genes were then ligated into 
sequencing vectors M13mpl8/19 and sequenced by di-deoxy chain termination. At least 
two plaque-purified clones containing the fusion protein gene were sequenced for each 
vims.
4.2.1 Sequence of the teAl fusion protein 2ene The deduced nucleotide sequence for the 
fusion gene of mutant teAl and its predicted amino acid sequence revealed seven coding 
changes in comparison to the wild-type sequence of strain A2 (Table 12).
What is immediately apparent is that as predicted by Caravokyri , (1990), nearly 
all coding changes in the mutant occurred in the F2-subunit of the protein. The number of 
coding changes appeared higher than expected (as compared to those occurring in mutant 
telC, Section 5.2.2) but this was probably due to the method used to generate this mutant, 
where a high concentration of mutagen and low stringency selection were used. Coding 
changes in the fusion gene product are described below.
There were changes at residue #4 and at residue #8 and these are also found in several 
isolates and strains of subgroup A viruses (Section 3.2.4), The change at residue #8 occurred 
at a nucleotide that has previously been defined as prone to variability (Anderson et al., 
1992). Both these changes in residue are thought to be conservative in nature with charge, 
hydrophobicity, and secondary structure forming characteristics remaining unchanged. These 
changes are thought not to be the site of the ts lesion or mobility phenotype because of their 
conservative nature, the fact that they are present in several subgroup A RS viruses, and the 
fact that they occur in the signal domain of the F2-subunit which is removed during transport 
through the endoplasmic reticulum to the Golgi apparatus (Section 1.7.5),
118
Table 12 Coding changes in m utant teAl compared to wild-type strain A2
Residue
#
Nucleotide
change
Amino acid Comments Domain
#4 CUA -*• AUA Leu -> lie Conservative F2 signal domain
#8 GCA -> ACA Ala —> Thr Conservative F2 signal domain
#66 £A A -*A A A Glu —> Lys Non-conservative F2 conserved #1 domain
#81 C A A -» CUA Gin —> Leu Conservative F2 conserved #1 domain
#102 £CA —> JJCA Pro -» Ser Non-conservative R  C^enninal domain
#379 AUA -> GUA De —> Val Variable residue Fi cysteine-rich domain
#447 A U G -»£U G Met -> Val Variable residue Fi conserved #3 domain
NB Those bases that are underlined and in bold type denote the changed nucleotide and its 
position in the codon triplet. Coding changes that are thought to be significant are shown 
highlighted in shaded boxes. Variable residues are those defined as such by Collins et al., 
(1984b).
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The change at residue #66 is a non-conservative change that could potentially have a signifi 
effect on fusion protein structure due to the replacement of an acidic residue with a basic residue (Glu 
Lys). This change alters the secondary-structure forming characteristics of this residue from strong a-heli 
forming/ strong P-sheet breaking residue to one that is a weak a-helix former/ moderate P-sheet breake 
as defined by Chou and Fasman, (1978).
The coding change at residue #81 (Gin -» Leu) is conservative in nature and was not predicted t 
have a structural effect. This change was thought unlikely to be the site of the ts lesion due to the patte 
of coding changes in the revertant viruses (Sections 4.2.3 and 4.2.4.).
The coding change at residue #102 (Pro —» Ser) is a non-conservative change and may have th 
potential to alter protein structure by replacing an a-helix breaking residue with an a-helical formin 
residue (Chou and Fasman, 1978). However, a change from proline to alanine at residue #102 was foun 
in many subgroup A RS viruses (Section 3.2.4), and a change from Pro —» Ser was reported in 50% 
cDNA clones sequenced by Collins et al., (1984b). This feature will be discussed later in Section 4.3.
There were two coding changes located in the F^subunit of the fusion protein, at residues #379 (II 
—» Val) and residue #447 (Met —» Val). These are not thought to be actual coding changes specific to th' 
mutant, but rather to be errors in the original published consensus sequence of the wild-type strain A 
(Collins et al., 1984b; Section 3.3.1) since these changes are found in all naturally occurring isolates 
RS virus, both subgroup A and B and also in bovine strains of RS viruses (Section 3.3.3). Therefore the 
are thought to be two potential ts lesion-causing changes in mutant mAI (residues #66 and/or #102).
4.2.2 Analysis of the fusion gene sequence of fully and partially revertant viruses Revertant viruses 
were isolated from mutant MAI, essentially by picking and purifying viral plaques that grew at the non- 
permissive temperature. This was possible because of the high rate of reversion of the parental mutant 
in the absence of mutagenisation. As described previously (Caravokyri, 1990), fully revertant viruses 
had a rate of growth equivalent to that of the wild-type virus and were far more prevalent 
(approximately 90%)
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than partially revertant viruses (10%). The revertant virus isolates were classified on the basis of 
their efficiency of plating (Table 13). A coefficient of efficiency of plating < 0.3 and > 10'2 was 
used to define a partially revertant virus (i.e. one that remained partially temperature-sensitive). 
The revertants were also tentatively characterised in terms of the electrophoretic mobility profiles 
of their fusion proteins under non-reducing conditions (Figure 16). The pattern of reversion is 
complex, with the partial revertant viruses being present at lower frequency than full revertants. 
One fully revertant and one partially revertant virus was analysed for their fusion gene sequence.
4.2.3 Fusion gene sequence of a fully revertant virus Sequence analysis of the fusion gene of 
the fully revertant virus is summarised in Table 14 and important coding changes shown in 
Figures 17 and 18 Determination of the predicted amino acid sequence of this virus revealed 
that residues #4, #8 and #81 were restored to the wild-type sequence. Importantly, the change at 
position #66 (Glu —» Lys) had been lost, with the residue reverting to the amino acid (glutamic 
acid) found in the wild-type strain. The effect of this was to remove one of the two potential ts- 
causing mutations. The remaining coding changes found in mutant tsAl had been retained, 
including the two variable residues of strain A2 (residues #379 and #447 of the F!-subunit). 
Unexpectedly, one extra coding change had been acquired at residue #509 (Ser —» Thr), located 
in the conserved region (C#3) of the Fi-subunit of the fusion protein. This change is conservative 
in nature and may not affect fusion protein function or mobility, but since it occurs in the 
conserved C#3 region of the protein, an effect on structural features cannot be dismissed.
4.2.4 Fusion gene sequence of a partially revertant virus Sequence analysis of the fusion gene 
of the partial revertant virus is summarised in Table 15 and important coding changes shown in 
Figures 17 and 18. A more complex pattern of changes was observed in this revertant virus. 
Most of the coding changes acquired in mutant /.v A1, including the mutations at residues #66 and 
#102 potentially associated with the ts lesion, had been retained
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Table 13 Efficiency of plating of m utant feAl and its ts* revenants
‘....Efficiency of plating = Viral yield at 39°C
Viral yield at 33°C
The non-permissive temperature for mutant teAl is >37°C.
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Figure 16 . Identification of type of revertant bv fusion-protein 
mobility on SDS-PAGE analysis.
Lane
1 2 3 4 5 6 7
Total protein was harvested from virus-infected BS-C-1 cells at the permissive 
temperature and the proteins immunoprecipitated (to reduce the sample volume) with 
bovine polyclonal anti-RS virus antibody at a dilution of 1:100 as described in Section 
2.2.3. Samples were then run on a 10% SDS-PAGE under non-reducing conditions and 
the proteins transfered via Western-blotting onto a nitrocellulose filter which was 
developed as described in Chapter 2. Three RS viral proteins are shown; the fusion 
protein (F), the nucleoprotein (N) and the phosphoprotein (P). Lanes 1, 2, 3 and 7 show 
characteristic retarded fusion mobility found in the fully revertant viruses. Lane 4 shows 
wild-type fusion protein mobility characteristic of the partially revertant viruses. Lane 5 is 
the wild-type virus A2, and lane 6 is the mutant virus tsA1.
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Table 14 Coding changes in a fully revertant virus in comparison to m utant fsAl
Residue Nucleotide Amino acid Protein Comments
# change domain
#4 AUA -> CUA lie —» Leu F2 signal Restores A2 sequence
#8 ACA -» GCA Thr —» Ala F2 signal Restores A2 sequence
#66
—  
AAA —> Q AA Lys —> Glu F2 conserved #1 Restores A2 sequence
#81 CUA -> CAA Leu —¥ Gin F2 conserved #1 Restores A2 sequence
#102 none. Ser F2 C-terminal Retains teAl sequence
#379 none. Val Fi cysteine-rich Retains ¿sAl sequence
#447 none. Val Fi conserved #3 Retains tsAl sequence
#509 UCC -» ACC Ser —> Thr Fi conserved #3 Conservative change
NB Those letters underlined and in bold type denote the changed nucleotide and its position in 
the codon triplet. None, is where the predicted amino acid is the same as that of mutant /sAl. 
The coding change that is thought to be significant is shown highlighted.
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Table 15 Coding changes in a partially revertant virus in comparison to m utant teAl
Residue Nucleotide Amino Protein Comments
# change acid domain
#4 AUA -> CUA Ile —> Leu F2 signal Restores A2 sequence
#8 ACA -> GCA Thr —» Ala F2 signal Restores A2 sequence
#66 none Lys F2 conserved #1 Retains teAl sequence
#81 none Leu F2 conserved #1 Retains teAl sequence
#102 none Ser F2 C-terminal Retains teAl sequence
#103 4CA —> £ C £ Thr —* Ala F2 C-terminal Non-conservative change
#105 AAU AGU Asn —* Ser F2 C-terminal Conservative change
#379 none Val Fj cysteine-rich Retains teAl sequence
#447 none Val F i conserved #3 Retains teAl sequence
#509 UCC -» ACC Ser —> Thr F] conserved #3 Conservative change
NB Those letters that are underlined and in bold type denote the changed nucleotide and its 
position in the codon triplet. None, is where the predicted amino acid is the same as that of 
mutant teAl. The coding change that is thought to be significant is highlighted in a shaded box.
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in the partial revertant, whereas residues #4 and #8 had changed to restore the A2 sequence 
at these positions. However, there were a series of additional coding changes acquired in the 
F2- subunit encoding region of the gene. Immediately downstream of residue #102 there were 
two coding changes (residue #103 Thr -» Ala and residue #105 Asn —» Ser). The change at 
residue #105 is conservative in nature and the change at residue #103 is non-conservative, 
replacing an a-helix indifferent residue with a strong a-helix forming residue (Chou and 
Fasman, 1978). These changes are considered to be potentially important. The coding 
changes observed in the Fi-subunit of mutant fsAl, at residues #379 and #447 are retained in 
the partially revertant viruses as they are in the fully revertant viruses, and the partially 
revertant virus had also acquired the extra coding change at residue #509 (Ser —> Thr) found 
in the fully revertant viruses.
A summary of coding changes in mutant £sAl, and both classes of revertant viruses is 
given in Table 16.
4.3 Discussion There are two amino acid changes that are likely to be associated with the ts 
lesion and electrophoretic mobility phenotype, residue #66 (Glu —> Lys) and residue #102 
(Pro -> Ser). The presence of a serine residue at position #102 in two out of four cDNA 
clones analysed by Collins et al., (1984b), does not exclude this change as a true difference in 
coding sequence between the wild-type virus and its mutant. There is evidence that the 
original isolate of strain A2 was heterogenous (reviewed in Section 3.3.1), and it is feasible 
that the plaque purification process used during the generation of mutant teAl could have 
isolated a variant of the A2 virus that had the proline residue at this position. It is also equally 
possible that during the time between the original isolation of strain A2 and subsequent 
derivation of its ts mutant, and the time of the elucidation of the fusion gene sequence, the 
virus could have acquired mutations, possibly due to adaptation to growth in cultured cells.
The change at residue #66 involved the replacement of an acidic amino acid with one 
that is basic, thus altering the predicted secondary-structure forming characteristics from
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strong a-helix forming/ strong P-sheet breaking residue to one that is a weak a-helix former/ 
moderate P-sheet breaker. Therefore this amino acid change has the potential to alter the loop 
structure (residues #62 to 78) that separates the N-terminal region from the C-terminal (F2h 
containing) region o f the F2-subunit. This loop-forming region is common to all 
paramyxovirus fusion proteins (Chambers et al., 1992) and is therefore thought to be an 
important structural feature of the protein. The acquisition o f the coding change at residue 
#66 could possibly destabilise the loop and thereby account for the restricted growth of 
mutant £sAl at high temperatures. Loss of this change could possibly re-stabilise the loop 
structure and allow for growth at the higher temperature. The change at residue #102 alters 
the amino acid characteristic from a strong a-helix breaker to an a-helix indifferent residue. 
This could remove an a-helix breaking residue and potentially lengthen the F2h sequence of 
a-helixes (residue #79 to #100) described by Chambers et al., (1992) as common to all 
paramyxoviruses, and hence structurally important. The coding change at residue #509 (Ser 
—> Thr) whilst considered conservative, occurs in the conserved C#3 region of the Fi-subunit 
and may have a structural effect. However, the pattern of acquisition and loss of coding 
changes in the F2-subunit conforms to acquisition or loss of phenotypes, suggesting that it is 
changes in the F2-subunit that account for the two phenotypes. The other coding changes 
found in the fusion protein of mutant ¿sAl are thought to be irrelevant.
The acquisition of wild-type growth characteristics at the non-permissive temperature 
by fully revertant viruses accompanied the loss of the coding change at residue #66. Therefore 
this mutation may be the site of the ts lesion, possibly accomplishing this in the way described 
above.
Analysis of the additional coding changes observed in the partially revertant viruses 
(specifically residues #103 and #105), and comparison with the known acquisition of wild- 
type mobility in this class of revertant, suggests that the mutation causing the mobility shift is 
the change at residue #102. It is proposed that the mobility phenotype is caused by disruption 
in the C-terminal secondary structure (specifically F2h) of the F2 subunit by extending the a-
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helix structure. Acquisition of the extra coding change at residue #103 may modify the disrupted 
C-terminal secondary structure sufficiently to counteract the change at residue #102 which 
appeared first in mutant fsAl. With the partial revertant virus still retaining the presumptive ts 
lesion at residue #66 it is proposed that as well as correcting for mobility, the change at residue 
#103 also partially reverses the ts lesion, possibly by modification of the local structure of this 
subunit and stabilising the disrupted loop structure.
The genetic complexity of mutant teAl is probably a consequence of the conditions of 
mutagenesis which were designed to maximise the yield of mutants, rather than induce single site 
mutations.
4.4 Expression of the fusion proteins of mutant tsA! and its revertant viruses The above 
conclusions are that sequence changes in the fusion gene lead to structural changes in the 
fusion gene product that accounted for both the ts and F protein mobility phenotypes. 
However the mobility phenotype might be a function of changes in the interaction of the 
fusion gene with other viral proteins. In order to confirm the role of the F protein it was 
necessary to express the fusion gene product in isolation from the other viral proteins. The 
method chosen was to insert the fusion genes from the ts mutant, both types of revertant 
viruses, and the wild-type strain A2, seperately into an expression vector and transiently 
transfect mammalian cells in tissue-culture and examine the expressed viral fusion protein.
The expression vector chosen for this work was vector pCMVl (Figure 19). This utilises the 
human cytomegalovirus immediate early promoter which is of high efficiency. The fusion 
genes previously sequenced were ligated into this vector to determine whether the 
electrophoretic mobility phenotype was retained when the F gene were expressed 
independently of the rest of the genome. Expression levels were enhanced by the use of type 
293 mammalian cells which had been adapted from HeLa cells by the insertion of the 
adenovirus E1A gene (Graham and Van der Ebb, 1973). The E1A product is a powerful 
transactivator of the CMV promoter and has also been demonstrated as being a DNA binding 
protein that can
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Figure 19. Eukaryotic expression vector 
PCMV1
Mlul
Plasmid details
The pCMV plasmids are a series of mammalian expression vectors developed In David 
Russell's laboratory (University of Texas, Dallas, USA.). The vector backbone is pTZ18R, 
containing a bacteriophage f1 origin of replication for production of single stranded DNA, 
and an amplclllin-reslstance gene. The CMV region consists of nucleotides -760 to +3 of 
the strong promoter-regulatory region of human cytomegalovirus (Towne strain) major 
immediate early gene. The human growth hormone fragment (hGH) contains 
transcription termination and poly-adenylation signals representing sequences 1533 to 
2157 of this gene. The SV40 origin of replication and early region promoter-enhancer are 
also Included In the construct. The promoter In this fragment is oriented such that 
transcription proceeds away from the CMV/hGH cassette.
1 3 2
stabilise transfected DNA and prevent early degradation by cellular enzymes (Akusjarvi,
1993). After transfection the cellular proteins were labelled with [35S] methionine and the 
fusion protein was removed from the protein pool by immunoprécipitation with a 
polyclonal bovine anti-RS virus serum. After analysis on SDS-PAGE under non-reducing 
conditions, the mobility phenotype was determined by autoradiography (Figure 20). 
Normal wild-type mobility was observed in strain A2 and the partially revenant virus, and 
retarded mobility observed in both the teAl mutant and the fully revenant virus. This 
confirmed that the coding changes in the F gene were responsible for the mobility 
differences observed, and that interaction with other viral proteins was not involved in this 
phenotype.
4.5 Conclusion There are two distinctive phenotypes observed in the mutant virus frAl, 
temperature-sensitivity and a retarded fusion protein mobility in non-reducing gels. It is 
suggested that the site of the ts lesion is located at residue #66 (Glu —> Lys) and that of 
the mobility phenotype at residue #102 (Pro —> Ser). The nature of reversion is complex 
with two classes of revenant viruses observed; a fully revenant virus which has wild-type 
growth characteristics but still, retains retarded fusion protein mobility; and a partially 
revenant virus that possesses near wild-type growth characteristics and wild-type mobility. 
The coding change correcting for the mobility phenotype, and partially correcting for the 
ts phenotype in the partial revenant viruses, has been tentatively identified as additional 
coding changes at residues #103 and #105. For the fully revenant viruses it has been 
deduced that changing residue #66 to the wild-type amino acid fully corrects for the ts 
phenotype. In vitro expression of the fusion gene products of mutant, revenant and wild- 
type viruses in mammalian cells has confirmed that the mobility phenotype is solely a 
consequence of changes in the fusion protein gene.
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Figure 20. Expression of the fusion proteins of mutant tsA l. Full 
and Partial revertant viruses.
Viral fusion protein genes were inserted into the pCMVl expression vector and transfected into 
monolayers of 293 cells. After 36 hours the expressed proteins were labeled for 4 hours with 
radioactive methionine. Viral proteins were then immunoprccipitatcd with murine monoclonal 
anti-F antibody (Mab F8) at a dilution of 1:100. Samples were then run on a 10% SDS-PAGE 
under non-reducing conditions overnight. This over-run was to ensure that the expressed 
fusion protein mobility differences were emphasised. The gel was then dried and exposed 
as described in Chapter 2 in order to visualise the expressed fusion proteins which have either 
wild-type mobility (Fwt) or retarded mobility (Fr). Lane 1 shows the fusion protein from the 
partially revertant virus. Lane 2 shows the fusion protein from the fully revertant virus. Lane 3 
shows the fusion protein isolated from the mutant tsAl and lane 4 shows the fusion protein from 
the wild-type virus A2. Lane 3 is the negative control of the expression vector containing no insert.

CHAPTER FIVE
Genetic mutations in the fusion gene of vaccine-candidate mutant *5lC
5.1 Introduction A candidate ts-mutant vaccine has been derived from the RSS-2 strain of 
RS virus (Section 1.10). The conditions under which mutant telC was derived were chosen 
to optimise the recovery of single-site ts lesions, with the generation of the mutant telC via 
intermediate viruses (tel A and telB). Different mutagenising agents were employed at each 
stage of the process. Since the ts lesion in the teAl candidate vaccine derived by Chanock 
and colleagues (Gharpure et al., 1969; Wright et al., 1982) appeared to be located in the 
fusion protein gene (Section 4.3), it was appropriate to investigate the F protein gene of 
mutant telC. A formalin-inactivated vaccine derived by Chanock and colleagues in the 1960s, 
induced an unbalanced immune response in children which was responsible for exacerbated 
disease on subsequent natural infection of the children with RS viruses. This incident is now 
considered to be due to the destruction of F and/or G protein epitopes by the inactivation 
treatment. It was important therefore to ascertain whether in the derivation o f mutant telC 
the fusion protein gene had been altered and whether any observed nucleotide changes could 
potentially affect known epitopes on the fusion protein.
5.2 Results The isolation of the wild-type strain RSS-2 and all subsequent characterisation of 
the original isolate, the derivation of the ts mutants, and preparation of stock virus were carried 
out in human diploid (MRC-5) cells (McKay et al., 1988). Therefore all viral manipulations 
described here were performed in this cell line.
5.2.1 SDS-PAGE analysis of fusion proteins SDS-PAGE analyses of the fusion gene products 
from the three mutants (telA, telB and telC) synthesised at the permissive temperature have 
confirmed that the fusion proteins from mutants (telA, telB and telC) cannot be differentiated 
from wild-type RSS-2 strain by electrophoretic mobility (Figure 21).
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The fusion gene products from all three mutants and the wild-type virus showed the same 
mobility for F i,2 on non-reducing and for Fi and F2 subunits on reducing gel SDS-PAGE 
(C.R.Pringle, personal communication). Quantitative differences in samples are probably due 
to inequalities in the amounts loaded in the different tracks.
5.2.2 The fusion protein gene sequence of mutant falC Determination of the nucleotide 
sequence of the fusion protein gene of telC and its intermediates was carried out by PCR 
amplification o f the full length gene via a cDNA intermediate generated from total RNA 
extracted from virus-infected cell monolayers. The primers, PCRF1 and PCRF2 were 
designed to be complementary to the 5' and 3' ends of the gene respectively, both 
incorporated a Sma 1 restriction endonuclease site which was used to insert the full-length 
gene directly into vectors M13mpl8/19. Two plaque-purified M13 cultures of each mutant 
were sequenced as described (Section 2.3.21).
There are eight nucleotide differences between mutant /slC and the wild-type RSS-2, 
potentially coding for four amino acid changes. Nucleotide changes occur in all three codon 
positions and as expected, mutations in the third codon position (residues #73 GAJJ —> GA£; 
#166 AAG -> AAA; #316 CUA -> CU£ and #447 GUfi -> GUJD do not change the 
encoded amino acid residue. However mutations in both the first codon (#434 JJCA —► ACA 
and #523 GAU —> AAU) and the second codon positions (#1301 A<£A —> A£A and #1580 
A£A —> AJJA) do give rise to potential amino acid changes. The four amino acid changes 
appear to identify three mutational sites. The nucleotide changes for each of the three 
mutational sites #1, #2 and #3 are shown in detail for each ts mutant (Figures 22, 23 and 24) 
and the data for telC are summarised in Table 17.
Mutation site #1 (residue #35 Ser —> Thr) is located in the F2 subunit of the fusion 
protein, in a putative a-helical region F2h (Section 1.7.5 Figure 5). The serine to threonine 
exchange represents a conservative change with relative size, charge and hydrophobicity 
profiles unaltered. Mutation site #2 lies within the Ft subunit in the cysteine-rich domain
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Table 17 Summary of the coding and non-coding changes in the fusion gene
of felC compared to the wild-type virus RSS-2
Nucleotide changes Coding changes
Nucleotide # Codon Triolet Amino acid # Amino acid
103 JJCA -* ACA 35 Ser Thr
219 GAU -» GAÇ 73 No change
498 AAG -» AAA 166 No change
948 CUA -> CUG 316 No change
1282 £A U  -> AAU 
1301 A gA -> A £A
428
434
Asp -> Asn 
Arg -> Thr
1341 G U e ^ G U H 447 No change
1580 A£A -> AJJA 523 T h r-> lie
N.B. Letters in bold and underlined denote a base within the codon which was mutated in 
fslC. Coding changes are highlighted in shaded boxes.
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(residues #312 to #440; Section 1.7.4 Figure 4). There are two changes in amino acids 
(residue #428 Asp —> Asn and residue #434 Arg —> Thr) which have altered bases in their first 
and second codons respectively (#428 GAU —> AAU and #434 AGA —> A£A). These 
changes are less conserved in that the aspartic acid to asparagine change removes an acidic 
amino acid and replaces it with a neutrally charged residue, but the hydrophilic nature of this 
residue is retained. The change of arginine to threonine also alters the charge of the 
substituted molecule from basic to neutral but the hydrophilic nature once again is retained. 
However, there is a size change from large to small. The retention of hydrophilic 
characteristics implies that these amino acids lie on the surface of the folded protein. The 
substituted amino acid sequence present at this site is identical to that found in the wild-type 
strain A2 (Collins el al., 1984b).
The residues present in Is 1C at position #428 and #434 are found in all strains of RS 
viruses that have been sequenced, other than the RSS-2 wild-type virus (Section 3.2.5), This 
raises two possibilities, firstly the original published sequence data for strain RSS-2 could be 
in error at these two positions; secondly, these two sites may indeed be valid mutations that 
appear to be linked suggesting a possible structural role. To investigate the first possibility, 
the F gene from wild-type strain RSS-2 was PCR amplified, cloned into M13mpl9 and 
sequenced across the three identified mutational sites. The nucleotide sequence at sites #1 and 
#3 were found to be as published, however the sequence at site #2 was found to agree with 
that found in mutant to 1C (Figure 25) and all other strains of RS virus. Thus it would appear 
that the original sequence published by Baybutt and Pringle (1987) is in error at nucleotides 
#1282 and #1301 (residues #428 and #434) and there are no mutational changes in this 
region. Mutation site #2, therefore, is an artefact.
Mutation site #3 (Thr —> lie) occurs in the second base position of the codon (A£A 
—> AT A). This change is located in the Fi subunit of the fusion protein immediately upstream 
of the membrane anchor region (Section 1.7.4 Figure 4). The change is conservative in that
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both the original and substituted residues are hydrophobic, neutrally charged and of similar
size.
5.2.3 The fusion gene sequence of intermediate mutants tolA and tolB Analysis of the 
fusion protein gene sequences of the intermediate mutant viruses to 1A and tolB was used to 
establish at which step in the derivation of the triple ts mutant to 1C, the mutations occurred. 
Of the nucleotide mutations in tolC (excluding the two errors at residues #428 and #434) two 
non-coding nucleotide changes (#166 AA£ —> AAA and #523 AC A —> AUA) and one 
coding change (residue #527 Thr —> lie) are also present in the fusion protein gene of mutants 
tolA and tolB. Therefore the remaining four nucleotide mutations that only appear in mutant 
to 1C, of which only one introduces a coding change (residue #35 Ser —> Thr), must have been 
introduced during the mutational step from tolB to tolC. The sequential accumulation of 
mutations in the fusion protein genes from tolA through to tolC is shown in Section 5.2.2 
Figures 22, 23 and 24 and summarised in Table 18.
5.3 Discussion Three temperature-sensitive mutants (tolA, tolB and tolC) have been 
sequentially derived from the non-ts wild-type strain RSS-2 using different mutagenising 
agents. The three mutants have restrictive temperatures of 39°C, 38°C and 37°C 
respectively (McKay el al., 1988; Pringle et al., 1993). All three mutant viruses have 
RNA-positive phenotypes and synthesise viral polypeptides intracellularly at their non- 
permissive temperatures. The single (tolA) mutant when administered intranasally in low 
dose to adult volunteers, had reduced disease-inducing potential in comparison to the 
wild-type virus RSS-2. The double (tolB) and triple (tolC) mutants, however, gave 
greater reduction in disease-inducing potential with approximately equivalent levels of 
attenuation (Watt et al., 1988; Pringle et al., 1993). All three mutants induced good 
immune responses, and mutant tolC was considered to be the most suitable as a vaccine 
because of its potentially greater genetic stability.
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Table 18 Summary of the location of nucleotide changes in the fusion gene of telC
and intermediates tel A and telB com pared to the wild-tvpe strain RSS-2
Nucleotide change Residue change tel A telB telC
Amino acid # Codon triplet
35 UCA &CA Ser Thr NO NO YES
73 GAU -> GAC No change NO NO YES
166 AAG-* AAA No change YES YES YES
316 CUA -> CUG No change NO NO YES
447 GUG -* GUU No change NO NO YES
523 A£A AHA T hr-*  He YES YES YES
N.B. Letters in bold and underlined denote the mutated base within the codon.
YES - denotes presence of mutation in the mutant defined in the top column. 
NO - denotes absence of mutation in the mutant defined in the top column. 
Coding changes are highlighted in shaded boxes
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The sequence data for mutation site #1 shows no change in hydrophobicity in this 
region of the F2 subunit and is not thought to alter the predicted structure of the fusion 
protein. It is therefore unlikely that the change in residue at position #35 has a role in 
determining temperature-sensitivity changes between telB and telC despite this region 
being highly conserved between human and bovine strains of RS viruses. Mutation site #3 
(residue #523 Thr —> lie) is located immediately upstream of the putative membrane 
anchor region (residue #525 to #550). The substituted and substituting amino acids 
possess the same hydrophobic moment and charge suggesting that this residue change is 
conservative. However, because this change occurs in a region which is highly conserved 
between bovine and human strains of RS virus (Section 3.2.5) it is possible that it may be 
structurally important. The subsequent lowering of the restrictive temperature of mutant 
£slB could be due to other mutations in the viral genome. The fact that both mutation sites 
occur in regions of high conservation, not just within human strains of RS virus but also in 
RS viruses of other hosts, and are also retained in all three mutants, suggests that the 
changes observed in mutants tel A, to IB and to 1C are not random errors occurring during 
the sequencing of their genes.
5.4 Conclusion The mutations detected in the fusion gene of is 1C are not located in 
known epitopes, therefore it is unlikely that the two coding changes observed in the fusion 
protein gene of the to 1C candidate vaccine have altered the antigenic properties of the 
virus, since the F protein is the principle inducer of neutralising antibody.
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CHAPTER SIX
General discussion
6.1 Natural variation in the fusion protein gene of  subgroup A_RS viruses The data 
presented in this thesis together with published sequences show that the amino acid 
identity of the fusion protein genes of subgroup A strains is high (97% —> 99.4%). 
Between subgroups there is a lower degree (90%) of amino acid identity, the amino acid 
identity between human and bovine RS viruses being only 80%. The F2-subunit encoding 
region of the gene has most variation, specifically in the signal and C-terminal domains.
Each of the five Birmingham isolates used in this study was originally classed in a 
separate lineage (SHL 1 to SHL 5) based on the relatedness of their SH and N protein 
genes (Cane and Pringle, 1991). The distinctiveness of the five lineages was confirmed by 
sequencing of the G protein gene (Cane el al., 1993). The relatedness of the fusion protein 
genes of the five isolates representing the five lineages SHL1 to SHL5 (Figure 10) 
showed that the pattern of relatedness of the F proteins approximated that of the lineages 
(Figure 2) as previously defined by SH, N and G protein gene analysis.
The degree of homology in the fusion protein gene of subgroup A RS viruses 
appears similar to that found in the fusion protein genes of clinical isolates of PIV 3 where 
the gene has 94.5% to 95.5% homology, and their predicted products have greater than 
97% amino acid identity (Van Wyke Coelingh and Winter, 1990). Despite low amino acid 
difference, the clinical isolates of PIV 3 possess antigenic differences similar to those 
found in laboratory variants selected by and resistant to neutralising anti-F monoclonal 
antibodies (Van Wyke Coelingh and Winter, 1990). Therefore, by analogy to PIV 3, the 
amino acid variation within subgroup A RS viruses may have an effect on subgroup A 
virus antigenicity Whilst no variation in amino acid identity in subgroup A viruses has 
been mapped to the four known antigenic areas, antigenic variation could be caused by
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amino acid variation in the C-terminal domain o f the F2-subunit. By analogy with NDV, this 
is thought to interact with the H box region (Figure 11) near the Fi-subunit N-terminal 
domain. The area downstream of the H box region is highly antigenic (containing three of the 
four known antigenic areas) and so disruption of this interaction between subunits could 
possibly alter conformational epitopes in this region. Secondary structure alterations in the C- 
terminal region of the F2-subunit has been suggested as a potential consequence of amino 
acid variation using computer analysis. The presence of antigenic variation between subgroup 
A isolates could be tested by assay against a panel of anti-F Mabs, by dot-blot, Western blot, 
or ELISA analysis. However, in any analysis o f the contribution of F protein variability to 
antigenicity, it will be necessary to study the anti-F response of each isolate in the absence of 
other viral proteins. This would necessitate the cloning and expression of the fusion protein 
genes from isolates and analysing the immune response in an animal model.
In other paramyxoviruses, amino acid variation occurs at the cleavage site and affects 
infectivity; e.g. PIV 3 (Van Wyke Coelingh and Winters, 1990); NDV (Toyoda et al., 1987; 
Glickman et al., 1988); and Sendai virus (Cho^pm a(\A Schu.A, 19SO). However only a single 
non-coding nucleotide change in the cleavage site of the subgroup A RS viruses examined in 
this study has been observed, so no direct affect on infectivity would be expected.
6.2 Induced variation in the fusion protein gene of subgroup A RS viruses Evidence 
has been presented to indicate that the site of the ts lesion in mutant /.vAl is located at residue 
#66 (Glu —> Lys) and that of the mobility phenotype at residue #102 (Pro —> Ser). Whilst the 
change at residue #102 occurs in the variable C-terminal region (residues #101 to #105), the 
putative ts-causing lesion occurs in the conserved (C #1) region of the subunit. This suggests 
that this domain is an important structural region.
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Characterisation of the phenotype of mutant teAl identified the fusion protein gene 
as the likely site of the ts lesion (Belshe et ah, 1978; Caravokyri, 1990) and the 
sequence data derived in this study supports this hypothesis. However, coding changes 
occurring elsewhere in the genome of mutant ¿sAl cannot be ruled out. Mutation in the 
matrix protein can result in altered fusion protein function in ts mutants of the 
paramyxovirus NDV (Peeples and Bratt, 1984). Consequently the matrix (M) protein gene 
of this mutant and both classes of revertant viruses were sequenced for at least one clone 
of each gene and no coding changes were observed (data not shown). This does not 
exclude the possibility, however, that lesions are present in other genes which may be 
responsible for the ts and attenuation phenotype. It is evident that the isAl virus is 
genetically complex and several lesions may contribute to the phenotypes. However, the 
evidence presented in this thesis favours the hypothesis that the ts and mobility mutations 
are located in the F protein gene.
Analysis of the nature of reversion in other paramyxoviruses, such as the group D 
ts mutants of NDV, has provided evidence of the importance of the amphipathic a-helix 
(AAH) in providing the structural requirements for correct F protein processing (Wang et 
al., 1992). They found that the ts lesion was located in the AAH (also called the H box) 
region of the Fi-subunit. Two classes of revertant were obtained. One type had 
compensating mutations in and around the original lesion. The second type had coding 
changes localised within the F2-subunit. These authors concluded that the Fi AAH region 
interacted with the F2-subunit, and that the original ts lesion and also the revertant 
mutations, resulted in changes in the secondary structure of the AAH region, possibly by 
disrupting or weakening the a-helix motif. The ts lesion of the teAl mutant of RS virus 
occurred in the C#l region of the Fj-subunit and revertant mutations occurred in and 
around the original site of lesion. By analogy with the NDV model described above, the ts 
lesion may prevent correct interaction between the AAH (H box) and the F2-subunit such 
that changes in the secondary structure are fully or partially corrected by subsequent 
changes in the revertant viruses.
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Transient in vitro expression of the fusion gene products of mutant, revertant and 
wild-type viruses in mammalian cells has confirmed that the mobility phenotype is solely a 
consequence of changes in the fusion protein gene. The presence of the mobility phenotype 
supports the theory that changes in the amino acid sequence may lead to structural changes in 
the fusion protein. This may potentially lead to changes in the antigenicity of this protein. It 
would therefore be of future interest to examine the reactivity profiles of mutant and revertant 
fusion proteins against a panel of anti-F monoclonal antibodies.
The appearance of revertant viruses in the nasopharynx of vaccinated infants 
suggested an unacceptable level of genetic instability and work on the development of 
tóAl as a vaccine was suspended. However, in recent years live virus vaccine for control 
of RS virus has gained favour again and mutant /sAl is being re-evaluated by 
R.M.Chanock’s group at the N.I.H. (C.R.Pringle, personal communication).
An alternative candidate vaccine restricted to growth at temperatures below 37°C, the 
triple mutant fslC, has been sequentially derived from wild-type strain RSS-2 using different 
mutagenising agents in order to minimise genetic instability. Two coding changes in the fusion 
protein gene were observed between the wild-type and temperature-sensitive virus, residue 
#35 (Ser —> Thr) and residue #523 (Thr —> lie) Both changes are conservative in nature and 
are not thought to effect the protein structure. Neither mutation is present in or near known 
epitopes.
The telC candidate live vaccine exhibites residual virulence in adults and is thought 
unsuitable for administration to sero-negative children without further modification. It is 
being used, however, to identify the genetic determinants of virulence. This entails the 
complete sequencing of the genome of the triple ts mutant, the single and double 
intermediate ts mutants, and their progenitor wild-type virus in order to identify the 
mutational lesions associated with both the ts and virulence phenotype Sequencing of the
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telC genome is virtually complete and analysis of the data indicates that mutations in one 
domain of the polymerase protein gene (L) are major determinants of loss of virulance, at 
least for URT infection in adults (C.R.Pringle, personal communication). The work 
reported in this thesis indicates that mutations in the fusion protein gene are probably not a 
factor in the attenuation of the virus. It has also established that the antigenicity of the 
fusion protein is unlikely to have been altered by the attenuation process and that there is 
little or no risk in inducing the paradoxical disease associated with the use of formalin- 
inactivated vaccine in the past.
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